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Summary 
Key words: VKM, Risk assessment, Norwegian Scientific Committee for Food Safety, 
Norwegian Food Safety Authority, coccidiostats, antimicrobials, resistance, poultry 
Background 
Antimicrobials revolutionized human as well as animal medicine in the 20th century by 
providing effective treatment of diseases caused by pathogenic microorganisms. However, 
microorganisms have the ability to develop antimicrobial resistant strains. This occurs when 
microorganisms mutate or when resistance genes are exchanged between them. The use of 
antimicrobial drugs accelerates the emergence of drug-resistant strains. A priority is to 
safeguard the efficacy of antimicrobial drugs we depend on for treatment of infectious 
diseases in humans. Use of antimicrobials in food animals can create a source of 
antimicrobial resistant bacteria that can spread to humans both by direct contact and 
through the food supply.  
Coccidiosis is an intestinal disease in animals caused by unicellular parasites called coccidia. 
As most of the damage of this infection is done by the time signs of the disease are 
widespread, preventive measures are preferred. Coccidiostats are animal feed additives used 
to prevent coccidiosis by inhibiting or killing coccidia. There are two major groups of 
coccidiostats; ionophores and non-ionophores, the latter also referred to as “non-ionophore 
coccidiostats” (but also called chemicals). One main difference between these groups is that 
ionophores also inhibit or kill some bacterial species, whereas non-ionophore coccidiostats do 
not. Consequently, some bacterial infections may also be controlled by ionophore 
coccidiostats, e.g. the poultry disease necrotic enteritis caused by the bacterium Clostridium 
perfringens (C. perfringens). 
Eleven different coccidiostats have been authorised for use in the EU, both ionophores and 
non-ionophore coccidiostats. Norway has been exempted from the EEA Agreement in this 
field and has approved only five; all ionophores. The two ionophore coccidiostats currently 
used in Norway are narasin for broilers and monensin for turkeys. 
Resistance to coccidiostats in coccidia and bacteria 
Development of resistance in coccidia to all eleven coccidiostats has been described in the 
scientific literature, but the prevalence of resistance is unknown. Cross-resistance between 
various ionophore coccidiostats has also been shown, i.e. development of resistance to one 
ionophore may also render the coccidia resistant to another ionophore. Various rotation and 
shuttle programmes with exchange between ionophores and non-ionophore coccidiostats are 
believed to prevent or delay development of resistance in coccidia. In Norway, such 
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programmes will have little effect as long as only ionophores and not non-ionophore 
coccidiostats are approved for use. 
Development of resistance against ionophores has also been observed in bacteria. In the 
Norwegian surveillance programme NORM-VET during the years 2002 - 2013, between 50 - 
80 % of the tested flocks had narasin resistant faecal enterococci, which are bacteria that 
are part of the normal intestinal microbiota.  However, the pathogenic bacterium C. 
perfringens has not been shown to be resistant against any ionophore. Cross-resistance in 
bacteria to more than one ionophore has been observed. In addition, a limited amount of 
data may indicate an association between narasin and resistance to the antibacterials 
bacitracin and vancomycin. As these are antibacterials used for treatment in humans, more 
research should be performed to validate these results. Non-ionophore coccidiostats, which 
do not have antibacterial effect, are not approved in Norway. If such coccidiostats were 
approved in Norway, coccidiostats with negligible probability of inducing resistance in 
bacteria would be available. 
Human exposure to resistant bacteria and coccidiostats 
Humans may theoretically be exposed to coccidiostat resistant bacteria from poultry in a 
number of ways, e.g. by handling live animals and their manure, through slaughtering and 
processing, and by preparation and consumption of poultry meat. Furthermore, bacteria of 
the human normal microbiota, which cover all skin and mucosal surfaces, might develop 
resistance if they are exposed to coccidiostats. 
In this assessment, the probabilities of exposure are classified as: Negligible (extremely low), 
Low (possible, but not likely), Medium (likely), High (almost certain) and Not assessable. 
The Panel has estimated the following probabilities of human exposure: 
• Handling manure from coccidiostat fed poultry without sufficient risk-reducing measures 
entails a high probability of exposure to both resistant bacteria and coccidiostats. Without 
proper protection, the probability of exposure to coccidiostats is also high when handling 
coccidiostat premixes and feeds containing coccidiostats without proper protection 
measures. Various treatments, e.g. composting, of the manure may reduce the 
probability. 
• The probability of exposure to resistant bacteria is medium for workers handling 
carcasses and raw meat on a daily basis if risk-reducing measures are not applied, 
whereas the probability of exposure to coccidiostats is negligible. 
• For consumers, the probability of exposure to coccidiostats is negligible. The probability 
for exposure to resistant bacteria is also negligible in heat treated food since heat 
treatment kills the bacteria. The probability of exposure to coccidiostat resistant bacteria 
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is low to medium if handling raw meat without proper hygienic procedures, because raw 
meat may harbour resistant bacteria.  
Risk-reducing measures will lower the probabilities. 
However, little is known concerning the consequences of human exposure to coccidiostat 
resistant bacteria or to to coccidiostats. There is little information in scientific literature 
indicating whether such bacteria in fact will colonize the human body, either transitionally or 
permanently. Furthermore, there is no information on the probability of exchange of 
resistance genes from transferred bacteria to bacteria of the human natural microbiota or to 
pathogens. Likewise, the Panel has no information on the level of exposure, e.g. the amount 
of coccidiostats and their metabolites, or the time period, necessary for the various bacteria 
to give rise to resistant variants. As coccidiostats are not used to treat infectious diseases in 
humans, concern of resistance is related to possible cross- or co-resistance with 
antibacterials considered important in human medicine. Such resistance has so far not been 
confirmed. 
Use of therapeutic antibacterials for poultry 
If the ionophore coccidiostats used in Norway are replaced by one or more non-ionophore 
coccidiostat with no antibacterial effect and no other changes are done, the coccidiostats 
used will no longer inhibit the bacterium Clostridium perfringens, which is the cause of 
necrotic enteritis. Over time this will likely to lead to a need for intermittent or continuous 
use of higher levels of therapeutic antibacterials due to increased incidence of this desease in 
poultry production. The magnitude of the increase is difficult to predict. 
Alternatives to in-feed antimicrobials 
Eradication from the birds’ environment of coccidia causing coccidiosis is difficult to achieve 
because the coccidia form oocysts that survive outside the host and resist commonly used 
disinfectants.  
Vaccination with non-pathogenic vaccines is now used increasingly in commercial Norwegian 
broiler farms, instead of in-feed coccidiostats. So far coccidiosis has not been reported as a 
problem in this transition process to broiler rearing without in-feed coccidiostats in Norway. 
Non-antimicrobial feed additives with purported health-promoting benefits, i.e. acid-based 
products, probiotics, prebiotics, synbiotics, yeast-based products, plant-derived products, 
combinations of these, and other products have been developed and used in feed. These 
products have been tested for efficacy against coccidia with conflicting, non-consistent or 
non-convincing results. The majority of these products appear to target the bacterial 
microbiota rather than coccidia. The Panel has not assessed possible effects of other types of 
management changes.  
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Sammendrag på norsk 
Antimikrobielle midler har revolusjonert medisinen i det 20. århundre ved å gi effektiv 
behandling mot infeksjonssykdommer. Mikroorganismer har imidlertid evnen til å utvikle 
reistens mot slike stoffer. Bruk av antimikrobielle midler bidrar til utvikling av resistente 
stammer. Det er viktig å forsøke å hindre resistens mot antimikrobielle stoffer som vi er 
avhengige av for behandling av smittsomme sykdommer hos mennesker. Bruk av 
antimikrobielle midler til matproduserende dyr kan skape en kilde til resistente bakterier som 
kan spres til mennesker både ved direkte kontakt og gjennom mat.  
Koksidiose er en tarmsykdom hos dyr forårsaket av encellede parasitter som kalles koksidier. 
Ettersom det meste av skaden har skjedd før man rekker å oppdage infeksjonen, foretrekkes 
preventive tiltak. Koksidiostatika er tilsetningsstoffer i dyrefôr som brukes til å forebygge 
koksidiose ved å hemme eller drepe koksidier. Det er to store grupper av koksidiostatika; 
ionoforer og ikke-ionoforer, sistnevnte blir også referert til som «kjemiske koksidiostatika». 
En hovedforskjell mellom disse gruppene er at ionoforer også hemmer eller dreper enkelte 
bakteriearter. Det gjør ikke kjemiske koksidiostatika. Følgelig kan noen bakterielle infeksjoner 
også bli kontrollert av ionofore koksidiostastika, f.eks fjørfesykdommen nekrotiserende 
enteritt som forårsakes av bakterien Clostridium perfringens (C. perfringens). 
Elleve ulike koksidiostatika har blitt godkjent for bruk i EU, både ionoforer og kjemiske 
koksidiostatika. Norge har blitt unntatt fra EØS-avtalen på dette feltet og har godkjent bare 
fem; alle ionoforer. De to ionofore koksidiostatika som brukes i Norge i dag er narasin for 
slaktekylling og monensin for kalkuner. 
Resistens mot koksidiostatika i koksidier og bakterier 
I den vitenskapelige litteraturen er det beskrevet resistens mot alle elleve koksidiostatika hos 
koksidier, men prevalensen av resistens er ukjent. Kryssresistens mellom ulike ionofore 
koksidiostatika er også vist, det vil si utvikling av resistens mot en ionofor kan også gi 
resistens mot en annen ionofor. Forskjellige såkalte «rotasjons-» og «skyttel-» programmer 
med veksling mellom ionoforer og kjemiske koksidiostatika er antatt å forhindre eller forsinke 
utvikling av resistens hos koksidier. I Norge vil slike programmer ha liten effekt ettersom 
bare ionoforer og ikke kjemiske koksidiostatika er godkjent for bruk. 
Det er observert at bakterier også kan utvikle av resistens mot ionoforer. I det norske 
overvåkingsprogrammet NORM-VET ble det i årene 2002 – 2013 funnet at mellom 50 og 80 
% av de testede slaktekylling– og kalkunflokkene hadde narasinresistente enterokokker, dvs 
bakterier som er en del av den normale tarmfloraen. Det har imidlertid ikke vært rapportert 
at sykdomsfremkallende C. perfringens som har vært resistente mot noen ionofor. Kryss-
resistens mellom ionoforer er observert hos bakterier, på samme måte som hos koksidier. I 
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tillegg kan en begrenset mengde data tyde på at det hos bakterier kan være en 
sammenheng mellom narasin og bacitracinresistens, og mellom narasin og 
vancomycinresistens. Ettersom bacitracin og vancomycin brukes til behandling av 
mennesker, bør det forskes mer for å bekrefte eller avkrefte disse resultatene. Kjemiske 
kosidiostatika som ikke har antibakteriell effekt har neglisjerbar risiko for å indusere resistens 
i bakterier. Kjemiske koksidiostatika er imidlertid ikke godkjent i Norge. 
Human eksponering for resistente bakterier og koksidiostatika 
Mennesker kan teoretisk sett bli utsatt for koksidiostatika-resistente bakterier fra fjørfe på en 
rekke måter, f.eks ved håndtering av levende dyr og gjødsel, ved slakting og prosessering, 
og ved bearbeiding og inntak av fjørfekjøtt. Bakterier i normalefloraen hos mennesker, som 
dekker alle hud- og slimhinneoverflater, kan teoretisk utvikle resistens hvis de blir utsatt for 
koksidiostatika. 
Sannsynlighet for eksponerig klassifiseres på følgende måte: Neglisjerbar (ekstremt lav), Lav 
(lite sannsynlig, men mulig), Middels høy (sannsynlig), Høy (nesten sikker), Ikke 
klassifiserbar (ikke mulig å anslå nivå på sannsynligheten). 
Faggruppen har konkludert med følgende sannsynligheter for at mennesker kan bli 
eksponert: 
• Håndtering av gjødsel fra fjørfe gitt fôr tilsatt koksidiostatika uten tilstrekkelige 
risikoreduserende tiltak innebærer en høy sannsynlighet for eksponering for både 
resistente bakterier og for koksidiostatika. Behandling av gjødsel, f.eks. kompostering 
kan redusere sannsynligheten. Uten tilstrekkelig beskyttelse, er sannsynligheten for 
eksponering for koksidiostatika også høy ved håndtering av koksidiostatika-holdig 
premiks- blandinger for tilsetning til fôr.  
• Sannsynligheten for eksponering for resistente bakterier er middels høy for arbeidere 
som tilnærmet daglig håndterer slakt og rått kjøtt uten risikoreduserende tiltak, mens 
sannsynligheten for eksponering for koksidiostatika er neglisjerbar. 
• For forbrukerne, er sannsynligheten for eksponering for koksidiostatika neglisjerbar. 
Sannsynligheten for eksponering for resistente bakterier er også ubetydelig i 
varmebehandlet mat, men lav til middels høy hvis man håndterer rått kjøtt uten 
tilstrekkelige hygieniske rutiner. 
Risikoreduserende tiltak vil redusere sannsynligheten for at mennesker utsettes for 
koksidiostatika og resistente bakterier. 
Det finnes lite kunnskap om konsekvenser av eksponering av mennesker for resistente 
bakterier og for koksidiostatika. Det er lite informasjon i vitenskapelig litteratur om hvorvidt 
bakterier som er resistente mot koksidiostatika vil slå seg ned, enten kortvaring eller 
permanent, hos mennesker. Videre er det ingen informasjon om sannsynligheten for 
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overføring av resistensgener fra fjørfebakteriene verken til bakterier i menneskers naturlige 
bakterieflora eller til sykdomsfremkallende bakterier. Likeledes har faggruppen ingen 
informasjon om graden av eksponering, for eksempel mengden av koksidiostatika og deres 
nedbrytningsprodukter eller tidsperioden, som er nødvendig for at bakterier hos mennesker 
skal utvikle resistente varianter. Koksidiostatika brukes ikke ved behandling av smittsomme 
sykdommer hos mennesker. En eventuell risiko er derfor spesielt knyttet til om det er en 
sammenheng mellom koksidiostatika og resistens hos bakterier mot antibakterielle midler 
som er viktige i humanmedisin. Slik sammenheng har så langt ikke blitt bekreftet. 
Bruk av terapeutiske antibakterielle midler hos fjørfe 
Dersom ionofore koksidiostatika som brukes i Norge blir erstattet av et eller flere kjemiske 
koksidiostatika uten antibakteriell virkning, og ingen andre endringer gjennomføres, vil de 
koksidiostatika som brukes ikke lenger hemme bakterien Clostridium perfringens som kan gi 
nekrotiserende enteritt. Dette vil trolig over tid føre til et behov for intermitterende eller 
kontinuerlig bruk av høyere nivåer av terapeutisk antibiotika på grunn av økt forekomst av 
nekrotiserende enteritt. Hvor mye høyere forbruket av terapeutiske antimikrobielle midler 
kan bli er vanskelig å forutsi. 
Alternativer til koksidiostatika i fôret 
Utrydding av koksidier i fuglenes miljø er ønskelig, men det er vanskelig fordi koksidiene 
danner oocyster som overlever utenfor verten og som f.eks. motstår vanlig brukte 
desinfeksjonsmidler. 
Vaksinasjon med ikke-patogene vaksiner i stedet for koksidiostatika i fôret brukes i økende 
grad i kommersielle norske slaktekyllig-besetninger. Så langt har ikke koksidiose blitt 
rapportert å være et problem. 
Ikke-antimikrobielle fôrtilsetninger med påståtte helsebringende fordeler, dvs. syrebaserte 
produkter, probiotika, prebiotika, synbiotika, gjærbaserte produkter, plantebaserte 
produkter, kombinasjoner av disse, og andre produkter har blitt utviklet og markedsføres. 
Disse produktene er testet for effekt mot koksidier med motstridende, ikke-konsistente eller 
ikke-overbevisende resultater. De fleste av disse produktene synes å være rettet mot 
bakteriefloraen i stedet for mot koksidier.  
Faggruppen har ikke vurdert mulige effekter av andre former for driftsendringer.  
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Abbreviations and glossary 
Abbreviations 
AGP Antibiotic growth promoters 
DANMAP The Danish Programme for surveillance of antimicrobial consumption and 
resistance in bacteria from animals, food and humans 
http://www.danmap.org/ 
EFSA European Food Safety Authority, http://www.efsa.europa.eu/ 
EUCAST  The European Committee on Antimicrobial Susceptibility Testing, 
http://www.eucast.org/ 
FAO Food and Agriculture Organization of the United Nations 
FDA U.S. Food and Drug Administration, http://www.fda.gov/ 
FINRES-vet The Finnish antimicrobial resistance monitoring programme, 
http://www.evira.fi 
LOD Limit of Detection 
LOQ Limit of Quantification 
MIC  Minimum Inhibitory Concentration, the lowest concentration of a given agent 
that inhibits growth of a microorganism under standard laboratory conditions. 
MIC data can provide information about the activity of antimicrobials 
MRL Maximum Residue Limit, the legal maximum concentration of a residue, 
resulting from the registered use of an agricultural or veterinary chemical 
NFSA Norwegian Food Safety Authority, http://mattilsynet.no/ 
NIPH  Norwegian Institute of Public Health Institute, http://www.fhi.no/ 
NORM-VET The Norwegian monitoring programme on antimicrobial resistance in bacteria 
from food, feed and animals http://www.vetinst.no/eng/Publications/NORM-
NORM-VET-Report 
NVI  Norwegian Veterinary Institute, http://www.vetinst.no 
OIE The World Organization for Animal Health, http://www.oie.int/ 
PCR Polymerase Chain Reaction 
P95-exposure The estimated exposure at the 95-percentile 
SWARM The Swedish Veterinary Antimicrobial Resistance Monitoring programme 
http://www.sva.se/en/antibiotics-/svarm-resistance-monitoring 
TTGE Temporal temperature gradient gel electrophoresis. 
VMPs  Veterinary medicinal products 
VKM  Norwegian Scientific Committee for Food Safety, http://www.vkm.no/ 
WHO  World Health Organization, http://www.who.int/en/ 
  
 




Acquired resistance: is resistance to a particular antimicrobial agent, to which the 
microorganism previously was susceptible. The change is the result of genetic alteration in a 
microorganism due to mutation(s), the acquisition of foreign genetic material or a 
combination of both mechanisms. 
Antibacterials: A general term for the drugs (antibiotics), chemicals, or other substances 
that either kill or inhibit the growth of bacteria. 
Antibiotics: Traditionally; natural organic compounds produced by microorganisms, acting 
already in low concentration against other microorganisms. Today “antibiotics” comprises 
also synthetic and semisynthetic compounds with similar effects. 
Antimicrobials: A general term for the drugs (antibiotics), chemicals, or other substances 
that either kill or inhibit the growth of microbes. The concept of antimicrobials applies to 
antibiotics, disinfectants, preservatives, sanitizing agents and biocidal products in general. 
Antimicrobial resistance is defined as by Davison et al. (2000); a property of bacteria that 
confers the capacity to inactivate or exclude antibiotics, or a mechanism that blocks the 
inhibitory or killing effects of antibiotics. 
1. The ability of a microorganism to withstand an antibiotic. 
2. A relative term which provides an interpretation of the clinical significance of 
concentrations of an antimicrobial that inhibits the growth of an organism or kill it in 
laboratory systems (in vitro). 
3. Either microbiological resistance, where resistant organisms are those that possess any 
kind of resistance mechanism or resistance gene, or clinical resistance, where a 
bacterium is classified as susceptible or resistant depending on whether an infection with 
that bacterium responds to therapy or not. 
Coccidia: Microscopic, spore-forming, single-celled, eukaryote parasites of the subclass 
Coccidiasina. Unless otherwise noted, the term “coccidia” in this assessment is used to 
describe coccidia of the genus Eimeria which can infect poultry. 
Coccidiostats: Agents added to animal feed (as for poultry) that serves to retard the life 
cycle or reduce the population of pathogenic coccidia to the point that disease is minimized 
and the host develops immunity. 
Conjugation: Transfer of genetic material between different bacterial cells by direct cell-to-
cell contact. 
Co-resistance:  Occur when the genes specifying different resistant phenotypes are located 
together on a mobile genetic element (like plasmid, transposon, integron). 
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Cross-resistance: Resistance occurring when the same or similar mechanism(s) of 
resistance applies to different antimicrobials. 
Cut-off values: Microbiological cut-off values are defined for the purpose of distinguishing 
resistant from susceptible strains. Epidemiological cut-off values are used for surveillance, 
whereas clinical cut-off values are used to predict the effect of an antimicrobial in a clinical 
setting. More explanation in NORM-VET report 2014. 
Eukaryotes: Any organism having as its fundamental structural unit a cell type that 
contains specialized organelles in the cytoplasm, a membrane-bound nucleus enclosing 
genetic material organized into chromosomes, and an elaborate system of division by mitosis 
or meiosis, characteristic of all life forms except bacteria, blue-green algae, and other 
primitive microorganisms. Coccidia are eukaryotes. 
Genetic transmission of antimicrobial resistance: Between microbes is both ‘vertical’ 
(new generations inherit resistance genes) and ‘horizontal’ (bacteria share or exchange 
sections of genetic material with other bacteria, including bacteria of other species). 
Environmental spread of antimicrobial resistance takes place as the microbes move from 
place to place; via animals, persons, food and feed, water and wind, airplanes and cars, etc. 
Gram-negative bacteria: Most bacterial species can be differentiated into two large 
groups (Gram-positive and Gram-negative) based on the physical properties of their cell 
walls by bacteriological laboratory technique called Gram staining (developed by Hans 
Christian Gram in 1884). 
Intrinsic resistance: The inherent or innate ability of a microbial species to resist a 
particular antimicrobial agent. Intrinsic resistance occurs in organisms that have not been 
susceptible to that particular antimicrobial agent. 
In vitro: In an artificial environment, such as a test tube; not inside a living organism (Latin 
for “in glass”). 
In vivo: Being or occurring within a living organism or in a natural setting. 
Microbiota: Collective term for microflora (i.e., any type of microorganisms) that may be 
found within a given environment. 
Minimum Inhibitory Concentration (MIC): The lowest concentration of a given agent 
that inhibits growth of a microorganism under standard laboratory conditions. MIC data can 
provide information about the activity of antimicrobials. 
Pathogen: An agent that is capable of causing disease. Bacteria and coccidia may be 
pathogens. 
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Pathogenic: Capable of causing disease. 
Percentile: A common used term for visualising the low, medium and high occurrences of a 
measurement (e.g. acrylamide intake) by splitting the whole distribution into one hundred 
equal parts. The 95-percentile is the value (or score) below which 95 percent of the 
observations may be found. 
Prebiotics: Non-digestible food ingredients that beneficially affect the host by selectively 
stimulating the growth and / or activity of a limited number of bacterial species already 
resident in the colon, and thus attempt to improve host health. 
Probiotics: Live microorganisms which, when administered in adequate amounts, confer a 
health benefit on the host. 
Prokaryot: Any organism in which the genetic material is in a single DNA chain that is not 
enclosed in a nucleus. Bacteria are prokaryotes. 
Rotation progamme: A programme where the coccidiostats used are changed at regular 
intervals. 
Shuttle programme: Two or more coccidiostats are used during the grow-out of a poultry 
flock, e.g. one for starter and others for grower and finisher. 
Susceptibility: Describes the degree to which a target microorganism is affected by an 
antimicrobial agent. 
Synbiotic: Refers to nutritional supplements combining a mixture of probiotics and 
prebiotics in a form of synergism. The concept of synbiotics was proposed to “characterise 
some colonic foods with interesting nutritional properties that make these compounds 
candidates for classification as health-enhancing functional ingredients” (Gibson and 
Roberfroid, 1995). 
Therapeutic antibiotics: Antimicrobials used to treat clinical diseases caused by microbes, 
as opposed to antimicrobials used for prevention. 
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Background as provided by the 
Norwegian Food Safety Authority 
Coccidiostats are authorised for use as an additive in feed for chickens and turkeys. Eleven 
different coccidiostats have been authorised for use in the EU. Norway has been exempted 
from the EEA Agreement in this field and has approved only five. The reason is that these 
five were already in use in Norway when the EEA Agreement was signed in 1994. In the light 
of the extent of the production of poultry for slaughter at the time and Norway's restrictive 
approach to feed antibacterials and coccidiostats, exemption was granted from approval of 
the other coccidiostats that are authorised in the EU. 
Norwegian Food Safety Authority has discussed with the feed industry, relevant 
organisations and institutions to establish whether it would be appropriate to ask for the 
exemption for coccidiostats under the EEA Agreement to be repealed. The same enquiry was 
repeated to the Norwegian Ministry of Agriculture and Food in 2011. This would simplify our 
regulations and unify all the regulations concerning limit values for coccidiostats contents in 
feed and limits for permitted residual values in food. The feedback from the industry was 
largely that there was unlikely to be a professional basis for more/other coccidiostats than 
those that are currently permitted, but that it would be completely safe to use all those that 
had been authorised by the EU. Nevertheless, the Ministry of Agriculture and Food did not 
see the need for an amendment of the EEA Agreement on this matter. 
The EU intended to ban coccidiostats as a feed additive with effect from 2012. Trials were 
conducted in a number of European countries to identify alternative measures to reduce or 
prevent coccidiosis in poultry. The conclusion was that neither vaccination nor other 
measures tested could replace the use of coccidiostats in feed. Coccidiostats as a preventive 
measure to manage coccidiosis in commercial poultry farming are necessary for reasons of 
both animal health and animal welfare. The proposal to ban coccidiostats as a feed additive 
was therefore put on ice. Authorised coccidiostats are currently being evaluated by the EFSA 
for re-authorisation as and when the current authorisations expire. With regard to the 
coccidiostats approved in Norway, we will comply with the EU regulations in full. 
Recently concern has been raised that the use of coccidiostats in feed could result in the 
development of bacteria with antimicrobial resistance in both humans and animals. It is 
therefore necessary to evaluate whether, and potentially how, the use of coccidiostats in 
feed for poultry can contribute to an increased occurrence of bacteria with antimicrobial 
resistance. It would also be appropriate to evaluate whether there are differences between 
the various coccidiostats and the status of the use of those approved in Norway compared 
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with the others that have been authorised for use in the EU with regard to the development 
of potential antimicrobial resistance. 
The development of antimicrobial resistance is an increasing problem. Given the suggestions 
that the widespread use of coccidiostats as a feed additive for poultry might be a 
contributing factor to this development, it would be desirable to evaluate the 11 EU-
approved preparations with regard to potential development of antimicrobial resistance. 
Narasin is the active ingredient most commonly used in Norway and dominates broiler 
chicken production. In addition to acting as a coccidiostat, narasin has also been found to 
have an antimicrobial effect on gram-positive bacteria including enterococci, staphylococci 
and C. perfringens. The latter may cause necrotic enteritis in chicken, and narasin in feed h 
preventative effect. Gram-negative bacteria such as E. coli are resistant to narasin. For such 
reasons the use of narasin should be assessed separately. 
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Terms of reference as provided by the 
Norwegian Food Safety Authority 
1. To what extent can the 11 EU-authorised coccidiostats induce resistance and/or cross-
resistance in bacteria? 
2. To what extent can the 11 EU-authorised coccidiostats induce resistance in coccidia? 
3. Are there advantages or disadvantages associated with the development of resistance in 
bacteria under the current practice in Norway with only five coccidiostats available 
compared to the 11 EU authorised coccidiostats? 
4. Are there advantages or disadvantages associated with the development of resistance in 
coccidia under the current practice in Norway with only five coccidiostats available 
compared to the 11 EU authorised coccidiostats? 
5. What are the risks of antibacterial resistance being developed in and/or transferred to 
people (workers) handling coccidiostat preparations, feed, poultry, poultry meat or 
manure from poultry production using coccidiostat feed additives? If so, what risk-
reducing measures are available? 
6. What are the risks of antibacterial resistance being developed in and/or transferred to 
people (consumers) handling and eating meat from poultry production using coccidiostat 
feed additives? 
7. What are the risks of an increase in the therapeutic use of antimicrobials in poultry 
production under current production practices if coccidiostats with antibacterial effects 
are replaced by coccidiostats without such effects? 
8. Do alternative measures exist that can be employed to reduce the risk of coccidiosis in 
broiler chickens as effectively as coccidiostats? 
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Terms of Reference in Norwegian 
1. I hvilken grad har de 11 EU-godkjente koksidiostatika evne til å kunne fremme resistens 
og/eller kryssresistens hos bakterier? 
2. I hvilken grad har de 11 EU-godkjente koksidiostatika evne til å fremme resistens hos 
koksidier? 
3. Er det fordeler eller ulemper for utvikling av resistens hos bakterier med dagens praksis i 
Norge, der det er betydelig færre koksidiostatika (bare 5 preparater) å velge blant, 
sammenlignet med EU der 11 koksidiostatika er godkjent? 
4. Er det fordeler eller ulemper for utvikling av resistens hos koksidier med dagens praksis i 
Norge, der det er betydelig færre koksidiostatika (bare 5 preparater) å velge blant, 
sammenlignet med EU der 11 koksidiostatika er godkjent? 
5. Er det risiko for utvikling og/eller overføring av antibakteriell resistens hos mennesker 
som håndterer koksidiostatika-preparater, fôr, fjørfe, fjørfekjøtt eller gjødsel som følge av 
at fôr tilsatt koksidiostatika er brukt i fjørfeproduksjonen? I så fall hvilke risikoreduserende 
tiltak finnes? 
6. Er det risiko for utvikling hos og/eller overføring av antibakteriell resistens til mennesker 
som håndterer og spiser fjørfekjøtt som følge av at fôr tilsatt koksidiostatika er brukt i 
fjørfeproduksjonen? 
7. Er det risiko for økning i terapeutisk bruk av antibiotika i fjørfeproduksjonen, dersom en 
tilsetter koksidiostatika uten antibakteriell effekt i fôret? 
8. Hvilke tiltak er aktuelle for å redusere risikoen for koksidiose i slaktekyllingproduksjonen, 
slik at bruk av koksidiostatika blir unødvendig? 
  
 





1.1 Why is antimicrobial resistance a concern? 
An antimicrobial agent is a compound that can destroy or inhibit the growth of 
microorganisms. Both antibacterials and coccidiostats are antimicrobials, intended for use 
primarily against bacteria and coccidia, respectively. 
Antimicrobials revolutionized human as well as animal medicine in the 20th century by 
providing effective treatment of diseases caused by pathogenic microorganisms. However, 
microorganisms have the ability to develop antimicrobial resistant strains. The evolution of 
such strains is a natural phenomenon. This occurs when microorganisms replicate 
themselves erroneously causing mutations or when resistance traits are exchanged between 
them. The use of antimicrobial drugs accelerates the emergence of drug-resistant strains 
(http://www.who.int/mediacentre/factsheets/fs194/en/). 
Use of antimicrobials in food animals can create a source of antimicrobial resistant bacteria 
that can spread to humans by contact with such bacteria, either directly from the animals or 
through the food supply (Figure 1.1-1). Emergence of resistance in non-pathogenic bacteria 
does not pose an immediate threat to humans and animals. However, they may transfer 
their resistance genes to pathogenic bacteria and thereby reduce the possibilities of treating 
and managing infectious diseases. It is therefore important to keep the prevalence of 
resistant strains, pathogenic and non-pathogenic, as low as possible. 
WHO has classified antimicrobials according to their importance for human medicine 
(http://www.who.int/foodsafety/areas_work/antimicrobial-resistance/cia/en/). Antimicrobials 
classified as “critically important” should be reserved for treatment of severe infections in 
humans. A priority is therefore to safeguard the efficacy of antimicrobial drugs we depend on 
for treatment of infectious diseases in humans. Improved management of the use of 
antimicrobials in food animals on a world-wide basis, particularly reducing those critically 
important for human medicine, is recognized as an important step towards preserving the 
benefits of antimicrobials for people. 
 




Figure 1.1-1 Spread of resistant bacteria between different compartments in the society. The 
present assessment includes humans, poultry and poultry meat. 
1.2 Definition, development and spread of antimicrobial 
resistance  
Resistance against antimicrobials can be either intrinsic or acquired. Intrinsic resistance is the 
innate ability to resist activity of a particular antimicrobial agent in an organism that has 
never been susceptible to that particular drug. Acquired resistance can be defined as the 
capacity of a species or strain of microorganism to survive exposure to drug formerly 
effective against it, due to genetic mutation and selection for and accumulation of genes 
conferring protection from the agent (http://www.merriam-webster.com/medical/resistance). 
In this assessment the expression “resistance” refers to acquired resistance, unless 
specifically stated otherwise. 
The difference between “resistant” and “non-resistant” is not always clearly defined, and the 
terms “reduced susceptibility” or “reduced sensitivity” can therefore sometimes be 
scientifically more correct than “resistant”. However in this assessment, only the terms 
“resistance” and “resistant” will be used to ease readability. 
When microorganisms are exposed to an antimicrobial, any cells with random mutations in 
the DNA rendering them resistant to this antimicrobial will have a proliferative advantage 
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(Figure 1.2-1). Consequently, large numbers of this strain may rapidly arise. In the case of 
bacteria, the new resistant strain may also spread the resistance genes by horizontal gene 
transfer to other strains, from the same species but also from other bacterial species. Of 
particular concern is the development and spread of antibacterial resistance in pathogenic 
bacteria, and especially when they become resistant to multiple antibacterials.   
 
Figure 1.2-1 Development and spread of antibacterial resistance in the intestine of both humans 
and animals. 
Exposure to one antimicrobial may also render the microorganism resistant to other 
antimicrobials through cross-resistance and co-resistance. Cross-resistance occurs when the 
bacteria can use the same resistance mechanism against several antibacterials. Co-resistance 
can occur when mechanisms encoding resistance are genetically linked. Bacterial resistance 
genes are frequently contained in larger, often transferable, genetic elements, and as such 
may be ‘linked’ to other, unrelated resistance genes. In such cases, multiple resistance genes 
may be transferred in a single event, meaning that selection for one resistance gene will also 
select for the other resistance gene(s). 
Co-resistance between antibacterials and disinfectants has also been observed, e.g. for 
quaternary ammonium compounds (qac) and sulphonamide in Gram-negative bacteria 
(Sidhu et al., 2002). Furthermore, use of zinc and copper in animal feed has been linked to 
development of antibacterial resistance in bacteria. Resistance to zinc is often linked with 
resistance to methicillin in staphylococci, and resistance to is often associated with resistance 
to antibacterial drugs like macrolides and glycopeptides (e.g. vancomycin) (Yazdankhah et 
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al., 2014).The cross- and co-resistance between coccidiostats and disinfectant agents as well 
as metals with antibacterial properties have not been evaluated in this assessment. 
Experiments suggest that the use of antibacterial agents may also indirectly be associated 
with development of resistance through disturbances in the ecologic balance of the intestine, 
as indicated in Norwegian studies on horses, dogs and calves (Gronvold et al., 2010a; 
Gronvold et al., 2010b; Gronvold et al., 2011). Furthermore, in an overview article by Rice 
(2013) the author suggests that the spread of glycopeptide resistance in enterococci is 
promoted by the administration of non-glycopeptide. 
1.3 General information on coccidia 
Coccidia (Coccidiasina) constitute a subclass of microscopic, spore-forming, single-celled, 
eukaryote parasites with a complex structure and life cycle. They are obligate intracellular 
parasites, meaning that they must reproduce within a host cell. Almost all livestock can be 
affected by different types of coccidia. Poultry are infected by coccidia of the genus Eimeria. 
These are generally host-specific, and the different species parasitize specific parts of the 
intestinal tract. There are seven different Eimeria species that infect chicken ‒ E. acervulina, 
E. brunette, E. maxima, E. mitis, E. necatrix, E. praecox, and E. tenella ‒ and six that infect 
turkey ‒ E. adenoeides, E. dispersa, E. gallopavonis, E. innocua, E. meleagridis, E. 
meleagrimitis, and E. subrotunda. There are large variations in pathogenicity of the different 
Eimeria species. 
Unless otherwise noted, the term “coccidia” in this assessment is used to describe coccidia of 
the genus Eimeria which can infect poultry. 
The life cycle of Eimeria in poultry (Figure 1.3-1) takes place partly outside and partly inside 
the host, in which the latter is where both asexual and sexual stages of reproduction occur. 
It begins when active oocysts are picked up by the bird and swallowed. An oocyst is a 
capsule with a thick wall protecting the parasite eggs. Each oocyst has four sporocysts in it, 
and each sporocyst contains two sporozoites. In the digestive tract, the eight sporozoites are 
released from the oocyst, and they move into the epithelial cells lining the digestive tract 
where they develop into trophozoites. Within the host cells, the trophozoites undergo 
asexual reproduction to produce merozoites, which when released from the damaged 
epithelial cell can in turn penetrate other healthy epithelial cells causing further tissue 
damage. There may be several generations of asexual multiplication. However, this stage is 
self-limiting and eventually stops. A sexual stage then occurs at which the merozoites in host 
cells differentiate into either male (microgamonts) or female (macrogamonts) forms. The 
microgamonts divide to form microgametes, which fertilize the macrogamonts leading to the 
development of oocysts which are shed in the faces. 
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In the environment outside the host, fresh oocysts are not infective until they have 
sporulated. Under optimal conditions (20 – 30 °C with adequate moisture and oxygen), this 
requires 1–2 days. Once sporulated, the oocyst remains infective for months if protected 
from very hot, dry, or freezing conditions. Chickens pick them up by pecking on the ground 
or litter used for bedding in the house. 
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1.4 Coccidiosis in poultry 
Coccidiosis is a term used for intestinal health problems caused by several species of 
protozoan parasites of the genus Eimeria. Damage to the host is caused by the reproduction 
of the parasite in the intestinal epithelial cells. Pathogenicity is influenced by host genetics, 
nutritional factors, concurrent diseases, age of the host, and species of the coccidium 
(http://www.merckmanuals.com/vet/poultry/coccidiosis/overview_of_coccidiosis_in_poultry.h
tml).  
In chicken, signs of coccidiosis range from decreased growth rate to a high percentage of 
visibly sick birds with severe diarrhoea, and high mortality. Feed and water consumption are 
depressed. Eimeria necatrix and Eimeria tenella are the most pathogenic in chickens. Mild 
infections by Eimeria species, which would otherwise be classified as subclinical, may cause 
depigmentation and can potentially lead to secondary infection, particularly by Clostridium 
spp. Infection (for more details see section 1.6). 
Common signs of coccidiosis in infected turkey flocks include reduced feed consumption, 
rapid weight loss, droopiness, ruffled feathers, and severe diarrhoea. Wet droppings with 
mucus are common. Clinical infections are seldom seen in poults >8 wk old. Morbidity and 
mortality may be high. 
Most of the damage is done by the time signs of coccidiosis are widespread in the flock. This 
is the rationale behind the preventive medication (in-feed coccidiostats) that is common 
practice in conventional broiler and turkey rearing. 
1.5 General information on bacteria 
Bacteria are microscopic, single-celled organisms. They are prokaryotes, meaning that the 
DNA is not enclosed in a nuclear membrane, but resides in a nuclear region of the cell. 
Bacterial cells multiply by cell division, which may occur as often as approximately every 
twenty minutes under optimal conditions. 
Bacteria may well be the most successful life form on Earth when it comes to survival. 
Bacterial ancestors appeared approximately 3.5 billion years ago. Today there are estimated 
to be approximately 5×1030 bacteria on Earth (Whitman et al., 1998), forming a biomass 
which exceeds that of all plants and animals and appearing in almost any man-made or 
natural environment, including in soil, water and the atmosphere, as well as on and inside 
living organisms. 
The key to such success is the ability of bacteria to undergo rapid genetic adaptation to 
changing environments. This is mediated by mutations in the DNA and by horizontal gene 
transfer, which is defined as the exchange and stable integration of genetic material 
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between different strains or species (Doolittle, 1999). Various mechanisms for antimicrobial 
resistance are demonstrated in Figure 1.5-1, and mechanisms for gene transfer are 
described in Figure 1.5-2. 
The microbiota associated with humans and animals represent a complex assemblage of 
microorganisms covering all three domains of life (Bacteria, Archaea and Eukarya) (Ley et 
al., 2008). All body sites are colonized, with the lower gastrointestinal tract being the most 
densely populated. In number of cells, the microbiota generally outnumbers the host by a 
factor of 10. Therefore, the gut microbiota can be considered an organ in itself (O'Hara and 
Shanahan, 2006). 
Most bacterial species can be differentiated into two large groups ‒ Gram-positive and Gram-
negative ‒ based on the physical properties of their cell walls by a bacteriological laboratory 
technique called Gram staining developed by Hans Christian Gram in 1884. Due to the 
thicker cell wall of the Gram-negative bacteria, these are in general more inherently resistant 
to antibacterials than the Gram-positive bacteria. Most pathogenic bacteria are Gram-
negative. 
 
Figure 1.5-1 Examples of mechanisms used by bacteria to resist antibacterials. 
  
 




Figure 1.5-2 Main mechanisms used to transfer resistance genes between bacteria. 
1.6 Relevant bacterial infections in poultry 
Necrotic enteritis is caused by the intestinal bacterium Clostridium perfringens (C. 
perfringens). This bacterium is commonly found in caecal contents, but will under certain 
conditions start proliferating and producing toxins in the small intestine where damage is 
inflicted. Coccidial infection is considered the most important predisposing factor for necrotic 
enteritis. The interplay between coccidia and C. perfringens is therefore very important. As 
for coccidiosis, most of the damage is done by the time the clinical signs are widespread. 
The clinical form of necrotic enteritis causes diarrhoea and decreased appetite or anorexia, 
as well as signs associated with lethargy, such as ruffled feathers, relative immobility, and 
depression. Mortality rates can be up to 50%. In subclinical forms of necrotic enteritis there 
is no marked increase or peak in mortality and no clinical signs are present. Impaired 
production performance (growth and feed utilisation) is a main consequence of both sub-
clinical and clinical forms of coccidiosis and necrotic enteritis, as are poor quality of the litter 
bedding and adverse environmental conditions to the detriment of the birds’ welfare. 
Treatment requires the use of antibacterials, specifically penicillin, which is of importance to 
human medicine and its use should therefore be kept to a minimum in order to maintain the 
efficacy. Hence, prevention of both diseases is considered a better course of action than 
treatment. The Norwegian broiler industry has experienced three necrotic enteritis epidemics 
in the early 1970’s, mid-80’s and mid-90’s. The disease has been under control since the 
mid-90’s when narasin was introduced as an in-feed coccidiostat. Narasin is an ionophorous 
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coccidiostat which also exerts effect against Gram-positive bacteria including C. perfringens, 
the causative agent of necrotic enteritis. 
Gizzard erosion and ulceration syndrome (GEU) has been identified as a health 
problem in chickens since the early 1930’s. The gizzard mucosa becomes inflamed. Several 
causative factors have been suggested by Gjevre et al. (2013), including nutritional 
deficiencies, a toxin (gizzerosine) found in fish meal, and infection by C. perfringens and 
certain strains of Fowl adenovirus 1 (FAdV-1). All of these factors may play a part in the 
pathogenesis, but recent research suggests that FAdV-1 is an important primary pathogen 
(Grafl et al., 2012; Ono et al., 2003). The severity of GEU has been shown to be associated 
with intestinal counts of C. perfringens (Novoa-Garrido et al., 2006). GEU may therefore be a 
predisposing factor for necrotic enteritis. The ionophorous coccidiostat narasin does not 
prevent the emergence of GEU, but does reduce the severity of the gizzard lesions 
(Kaldhusdal et al., 2012). The majority of GEU cases are subclinical and impair production 
performance (Grafl et al., 2012), like most cases of coccidiosis and necrotic enteritis. 
Enterococcus hirae is an intestinal bacterium that has been associated with growth 
depression, septicemia, right-sided endocarditis, focal brain necrosis (encephalomalacia) and 
osteomyelitis in broilers. In many cases encephalomalacia causes locomotion problems and 
mortality towards the end of the first week after hatch, whereas the endocarditis is more 
typically found later on in the grow-out period. E. hirae shows biochemical characteristics 
that are between Enterococcus faecium and Enterococcus durans (Thayer and Waltman, 
2013). Clinical disease associated with E. hirae has been detected in Norwegian broilers 
offered in-feed narasin. This disease emerged as a problem in Norwegian broilers around 
year 2000, but does not appear to have been of major significance during recent years. 
1.7 Antimicrobial resistance testing 
 Bacteria resistance testing 1.7.1
The degree of antibacterial resistance is commonly measured as Minimum Inhibitory 
Concentration (MIC), i.e. the lowest concentration of a given agent that inhibits growth of a 
defined number of the microorganisms under standard laboratory conditions. 
To distinguish resistant from susceptible strains, microbiological cut-off values (also called 
break point values) are defined. So-called epidemiological cut-off values are used for 
surveillance, whereas clinical cut-off values are used to predict the effect of an antimicrobial 
in a clinical setting. In the present assessment, only epidemiological cut-off values are used. 
These are the MIC- values for each antibacterial agent that distinguishes wild-type 
populations of bacteria from those with acquired or selected resistance mechanisms. For 
more information on cut-off values; see (NORM/NORM-VET, 2014). Depending on the test 
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system, a cut-off value is given as either a concentration (in mg/L or μg/ml) or a zone 
diameter (in mm). Cut-off values for an antibacterial agent may differ between different 
bacterial species. The European Committee on Antimicrobial Susceptibility Testing - EUCAST 
gives recommendations for cut-off values to be used. 
Surveillance of antibacterial resistance in animals and animal products include testing of both 
pathogenic bacteria, as well as commonly occurring bacteria that normally are non-
pathogenic. The Gram positive bacterial species Enterococcus faecalis (E. faecalis) and 
Enterococcus faecium (E. faecium) are commonly used intestinal bacteria to monitor 
antibacterial resistance in animals, including poultry. 
 Coccidia resistance testing 1.7.2
Coccidiostat resistance of coccidia field isolates is studied by the use of either in vivo or in 
vitro assays. In vivo anticoccicial sensitivity testing (AST) is a well-known technique to assess 
resistance of a certain coccidial isolate to different coccidiostats (Chapman, 1998; McDougald 
and Reid, 2003; Naciri et al., 2003; Peek and Landman, 2003). The assay requires the 
diagnostic slaughtering of a large number of chickens in order to determine the efficacy of 
the coccidiostats. Although a valid method for a certain isolate, this technique is not routinely 
used. The main reasons are the long duration and very high cost associated with the 
complicated, in vivo character of the test. The short period of testing (around six days) 
without allowing the initially naive birds to recover from an artificially high infective dose 
makes interpretation of the results complicated. However, in a review paper devoted to 
coccidiostat resistance in fowl coccidia, Abbas et al. (2011) cited the definition of resistance 
in the broad terms as given by the World Health Organization (1965): the ability of a 
parasite strain to survive and/or to multiply despite the administration and absorption of a 
drug given in doses equal to or higher than those usually recommended but within the limits 
of tolerance of the subject. Several authors have also described in vitro culture systems for 
studying invasion and development of Eimeria tenella  in the presence of ionophore drugs 
and other compounds These assays are based on counting intracellular sporozoites after 
fixation and staining of the E. tenella-infected cell monolayer. More modern methods of 
quantification are currently being studied, e.g. the use of quantitative PCR. 
1.8 Norwegian chicken and turkey production 
In Norway poultry meat production consist mainly of chicken (broiler) and turkey and a 
relatively small production of ducks. Geese and other species are of marginal importance in 
this assessment. The commercial poultry production has developed extensively in Norway 
during the last years. The chicken meat production has increased from 69 375 tonnes in 
2009 to 91 931 tonnes in 2013, the turkey production is stabilised at approximately 10 000 
tonnes in the same period while the duck production increased from 355 tonnes to 593 
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tonnes (Animalia, 2014). Since anti-coccidials are not used in duck feed, this production is 
not mentioned further in this document. 
The amount of organic poultry meat production of 83 tonnes for chicken and 130 tonnes for 
turkey is only 0.21% of the total poultry meat production (Animalia, 2014). Organic poultry 
meat production is done without the use of coccidiostats. 
The amount of poultry production without the use of coccidiostats has until 2015 been 
limited to the production of selected broiler brands in a few farms. Compensatory measures 
in these flocks has been limited to reduced animal density in early life, feeding that reduces 
energy intake and restricts growth, enrichment of the environment etc. Vaccination against 
coccidiosis has been used to some degree.  
Organic broilers have been produced according to EU legislation that includes restrictions 
according to age, density, feed and environment. Organic broilers are vaccinated against 
coccidiosis. 
The need for in-feed coccidiostats in poultry feed has been under investigation by the 
Norwegian poultry industry for several years. Different trials with different remedies have 
been performed, but no measures have been suggested that can compete with coccidiostats 
with regard to feed efficacy, animal health or –welfare (Kaldhusdal, 2006). 
In 2015 there has been a general commercial demand for broilers that are raised without the 
use of coccidiostats. High quality standard of management practices and feed combined with 
general good health status and vaccination against coccidiosis seems to be factors that now 
allows for Norwegian broiler production without the routine use of in-feed coccidiostats. (Atle 
Løvland, Nortura, personal communication). 
A study based on data from 2000 to 2004 produced data suggesting that at least 25 % of 
Norwegian broiler flocks were coccidia negative. However, the data suggested an increasing 
trend in the prevalence of infected flocks (Haug et al., 2008). 
Import to and export from Norway of poultry products varies with the market situation in 
Norway. Currently, there is no import but some export. 
1.9 The role of in-feed coccidiostats in broiler rearing 
A specialised broiler production first evolved in the USA, beginning with the rearing of single 
purpose meat type chickens in the 1920’s and developing further with separate hatcheries, 
feed-mills, farms and processing plants during the 1930’s and 1940’s 
(http://www.poultryegginstitute.org/educationprograms/PandEP_Curriculum/Documents/PDF
s/Lesson2/HistoryofPoultryProductionver3Pres.pdf). Intestinal disease, usually ascribed to 
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coccidiosis, was identified as an important problem from the start of the industry. Initially the 
problem was controlled through treatment of outbreaks of clinical disease, mainly by means 
of sulphonamides. Gradually the concept of preventive medication emerged with the 
realization that most of the damage is done by the time signs of intestinal disease is 
widespread in a flock. Preventive medication was implemented through routine incorporation 
of coccidiostats in broiler feeds. This routine was firmly established in 1948, when 
sulfaquinoxaline was introduced commercially as a poultry coccidiostat (Campbell, 2008). 
Sulfaquinoxaline was initially developed and tested for use in human medicine, but proved 
too toxic for humans. 
The sulphonamides were introduced into human medicine in the 1930s. New types of 
antimicrobials were developed during the 1940’s. These new substances were mostly 
produced by a microorganism and were antagonistic to the growth of other microorganisms 
in high dilution. The term ‘antibiotic’ was coined for these substances. Some of these new 
drugs were tested for efficacy against diseases in animals.  During such experiments it was 
found that some substances (e.g. chlortetracycline produced by Streptomyces aureofaciens); 
(Castanon, 2007) could enhance the growth and feed efficiency of chickens, and in 1951 the 
United States Food and Drug Administration approved the use of antibacterials as animal 
additives without veterinary prescription. Similar approvals were given in European countries 
during the 1950’ and 1960’s. This group of substances was named ‘antibiotic growth 
promoters (AGP)’. 
Whereas the coccidiostats were approved as a preventative medication against a specific 
disease problem such as intestinal coccidiosis, the use of AGPs was not based on efficacy 
against a specific disease, but rather that these substances improved production 
performance. It is, however, clear that researchers observed mitigating effect of AGPs on 
diarrhoea, and even suspected that the positive effects of these substances might be 
associated with their suppressive effect on the intestinal bacterium C. perfringens (Bakke et 
al., 1954). These observations preceded the detection of the important intestinal disease 
necrotic enteritis, which was described in its clinical form in 1961 (Parish, 1961) and its 
subclinical form in 1992 (Kaldhusdal and Hofshagen, 1992).  
The introduction of preventive in-feed medication during the late 1940s and early 1950s can 
be seen as an essential technological component in the development of the new broiler 
industry. It has been claimed that the anticoccidial drug sulfaquinoxaline ‘played an 
important part in the demotion of roast chicken from vaunted Sunday-dinner status to an 
unexpected position on the everyday menu of the Western world’ (Campbell, 2008). The 
AGPs were likely to play a similar part in this process, at least during the first decades of the 
industry’s history. 
Both AGPs and coccidiostats are antimicrobial agents, but they are grouped separately 
according to the microorganisms they act primarily against. In some cases a compound 
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belonging to one of these categories may also exert an effect against several types of 
microbes. The ionophorous coccidiostats such as narasin is an example of a group of 
compounds with efficacy against coccidia as well as bacteria.  
The Norwegian broiler industry was established during the 1960’s and 1970’s. Whereas 
tetracyclines as antibacterial growth promoters were included in Norwegian broiler feed 
already during the 1960’s, coccidiostats (amprolchloride) were not introduced until 1972. 
From 1972 both coccidiostats and antibacterial growth promoters were used routinely in 
Norwegian broiler feeds until 1995, when the broiler industry implemented a voluntary 
abolishment of the use of antibacterial growth promoters (Grave et al., 2004). 
The emergence of bacterial strains resistant to antibacterials was of concern to researchers 
already during the 1950 and 1960s (Anonymous, 1968; Bakke et al., 1954) published a 
report recommending that antibacterials used for disease treatment in human and veterinary 
medicine should not be used as growth promoters. Specifically, it was recommended that the 
use of penicillins, tetracyclines, tylosin, and sulfonamides as growth promoters be 
discontinued. This policy was implemented in Norway in 1972. 
However, in the 1990’s it was discovered that the antibacterial (avoparcin) used only for 
growth promotion in animals could confer cross-resistance to vancomycin (Grave et al., 
2004), an antibacterial on the World Health Organization’s List of Essential Medicines 
(http://www.who.int/medicines/publications/essentialmedicines/18th_EML_Final_web_8Jul13
.pdf , http://en.wikipedia.org/wiki/Vancomycin, 
http://en.wikipedia.org/wiki/WHO_Model_List_of_Essential_Medicines ). On this background 
avoparcin was banned in Norway from May 31, 1995. The avoparcin case demonstrated that 
avoiding the use of antibacterials that are used for treatment of diseases in humans or 
animals is not enough to prevent induction of antibacterial resistance that can endanger 
animal or human health. It is also crucial that substances used in animal feeds cannot confer 
cross-resistance to antibacterials of therapeutic importance. 
Avoparcin had been introduced in 1987, following an epidemic of necrotic enteritis in the 
Norwegian broiler population. The epidemic disappeared following the introduction of in-feed 
avoparcin in 1987, but necrotic enteritis reappeared as a severe disease problem shortly 
after the avoparcin ban in 1995. As a response to this development, the ionophorous 
coccidiostat narasin was approved for use in broiler feeds as from November 1995. Narasin 
was introduced because of the beneficial effect of this substance against C. perfringens and 
necrotic enteritis, as evidenced by experience from Sweden, where AGPs had been banned  
and narasin was used as the only in-feed medication as from 1990. The introduction of 
narasin in the broiler feed in Norway was followed by a gradual decline in prevalence of 
necrotic enteritis during 1996-98 (Lovland and Kaldhusdal, 2001), and the prevalence has 
remained low since then. 
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In 2003, the European Union banned the use of antibacterials as growth promoters 
(Regulation (EC) No 1831/2003), which was implemented from 2006. In Article 11 of this 
regulation, the European Union states that the use of coccidiostats as feed additives should 
be evaluated by December 2012. However, in 2008, the European Commission submitted a 
report on the use of these substances as feed additives and existing alternatives to the 
Council and the European Parliament 
(http://www.ipex.eu/ipex/cms/home/Documents/dossier_COM20080233). In this report, the 
European Commission recommended maintaining the current legislation and allows the use 
of coccidiostats, including ionophores, as feed additives because of the lack of alternatives 
and to preserve the economic viability of the poultry industry. Therefore, the use of in-feed 
coccidiostats is still approved. 
1.10 The role of in-feed coccidiostats in turkey rearing 
Turkeys are susceptible to the same kind of intestinal diseases as broiler chickens, and 
antibacterial growth promoters and coccidiostats have also been added to turkey feeds. The 
use of antibacterial growth promoters was abolished in turkey feeds in the same way as in 
broiler feeds (in 1995 in Norway, in 2006 in the EU). The transitional time period following 
the abolishment of growth promoters was characterised by an increased prevalence of 
clinical and subclinical necrotic enteritis. As mentioned above, these problems disappeared in 
the Norwegian broiler industry shortly after the introduction of the in-feed coccidiostat 
narasin. However, this compound cannot be used in turkey feeds, because narasin (and 
salinomycin) is too toxic to turkeys (Markiewicz et al., 2014). Necrotic enteritis has remained 
a challenge to the Norwegian turkey industry. However, the causes of persisting problems 
with necrotic enteritis in turkeys are unknown. Monensin is used most extensively as an in-
feed coccidiostat for Norwegian turkeys. Practical experience from Sweden and Norway 
suggests that narasin efficiently prevents necrotic enteritis in broilers. Monensin (Watkins et 
al., 1997) and lasalocid (Lanckriet et al., 2010), however, appear to have slightly higher 
minimum inhibitory concentration (MIC) values than narasin for C. perfringens, the causative 
agent of necrotic enteritis. 
1.11 Coccidiostats included in the present assessment 
The coccidiostats can be divided into two main groups; ionophores and non-ionophores, see 
Table 1.11-1 for overview. Ionophores are originally fermentation products of Streptomyces 
and other fungi species. Non-ionophore coccidiostats are most often chemically synthesised, 
and are thus sometimes referred to as “synthetic” or“chemicals”. One important difference 
between the two groups is that most of the ionophores display antibacterial effects. 
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Table 1.11-1  Coccidiostats used as poultry feed additives to control coccidiosis 
Compound Active 
substance 
Antibacterial activity Approved 
in Norway 





Active against Gram-positive 










Active against Gram-positive 





Active against Gram-positive 





Has limited antibacterial activity 
against Gram-negative 
microorganisms tested, and a 
minimal activity against selected 






No known antibacterial effect No 
Diclazuril No substantial antibacterial 
activity 
No 
Decoquinate Most tested strains of bacteria 
appear resistant to the effects of 
decoquinate at concentrations of 
> 64 mg /-1, substantially higher 
than the concentration of 
decoquinate expected in the 
digestive tract 
No 
Halofuginon No known antibacterial effect No 
Nicarbazin No known antibacterial effect No 
The ionophores are currently only used in animals, where they are considered “critically 
important in poultry” by OIE, the reason being that: “Ionophores are essential for animal 
health because they are used to control intestinal parasitic coccidiosis (Eimeria spp.) where 
there are few or no alternatives available” 
(http://www.oie.int/fileadmin/Home/eng/Our_scientific_expertise/docs/pdf/Eng_OIE_List_an
timicrobials_May2015.pdf). On the other hand, none of the ionophores are listed as “critically 
important”, “highly important” or “important” for use in human medicine, according to the 
WHO listing (http://www.who.int/foodsafety/areas_work/antimicrobial-resistance/cia/en/). 
 




According to EFSA (2004c), narasin is a polyether ionophore that exhibits both antibacterial 
and anticoccidial activities. It is used to prevent coccidiosis in poultry. 
Narasin, as other polyether ionophores, is effective against sporozoites and early and late 
asexual stages of coccidia in the intestine of the chicken. The biological activity of 
ionophores/narasin is based on their ability to form lipid soluble and dynamically reversible 
complexes with cations, preferably monovalent cations such as the alkaline ions K+, Na+ and 
Rb+. They function as carriers by mediating an electrically neutral exchange-diffusion type of 
cation transport across the membranes. The resultant changes in transmembrane ion 
gradients and electrical potentials produce critical effects on cellular function and metabolism 
of coccidia. 
Narasin is mainly active against Gram-positive bacteria. 
 Lasalocid sodium 1.11.2
According to EFSA (2004f), lasalocid belongs to the divalent polyether ionophore family. It is 
a feed additive for chickens for fattening (broilers) and chickens reared for laying. 
Lasalocid sodium, as for other ionophores, has different ionic affinities, binding divalent 
cations as well as monovalent ions, increasing their passage through biological membranes. 
This leads to the disruption of the normal physiological processes of cells. 
Coccidial sporozoites exposed to lasalocid sodium in the intestinal lumen exhibit considerable 
swelling, large vacuoles, pitting and holes in the surface suggesting extreme and potentially 
lethal osmotic damage. Any ionophore accumulated while coccidia sporozoites are exposed 
in the intestinal lumen continues its disruptive effects after host cells are invaded. 
Consequently, lasalocid sodium can selectively destroy intracellular sporozoites while 
remaining relatively non-injurious to the host cell. 
One study on rat, reported that lasalocid stimulated release of catecholamines from 
pheochromocytoma and this effect may be dependent on increasing intracellular Ca2+ 
(Perlman et al., 1980). 
Lasalocid sodium is active against Gram-positive bacteria, but not against Gram-negative 
bacteria. 
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 Monensin sodium 1.11.3
According to EFSA (2004e), monensin sodium is a polyether ionophore that exhibits both 
antibacterial and anticoccidial activities. It is a feed additive used to control coccidiosis in 
chickens for fattening (broilers), fattening turkeys and replacement layers. 
Monensin sodium acts as an ionophore, i.e. a chemical substance that complexes 
monovalent cations and facilitates the transport of the bound ion through biological 
membranes. Coccidial sporozoites exposed to monensin sodium in the intestinal lumen 
exhibit considerable swelling, large vacuoles, pitting and holes in the surface suggesting 
extreme osmotic damage which is potentially lethal. Development of a sporozoite that 
successfully invades a host cell is inhibited as the ionophore continues its destructive 
process. Monensin sodium selectively destroys intracellular sporozoites while remaining 
relatively non-injurious to the host cell (Chapman, 1993). It has been shown that monensin 
sodium has an effect on second generation merozoites but not upon developing 
gametocytes. 
Monensin sodium is primarily coccidiocidal in action and active against Eimeria acervulina, E. 
brunetti, E. maxima, E. mivati, E. necatrix and E. tenella of the chicken and E. melagrimitis, 
E. pallida, E. dispersa and E. adenoeides of the turkey. 
Monensin sodium is active against Gram-positive bacteria, but not against Gram-negative 
bacteria. 
 Salinomycin sodium 1.11.4
According to EFSA (2004d), salinomycin sodium is a monocarboxylic polyether ionophore 
with both antibacterial and anticoccidial effects. It is a feed additive used for control of 
coccidiosis in chickens for fattening. 
Salinomycin (SAL) is effective against sporozoites, and early and late asexual stages of 
coccidia in the intestine of the chicken. The biological activity of SAL is based on the ability of 
the ionophores to form lipid soluble, dynamically reversible complexes with mono- and 
divalent cations (preferably the alkali ions K+, Na+ and Rb+). SAL encloses the cation in a 
hollow ball, in the center of which the cation is fixed and immobilised. It functions as a 
carrier by mediating an electrically neutral exchange-diffusion type of cation transport across 
the membranes. The resultant changes in transmembrane ion gradients and electrical 
potentials often produce profound effects on cellular function and metabolism.  
SAL-Na is active against Gram-positive bacteria, but not against Gram-negative bacteria. 
 




According to EFSA (2011), maduramicin is a polyether ionophore. It is intended to be used to 
control coccidiosis in chickens for fattening. 
Maduramicin is considerably more potent as a coccidiostat than the other polyether 
ionophores that are used as coccidiostatic feed additives. These compounds are branch-
chained, polyoxygenated carboxylic acids that act as mobile carriers of cations by rendering 
cations lipid-soluble, thereby enabling them to pass across membranes. This process disrupts 
cationic cross-membrane gradients and is responsible for their anticoccidial activity. 
Maduramicin is active against Gram-positive bacteria, but not against Gram-negative 
bacteria. 
 Semduramicin sodium 1.11.6
According to SCAN (2002), semduramicin sodium is a monocarboxylic acid polyether 
ionophore. It is used to control coccidiosis in chickens for fattening. 
These compounds are branch-chained, polyoxygenated carboxylic acids that act as mobile 
carriers of cations by rendering them lipid-soluble, thereby enabling them to pass across 
membranes. This process disrupts cationic cross-membrane gradients and is responsible for 
their anticoccidial activity. 
Effect on bacteria: According to FDA semduramicin, an ionophorous agent, had no 
remarkable activity against Gram-negative microorganisms tested, and activity against 
selected Gram-positive control organisms was minimal 
(http://www.fda.gov/downloads/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/F
OIADrugSummaries/ucm062337.pdf). 
 Robenidine hydrochloride 1.11.7
According to EFSA (2004a), robenidine hydrochloride is a chemically synthesized substance. 
It is used to control coccidiosis in chickens for fattening and turkeys. 
Robenidine hydrochloride activity against Eimeria results from dual action exerted upon 
different stages of the parasite as it develops in the intestinal mucosa. Initially it acts as a 
coccidiostat and arrests the development of the first schizont generation. Secondly, 
robenidine hydrochloride is coccidiocidal, killing the second generation of schizonts and 
possibly the merozoites. 
The compound has no known antibacterial effect. 
 




According to EFSA (2010), diclazuril is a synthetic compound of the triazinone family. It is 
used to control coccidiosis in chickens for fattening. 
The exact mode of action of Diclazuril is not known but it has a potent coccidicidal action on 
some Eimeria strains (E. tenella and E. acervulina) and coccidiostatic action on others. 
According to the anticoccidial properties of triazinones, diclazuril is active against intracellular 
development stages of coccidia, namely during schizogony and gametogony. 
Diclazuril possesses negligible antifungal and no antibacterial activity at 100 µg/ml (Van 
Cutsem and Ribbens-Pavella, 1985). Diclazuril has no substantial antibacterial activity (EFSA, 
2014). 
 Decoquinate 1.11.9
According to EFSA (2003a), decoquinate is a 4-hydroxyquinoline, manufactured chemical 
synthesis. It is used to control coccidiosis in chickens for fattening. 
Based on data obtained from clinical studies, decoquinate is thought to act by arresting the 
development of sporozoites following their penetration of the gut epithelium. The degree of 
damage to the gut in terms of lesions is significantly reduced and oocyst output is also 
reduced. Decoquinate significantly inhibits mitochondrial respiration and electron transport in 
Eimeria. 
Most strains of bacteria appear resistant to the effects of decoquinate at concentrations of > 
64 mg l-1, substantially higher than the concentration of decoquinate expected in the 
digestive tract. 
 Halofuginone 1.11.10
According to EFSA (2003b), halofuginone hydrobromide is a synthetic derivate of an alkaloid 
originally isolated from an Asiatic plant, Dichroa febrifuga Lour. It is used to control 
coccidiosis in chickens for fattening and turkeys. 
Halofuginone hydrobromide (HBR) acts especially on the 1st
 
generation schizonts early after 
sporozoite invasion. HBR has a coccidiocidal activity against Eimeria maxima and Eimeria 
tenella. 
The compound has a cryptosporidiostatic effect on Cryptosporidium parvum. It is mainly 
active on the free stages of the parasite (sporozoïte, merozoïte). 
The compound has no known antibacterial effect. 
 




According to EFSA (2008g), nicarbazin is a non-ionophoric synthetic complex composed of an 
equimolar amount of 4,4’-dinitrocarbanilide (DNC) and 2-hydroxy-4,6-dimethylpyrimidine 
(HDP). It is used to control coccidiosis in chickens for fattening. 
Nicarbazin acts primarily by inhibiting the further development of the 2nd
 
generation and, to a 
lesser extent, 1st
 
generation schizont stage of Eimeria spp. parasites. The anticoccidial effect 
of nicarbazin was shown to be mediated to a large extent by its systemic absorption. 
The compound has no known antibacterial effect. 
1.12 Coccidiostat in-feed control programmes 
Various programmes are applied to prevent or delay development of coccidiostat resistance 
in coccidia (http://www.omafra.gov.on.ca/english/livestock/poultry/facts/coccidiosis.htm). 
Continuous program means that the same coccidiostat(s) are used indefinitely, usually 
until a problem develops, or until a new product is introduced on the market. This type of 
programme is used in Norway. 
Shuttle refers to the use of two or more products during the grow-out of a flock. The 
principle of shuttles is that the best drug is used for each phase of the grow-out i.e. most 
suitable coccidiostat is used for starter, while another coccidiostats are used for grower and 
finisher. Non-ionophore coccidiostats usually follow ionophores. This is to prevent late cycling 
of coccidiosis in the grow-out. 
Rotation means that a conscious decision is made to change the drug(s) used at a given 
time in the future i.e. every four months, after two crops etc. Shuttle programs may fit into 
rotation programs i.e. a decision may be made to use a shuttle program (coccidiostat A and 
B) for the summer. For the winter program other coccidiostats may be used in a shuttle, or 
only one coccidiostat. The key aspect of rotations is to alternate drug chemistries i.e. non-
ionophore coccidiostats follow ionophores. Use of two ionophores back to back in a rotation 
is unlikely to give desired results. Vaccines can also be included in a rotation programme. 
Clean-up program If coccidiocidal, non-ionophores coccidiostats can be used in order to 
reduce the infection pressure of coccidiosis (De Iguassu, 2005), in a so-called clean-up 
program. To achieve this, non-ionophore coccidiostats are preferably used during a complete 
grow-out, a so-called full program. Some producers do not, in order to limit risk of 
resistance, use non-ionophore coccidiostats in full program, but switch from one non-
ionophore coccidiostats to another in the same grow-out, i.e. shuttle program. 
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1.13 The chicken gastrointestinal (GI) tract microbiota 
Intestinal health is essential for production success, and changes in this complex system may 
lead to poor performance, increased mortality and condemnations as well as higher 
medication cost. Microbiota in the intestine of an animal species has evolved together with 
the host. The intestinal microbiota has an enormous metabolic potential and it affects both 
the nutrition and health of the host (Lan et al., 2005; Rantala and Nurmi, 1973; Rinttilä and 
Apajalahti, 2013) and shifts in intestinal microbiota can result in a series of implications, 
including disease, welfare, environmental and food safety concerns (Roberts et al., 2015). 
The domestic chicken (Gallus gallus domesticus) has a unique status as ‘both the model and 
the system’ – chickens are common model organisms for human biological research and also 
comprise a global economically valuable protein industry. The intestinal bacterial 
communities play important roles, in the influence on the immune system, in nutrition and 
for the health of the host by inhibiting the establishment of intestinal pathogens.  
Studies on the composition of the intestinal microbiota of chickens date back to 1901 
(Rahner, 1901) and continued in the 1940s (Shapiro and Sarles, 1949). Comprehensive 
surveys that attempted to culture as many of the intestinal bacteria as possible were mostly 
carried out until the 60s and 70s (Barnes, 1979; Barnes and Goldberg, 1962; Barnes and 
Impey, 1968; Barnes et al., 1972; Fuller, 1973a; Mead and Adams, 1975; Salanitro et al., 
1974), but few studies have been carried out using cultivation during the last decade 
(Kaldhusdal et al., 2001; Oakley et al., 2014a). Cultivation studies are technically difficult 
since strict anaerobic conditions have to be maintained during isolation and biochemical 
differentiation of the bacteria, and Gaskins et al. (2002) suggested that less than 20% of the 
bacterial taxa inhabiting the poultry gastrointestinal tract are recovered by cultivation. 
Why do we care about the intestinal microbiota of chickens? One answer is “healthy normal 
intestinal microbiota is the first line of defense for all animals to invading pathogens”. In 
chickens; during the first two to four days post hatched, streptococci and Enterobacteria 
colonize the small intestine and ceca. After the first week, lactobacilli predominate in the 
small intestine while mainly Escherichia coli and Bacteroides (anaerobes) colonize the ceca 
with lower proportion of facultative aerobe bacteria. Although other parts of the digestive 
tract of chickens might also be important sites of bacterial residents and for different 
pathogen-host microbiota interactions, the ceca have received most of the attention because 
the microbiota of the ceca is very diverse and caecal content may contain 1011 bacteria g-1 
(Apajalahti et al., 2004; Mead, 1997). Potential human pathogens such as Salmonella 
enterica and Campylobacter jejuni are frequently most numerous in the ceca (Barrow et al., 
1987; Doyle, 1991; Duchet-Suchaux et al., 1995). However, as earlier culturing and 
microscopic evaluations indicated that only a fraction of bacteria in the caecum of chicken 
could be grown in the laboratory, more recent studies have focused on the use of molecular 
methods to evaluate bacterial abundance and diversity (Amit-Romach et al., 2004; 
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Danzeisen et al., 2011; Gabriel et al., 2006; Gong et al., 2002b; Konsak et al., 2013; Lee and 
Newell, 2006; Lu et al., 2003; O'Hara and Shanahan, 2006; Oakley et al., 2014a; Oakley et 
al., 2014b; Oakley et al., 2013; Qu et al., 2008; Sekelja et al., 2012; Stanley et al., 2015; 
Stanley et al., 2013a; Stanley et al., 2013b; Stanley et al., 2014; Stanley et al., 2012; Torok 
et al., 2013; Torok et al., 2011a; Torok et al., 2011b; Torok et al., 2008; Van der Hoeven-
Hangoor et al., 2013; Van der Wielen et al., 2002a; Yeoman et al., 2012; Zhao et al., 2013; 
Zhu et al., 2002; Zoetendal et al., 1998). Recent progress in technology for microbial 
community analysis has evolved the understanding of the chicken intestinal microbiome, and 
it is now a general understanding that shifts in the microbial communities occur. These shifts 
can result in a series of implications including disease, reduced welfare, environmental and 
food safety concerns. 
The intestinal microbiota are classified as autochthonous or indigenous, when they are able 
to colonize the host’s epithelial surface or are associated with the microvilli, or as 
allochthonous or transient (associated to digesta or are present in the lumen) (Cole and 
Fuller, 1984; Savage, 1977). However, few studies have evaluated both the allochthonous 
and autochthonous microbiota of poultry (Gong et al., 2002a; Zhu et al., 2002).  
In the following part we focus on two studies that evaluated the gut microbiota of chickens 
(Oakley et al., 2014a; Zhu et al., 2002), and two recent review papers (Oakley et al., 2014b; 
Stanley et al., 2014).  
Zhu et al. (2002), carried out a survey of cecal bacteria by retrieval of 16S rRNA gene 
sequences from DNA isolated from the cecal content and the cecal mucosa. The ribosomal 
gene sequences were amplified with universal primers and cloned or subjected to temporal 
temperature gradient gel electrophoresis (TTGE). Partial 16S rRNA gene sequences were 
determined from the clones and from the major bands in TTGE gels. A total of 1,656 partial 
16S rRNA gene sequences were obtained and compared to sequences in the GenBank. 
Comparison indicated that 243 different sequences were present in the samples (Figure 
1.13-1). Overall, sequences representing 50 phylogenetic groups or subgroups of bacteria 
were revealed, but approximately 89% of the sequences represented just four phylogenetic 
groups (Clostridium leptum, Sporomusa sp., Clostridium coccoides, and enterics). Sequences 
of members of the Bacteroides group, the Bifidobacterium infantis subgroup, and of 
Pseudomonas sp. each accounted for less than 2% of the total gene sequences. Sequences 
related to the Escherichia sp. subgroup and from Lactobacillus, Pseudomonas, and 
Bifidobacterium spp. were generally between 98 and 100% identical to sequences already 
deposited in the GenBank. Sequences most closely related to those of the other bacteria 
were generally 97% or less identical to those in the databases and therefore might be from 
currently unknown species. TTGE and random cloning indicated that certain phylogenetic 
subgroups were common to all birds analysed, but sequence data from random cloning also 
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provided evidence for qualitative and quantitative differences among the cecal microbiota of 
individual birds reared under very similar conditions. 
 
Figure 1.13-1  Percentage of the total number of sequences obtained in the study by Zhu et 
al. (2002) that were classified by the sequence match program of the Ribosomal Database Project as 
belonging to different phylogenetic groups or subdivisions. Sequences most closely related to 
Eubacterium, Desulfovibrio, Clostridium propionicum, Xanthomonas, Clostridium botulinum, 
Acholeplasma-Anaeroplasma, Aeromonas, Rhizobium-Agrobacterium, and C. lituseburense groups 
were combined under “other groups.” (Source: Zhu et al. (2002) with permission)  
As a percentage of the total number of sequences obtained from each library, sequences 
related to those of the Selenomonas ruminantium subgroup predominate (Figure 1.13-2). 
These sequences were reported in all four libraries (cecal content; libraries 1A and 1B, and 
from the cecal mucosa; libraries 1C and 1D) and were therefore retrieved from bacteria in 
cecal content and the mucosa. Sequences representing the Phascolarctobacterium faecium 
and Veillonella parvula subgroups were also present in each of the libraries. Similarly, 
sequences representing the Ruminococcus gnavus subgroup of the Clostridium coccoides 
group of bacteria and the Clostridium leptum subgroup of the C. leptum group of bacteria 
were reported in all four libraries. Sequences assigned to most other subgroups were 
generally also represented in cecal content and the cecal mucosa libraries. A small number of 
sequences belonging to the Butyrivibrio fibrisolvens, Clostridium lituseburense, and 
Prevotella buccae subgroups were revealed only in the mucosal libraries. One sequence 
belonging to the Clostridium polysaccharolyticum and the Lactobacillus mali subgroups, 
respectively, was only reported in the cecal content libraries. Whether these findings indicate 
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true differences in the bacterial populations or are merely the result of chance events is not 
known. For example, sequences belonging to the S. paucivorans subgroup were reported in 
the cecal content and the mucosal clone libraries, but only in the libraries generated with 
primer pair 8FPL/1492RPL; out of 22 primers used for PCR. Similarly, sequences belonging to 
the Clostridium xylanolyticum and Ruminococcus hansenii subgroups were revealed only in 
the content and mucosal samples amplified with primer pair 515FPL/1492RPL.  
 
Figure 1.13-2  Percentages of sequences from clone libraries 1A to 1D most closely related to 
16S rRNA gene sequences from particular phylogenetic subgroups of bacteria. The libraries were 
obtained from DNA extracted from cecal content (libraries 1A and 1B) and from the cecal mucosa 
(libraries 1C and 1D) from one 6-week-old broiler. (Source: Zhu et al. (2002) with permission). 
Oakley et al. (2014a), evaluated the cecal bacterial communities at day of hatch (n = 5 
birds), 7d (n = 32), 21d (n = 27), and 42d (n = 36) post-hatch using direct 454 sequencing of 
16S rRNA gene amplicons from each bird in combination with cultivation-based recovery of a 
Salmonella typhimurium marker strain and quantitative-PCR targeting C. perfringens. By day 
21 post-hatch, a single genus (Faecalibacterium) accounted for 23-55% of sequences 
(Figure 1.13-3). Sokol et al. (2008), reported that Faecalibacterium prausnitzii has anti-
inflammatory properties and an inverse correlation with severity and recurrence of colitis in 
humans and murine models. Whether or not members of the genus Faecalibacterium have 
similar roles in chickens merits further investigations. By day 42, Faecalibacterium sequences 
were recovered at approximately equal proportions to Roseburia, a saccharolytic, butyrate-
producing bacterium reported by Duncan et al. (2002). In this respect, it is worth mention 
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that butyrate is known to increase disease resistance (Stanley et al., 2012). At day 42 
relatively abundant sequences were classified as Lachnospiracea incertae sedis, and 
Oscillibacter, previously encountered in chickens (Luo et al., 2013). Some of these members 
are known to produce short chain fatty acids (Katano et al., 2012; Lee et al., 2012). Data 
revealed by Oakley et al. (2014a) are consistent with previous results identifying various 
members of the poultry GI microbiome (Bjerrum et al., 2005; Geier et al., 2009; Gong et al., 
2008; Knarreborg et al., 2002; Oviedo-Rondón et al., 2010; Rehman et al., 2007; Sun et al., 
2013a; Tillman et al., 2011; Torok et al., 2013; Torok et al., 2011a; Torok et al., 2011b). 
Thus, exhaustive sequencing with modern methods from a fairly large number of birds can 
provides important new information regarding the generic composition of the chicken cecal 
microbial community and how the community changes over time. Proper understanding and 
management of temporal modulation of the GI tract microbiome will be important for 
maintaining bird health and improving productivity. 
  
Figure 1.13-3  Relative abundance at the genus level for sequences by treatment and time 
with taxonomic classifications performed with the RDP classifier as described in the text. Only 
sequences with a total relative abundance greater than 5% are shown. For day-of-hatch birds and 
each subsequent time point (7d, 21d, and 42 d post-hatch), the relative proportions are shown for 
each treatment. Day-of-hatch birds were proportionally high in Clostridium. Treatment designations 
are Ctl, control; FO, feed-only; WO, water-only; and FW, feed and water as described in the text. 
(Source: Oakley et al. (2014a) with permission).  
Sequencing data also demonstrated small treatment effects on taxonomic groups containing 
known pathogens (Figure 1.13-4, part A and B). Consistent with the cultivation data, 
Salmonella sequences decreased in relative abundance with time and were almost entirely 
absent by day 21 (Figure 1.13-4, part A and B). Sequences classified as Clostridium 
increased to a maximum of 0.5% at day 21, subsequently decreasing in relative abundance 
after 42 days of feeding (Figure 1.13-4; part A). In general, taxa considered as putative 
pathogens (Campylobacter, Clostridium, Escherichia/Shigella, Klebsiella and Salmonella) 
were a minor component of the bacterial community (<1.5% total relative abundance). 
 
VKM Report 2015: 30  47 
 
 
Quantitative-PCR for the Clostridium clade containing the C. perfringens subgroup was 
qualitatively consistent with the sequencing data and showed a significant increase in the 
abundance of this group from hatching to day 21 post-hatch, followed by a significant 
decline by day 42 to the same levels at day 7 (Figure 1.13-4; part B). 
 
Figure 1.13-4, part A and part B  Changes in relative abundance of putative pathogens 
by treatment and time. A) For each time point (7d, 21d, and 42 d post-hatch), the relative 
proportions are shown for each of the four treatments. Putative pathogens were defined using the 
intersection of independent taxonomic classifications with the RDP classifier and the Silva database as 
described in the methods. Sequences classified as Escherichia or Shigella by Silva are shown 
separately but not distinguished by RDP. Treatment designations are Ctl, control; FO, feed-only; WO, 
water-only; and FW, feed and water as described in the text. Note scale of Y axis. B) Number of gene 
copies of Clostridium as determined by quantitative-PCR for each time point. Treatments for each time 
point are grouped due to the non-significant effect of treatment. Quantitative loads of Clostridium 
were significantly higher at 21 d than 7d or 42 (p < 0.0001, one-sided t-tests). (Source: Oakley et al. 
(2014a) with permission). 
Based on their results, the authors concluded that over the 42 days experiment, the cecal 
bacterial community changed significantly as measured by a variety of ecological metrics and 
increases in the complexity of co-occurrence networks. Management of poultry to improve 
animal health, nutrition, or food safety may need to consider the interactive effects of any 
treatments with the dramatic temporal shifts in the taxonomic composition of the cecal 
microbiome as described here. 
Recently, two review papers have been published with regard to the gut microbiota of 
chickens (Oakley et al., 2014b; Stanley et al., 2014). Oakley et al. (2014b) revealed that 
Firmicutes, Bacteroides, and Proteobacteria are the most common phyla in the chicken ceca, 
with Actinobacteria accounting for the remainder (Figure 1.13-5a). At finer scales of 
taxonomic resolutions, the majority of sequence types can be shown to belong to various 
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members of the Clostridiales (Figure 1.13-5b). Although Clostridiales are known generally as 
important contributors to short chain fatty acid metabolism, further information of the 
members of this diverse group and their interactions merits evaluations.  
 
Figure 1.13-5, part a and part b  Relative proportions of bacterial phyla (a) and families 
(b) reported in chicken ceca. Data from Wei et al. (2013) represent publically available sequences 
retrieved as described. Data from Tillman et al. (2011) and Wise and Siragusa (2007) are re-analyzed 
from data included in the report from Oakley et al. (2013) representing 8 and 10 birds, respectively. 
Data from Kogut et al. are unpublished, collected, and analyzed as previously described by (Oakley et 
al., 2012; Oakley et al., 2013) representing 20 birds and ca. 20 000 sequencing reads. Data for each 
of these three flocks are from 3 weeks post hatch. Sequences from Wei et al. (2013) were additionally 
screened by removing sequences with ambiguous base calls, and all sequences were classified against 
a reference database of type strains from SILVA v115 (Pruesse et al., 2007). Many of the sequences 
reviewed in Wei et al. (2013) do not contain metadata regarding bird age, which can have strong 
effects on community composition and structure. For (b) families belong to the phylum Firmicutes 
unless otherwise noted; families followed by black squares belong to the Clostridiales. (Source: Oakley 
et al. (2014b), with permission).  
Stanley et al. (2014) revealed that other parts of the digestive tract of chickens might also 
be important sites of bacterial residents (Table 1.13-1) and the authors cited van der Wielen 
(Van der Wielen et al., 2002b) suggested that the bacterial communities originating from 
different gut sections should be considered as separate ecosystems. For example; the crop 
where starch breakdown and lactate fermentation is performed, the cell densities are up to 
109 cells g-1 (Rehman et al., 2007; Stanley et al., 2014) gizzard; low pH of gastric juices 
containing pepsin and HCl limits the total bacterial population level <108 g-1 , in contrast to 
caecum that harbor up to  1011 bacteria g-1. 
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Table 1.13-1 A general overview of the most abundant bacterial residents in the gastrointestinal 
(GI) tract of chicken. After Stanley et al. (2014). 
Section of 
GI tract 
Dominant and abundant bacteria References 
Crop Lactobacillus (dominant), Clostridiaceae, 
Bifidobacterium, Enterobacteriaceae, 
Enterococcus 
(Fuller, 1973a; Rehman et al., 2007; 
Sekelja et al., 2012) 
Gizzard Lactobacillus (dominant), Clostridiaceae, 
Enterococcus, coliforms 
(Fuller, 1973a; Rehman et al., 2007; 
Sekelja et al., 2012) 
Duodenum Lactobacillus (very dominant, up to 99% in some 
birds), Streptococcus, coliforms 
(Gong et al., 2002a; Konsak et al., 
2013; Lu et al., 2003; Salanitro et al., 
1974)  
Ileum Lactobacillus (very dominant), Streptococcus, 
coliforms, Enterobacteriaceae, Clostridiaceae  
(Gong et al., 2002a; Lu et al., 2003; 
Salanitro et al., 1974; Van der Hoeven-
Hangoor et al., 2013) 
Caecum Unknown and uncultured bacteria, Lactobacillus, 
Bacterioides, Clostridium, Bifidobacterium 
(Gong et al., 2002a; Lu et al., 2003; 
Stanley et al., 2013b; Torok et al., 
2011a; Zhu et al., 2002) 
Faeces Variations between sampling time, Lactobacillus, 
Clostridium, Fecalibacterium, Ruminococcus, 
Bacillus, Eubacterium, Fusobacterium 
(Sekelja et al., 2012; Zoetendal et al., 
1998) 
Pathogenic bacteria in the gastrointestinal (GI) tract 
In newly hatched chickens, the rapid establishment of an “adult-type” intestinal microbiota 
including pathogenic bacteria occurs. Several studies have reported pathogenic bacteria, 
Campylobacter jejuni, Salmonella typhimurium, Salmonella enteritis, Enterococcus, 
Escherichia coli, Yersinia enterocolitica and C. perfringens in the GI tract of chicken (Table 
1.13-2). In a review paper devoted to colonization factors of C. jejuni in the intestine of 
chickens, Hermans et al. (2011) revealed that C. jejuni have developed several survival and 
colonization mechanisms responsible for the bacterium highly adapted nature to the chicken 
host. It is generally accepted that Campylobacter adhesion to epithelial cells is an important 
step in successful colonization, and the caecum is the predominant site for colonization 
(Beery et al., 1988; Stern et al., 1988), but administration of selected probiotics in 
combination with prebiotics may reduce colonization (Arsi et al., 2015). According to Stern et 
al. (1988) as few as 35 cfu of C. jejuni can be sufficient for successful colonization in 
chicken. According to Brownell et al. (1970), the caecum is the main site of Salmonella 
colonization in chicken. 
Fuller (1973b) reported that E. coli were associated preferentially to the crop epithelium. In a 
later study, Snoeyenbos et al. (1982) reported highest colonization ration of E. coli in the 
caecum of holoxenic chickens in contrast to Barrow et al. (1988b) revealing that E. coli in the 
caecal contents were higher than those of the caecal epithelium. The verotoxin-producing E. 
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coli O157 is not generally reported in poultry, despite being able to colonise the caecum of 
chickens (Schoeni and Doyle, 1994). Soerjadi-Liem et al. (1984) reported that newly hatched 
monoxenic chickens subcutaneously injected or orally exposed to Y. enterocolitica, the major 
colonisation of the bacterium was revealed in the crop and caecum compared to the other 
regions of the GI tract. 
C. perfringens is a part of the “normal” intestinal microbiota of chicken, but the levels 
reported in the intestine vary considerably from sporadic and low numbers to 108 or more 
(Engberg et al., 2002; Ficken and Wages, 1997). Discrepancy seems to occur with regard to 
colonization of C. perfringens. (Vissiennon et al., 1994) reported C. perfringens in the 
intestinal lumen without adhesion onto the intestinal mucous membrane. Craven (2000) 
revealed that C. perfringens was recovered more frequently from the crop, proventriculus, 
duodenum, jejunum, ileum and caecum, but not the gizzard of chicken fed a 50% rye diet 
than birds fed the corn based diet. However, no conclusion could be drawn with respect to 
colonisation as the intestinal segments and their contents were investigated and no 
distinction could be made between the autochthonous (adherent) and the allochthonous 
bacteria. Pedersen et al. (2003) concluded that none of the three C. perfringens  type A used 
in their study was able to colonise the intestine permanently as they were eliminated within 
nine days. In contrast to these results, Collier et al. (2003) suggested colonization of C. 
perfringens to ileal and jejunal mucosa. 
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Table 1.13-2  Pathogenic bacteria in the gastrointestinal (GI) tract of chicken 
GI tract 
segment 
Pathogenic bacteria References 
Caecum Campylobacter jejuni (Beery et al., 1988; Stern et al., 1988) 
Campylobacter (Amit-Romach et al., 2004) 
“Fecal samples” Campylobacter (Gaucher et al., 2015) 
 Campylobacter jejuni (Bolder et al., 1999) 
Caecum Salmonella typhimurium (Brownell et al., 1969; Brownell et al., 
1970); (Snoeyenbos et al., 1982) 
 Salmonella typhimurium (Amit-Romach et al., 2004) 
“Fecal samples” Salmonella enteritis  (Bolder et al., 1999) 
Crop Escherichia coli (Fuller, 1973b) 
Caecum E. coli (Snoeyenbos et al., 1982); (Barrow et 
al., 1988a); (Amit-Romach et al., 2004) 
Small intestine E. coli (Hock E., 1997) 
Jejunum Enterococcus (Schokker et al., 2015) 
Crop and caecum Yersinia enterocolitica (Soerjadi-Liem et al., 1984) 
Small intestine Clostridium (Amit-Romach et al., 2004) 
Ileum Clostridium (Lu et al., 2006) 
Digesta in jejunum 
and ileum 
Clostridium perfringens (Collier et al., 2003) 
Ileum and caecum Clostridium-like (Olsen et al., 2008) 
Contents from 
ileum and caecum 
Clostridium spp. (Czerwiński et al., 2012) 
Ileum, caecum and 
rectum 
C. perfringens (Engberg et al., 2000) 
Jejunum, caecum,  C. perfringens (Mitsch et al., 2004) 
cloaca and feces C. perfringens was not 
changed at day 7 but 
significantly reduced at day 
21 in zinc bacitracin-fed 
chicken 
(Chee et al., 2010) 
“Fecal samples” C. perfringens (Bolder et al., 1999); (Knarreborg et al., 
2002); Gaucher et al., 2015) 
Preventing colonisation of foodborne pathogens in the digestive tract of poultry is of high 
importance to evaluate as contamination of poultry products by foodborne human 
pathogens, such as genus Camplyobacter and Salmonella is a considerable challenge for 
commercial producers in several countries. Readers with interest on this topic are referred to 
the review papers of Mead, Revolledo and Ghareeb (Ghareeb et al., 2015; Mead and Adams, 
1975; Revolledo et al., 2006) and the research paper of Varmuzova et al. (2015). 
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1.14 Do coccidiostats exert a growth promoting effect? 
Whereas coccidiostats are approved because of their efficacy against a specific disease 
condition (intestinal coccidiosis), antibiotic growth promoters (AGPs) were approved because 
of their ability to improve production performance, i.e. growth rate and feed efficiency. This 
distinction may seem to indicate that coccidiostats are used solely to prevent disease, 
whereas AGPs have been used only to increase profits for the farmers and the industry. 
However, in reality there is no clear-cut difference between these two aspects. Both groups 
of feed additives have prevented disease and therefore also improved production efficiency. 
The reason is that the diseases mitigated by these additives impair growth and feed 
utilization. Preventing these diseases therefore means not only improving broiler health but 
also increasing broiler growth and improving feed efficiency. 
The historical distinction between a disease-preventing and a growth-promoting group of 
feed antimicrobials may in part be caused by the fact that coccidiosis was identified as a 
health problem before the 1940’s, while necrotic enteritis was not described until 1961 
(Parish, 1961). 
Substances that were effective against coccidia were not effective (at least not to the same 
degree) against C. perfringens, and vice versa. There was therefore a need for two groups of 
feed additives, although the reason for this need was not recognized. 
The intestinal microbiota of broilers is complex and dynamic. Many other microbes than C. 
perfringens and coccidia (Eimeria spp.) are likely to affect the function and structure of the 
digestive system. This complexity is probably one of the reasons that the mode of action of 
the AGPs still is incompletely understood. 
In spite of the historical distinction between coccidiostats and AGPs, some of the used 
substances actually inhibit the growth of both coccidia and bacteria. The sulfonamides are an 
example of such substances, the polyether or ionophorous antibacterials is another. The first 
ionophore (monensin) was discovered in 1967 (Kevin et al., 2009), and several other 
ionophores, including narasin, were discovered during the following years. The ionophores 
show a broad spectrum of bioactivity, including antibacterial and anticoccidial activities. Their 
activity is characterized by a strong selectivity towards Gram-positive bacteria, as is a 
majority of the AGPs that have been used in broiler feeds. 
In conclusion, coccidiostats exert a ‘growth promoting’ effect by preventing intestinal 
diseases that adversely affect intestinal functions (in particular nutrient digestion and 
absorption), and consequently also impair feed utilization and growth of the birds. 
‘Prevention of diseases and intestinal microbiotia causing growth depression’ is probably a 
more appropriate designation for this effect than ‘growth promotion’. In any case, this effect 
of coccidiostats should not be confused with the growth promoting effect of hormones 
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administered to food-producing animals. Growth-promoting hormones were mostly used in 
cattle from the mid-1950s until the early 1970s, when a ban on diethylstilbestrol was 
imposed in the US (http://www.fao.org/docrep/004/X6533E/X6533E01.htm). 
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2 Hazard identification and 
characterisation 
2.1 Literature 
Coccidistat resistance in bacteria 
A literature search using relevant terms such as; Narasin AND bacteria, AND resistance using 
the Advanced Search Builder provided by PubMed (www.ncbi.nlm.nih.gov/pubmed) or Web 
of Science was performed. 
A similar search using the same terms, but Salinomycin / Monensin / Lasolocid / 
Maudoramicin / Non-ionophore / Diclazuril / Decoquinat / Halofuginon / Nicrabazin / Narasin-
Nicrabazin instead of narasin was also performed. The reference lists in the selected citation 
were scrutinized to identify additional articles or reports, overlooked by the searches. Titles 
and abstracts of all identified citations were screened and were excluded if they did not 
relate to the terms of reference. The titles of all hits were scanned, and for those that were 
of potential relevance, the abstracts were also scanned. Of these, for those of potential 
relevance, the full text was obtained and assessed whether it was of relevance to this 
Opinion. Original and review articles, and textbook content were included in this assessment. 
A list of the articles on coccidiostatics, which fulfilled the inclusion criteria with summary of 
the findings and main conclusion, is presented in Appendix I, Tables AI-1 – AI-5. 
Coccidiostat resistance in coccidia 
Search was provided by webofknowledge.com [v.519] using key words; anticoccidial 
resistance. Relevant literature was checked; newest to oldest and highest to lowest citation. 
Papers with highest citation were carefully checked for relevant papers published in peer-
reviewed open access scientific journals, and books, as well as minimally circulated 
investigations available as short communications, and abstract presented in books from 
international conferences. In addition, search using the following key words; Narasin / 
Lasolocid / Monensin / Salinomycin / Maudoramicin / Semduramicin / Robenidine / Diclazuril 
/ Decoquinat / Halofuginone and Nicrabazin was also performed. 
Effects of coccidiostats on intestinal microbiota 
Search was provided by webofknowledge.com [v.519] using the key words; Narasin / 
Lasolocid / Monensin / Salinomycin / Maudoramicin / Semduramicin / Robenidine / Diclazuril 
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/ Decoquinat / Halofuginone and Nicrabazin in combination with the following key words; 
bacteria / gut bacteria / intestinal bacteria / gut microbiota and intestinal microbiota. 
Transfer of resistance genes 
Literature searches using the terms Horizontal gene transfer or Lateral gene transfer 
combined with the terms Narasin, Salinomycin, Monensin, Lasolocid, Maudoramicin, 
Semduromicin, Robenidine hydrochloride, Diclazuril, Decoquinat, Halofuginon, Nicarbazin or 
ionophores were performed on PubMed. The searches provided a total of 114 scientific 
papers of which only two were relevant. A Google search provided one additional, relevant 
paper. 
Searches on PubMed using the terms Horizontal gene transfer or Lateral gene transfer 
combined with Eimeria did not provide any scientific papers. A Google search with the same 
terms did not provide any additional relevant information. 
Searches on PubMed using the terms Horizontal gene transfer or Lateral gene transfer 
combined with Eukaryotic parasite or Protozoa provided more than 200 scientific papers of 
which three, including a review from February 2015, were selected to be the most 
informative. 
Alternatives to in-feed antimicrobials 
Searches for use of in-feed anticoccidials and therapeutic antibacterials, alternatives to in-
feed antimicrobials, and use of therapeutic antibacterials if ionophorous anticoccidials are 
replaced by non-ionophorous anticoccidials or anticoccidial vaccines all followed the same 
procedure. References were searched in Web of Science and PubMed. Initial search strings 
were adapted to search engine and topic. The following terms were important in initial 
searches: (alternative OR replac*)/ (antibiotic*/ antibiotic growth 
promoter/coccidiostat/anticoccidial/broiler/turkey//poultry/necrotic enteritis/C. perfringens).  
The titles of all hits were scanned, and for those that were of potential relevance, the 
abstracts were also scanned. Of these, for those of potential relevance, the full text was 
obtained and assessed whether it was of relevance to this Opinion. New search terms were 
used if relevant key word were found during the search process. References in examined full 
text articles with potential relevance were scrutinized by means of new searches, and full 
text obtained if deemed appropriate. Original and review articles, and textbook content were 
included in this assessment. 
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2.2 Hazard identification and characterisation 
 Resistance to coccidiostats in bacteria 2.2.1
A list of scientific articles published in the international journals which fulfilled the inclusions 
criteria is found in Appendix I. Only original papers regarding the antibacterial activity of the 
coccidiostats and their ability to induce resistance in bacteria were included. Evaluation of 
data from the national antimicrobial surveillance programmes in Norway (NORM-VET), 
Sweden (SWARM), Denmark (DANMAP) and Finland (FINRES-vet) showed similar trends in 
resistance patterns of bacterial studied.  
Test materials for isolation of bacterial species in all of these studies were faeces. Test 
materials other than faeces have been specifically indicated in the Tables in the Appendix IV. 
The evaluated scientific articles gave limited information regarding antimicrobial agents used 
for therapeutically purposes of animals in these studies. 
Definite confirmation of cross or co-resistance between the coccidiostats and other 
antibacterial agents in bacteria is dependent on identification of gene(s) encoding resistance. 
However, the Panel is not aware of any scientific literature identifying such genes against 
any of the ionophores in any bacterial species. 
2.2.1.1 Narasin 
Thirteen original articles fulfilled the criteria (see Chapter 2.1) to be included in this part of 
the risk assessment. Enterococci (E. facium and E. faecalis) and Clostridium perferingens 
were the most frequently bacterial species examined for development of resistance. Data 
regarding development of resistance in many Gram-positive bacteria like staphylococci and 
including non-cultural species is lacking. Most of the studies were performed in poultry 
(faeces, meat). 
Resistance to narasin: 
Resistance against narasin in enterococci (primarily E. facium and E. faecalis) has been 
reported in several scientific papers, as well as in official surveillance reports, Appendix I, 
Table AI-1. High prevalence of resistance against narasin was observed in enterococci from 
broilers in Norway, Table 3.3.2-1. Similar data have also been observed in Sweden 
(SWARM). No resistance in C. perfringens has been reported in spite of widespread use of 
this ionophore in many countries for several decades (Johansson et al., 2004; Lanckriet et 
al., 2010; Martel et al., 2004; Silva et al., 2009b; Watkins et al., 1997).  
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Cross-resistance between narasin and other antibacterial agents: 
Cross-resistance between narasin and salinomycin was reported in enterococci isolated from 
animals, mainly broilers (Butaye et al., 2000; Butaye et al., 2001).  
In the Norwegian surveillance program NORM-VET, narasin resistant enterococci have been 
isolated from monensin fed turkeys (Table 3.3.2-1), indicating that monensin might induce 
narasin resistance. 
Using surveillance data from Norway from the years 2004-2014, a statistical association was 
observed between resistance against narasin and bacitracin in E. faecium  from broilers (See 
NORM-VET report 2014 and additional calculations where a possible cross-resistance 
between narasin and monensin in turkey isolates was taken into account Appendix II) 
However according to the NORM-VET report 2014 (NORM/NORM-VET, 2014): “ whether 
narasin resistance leads to cross-resistance with bacitracin or vice versa, or the presence of 
both resistances can be explained by some underlying cause(s) remains unclear. 
Consequently, in order to investigate if there is a possible causal relationship between the 
use of narasin and resistance to other antibacterials further studies are needed.” 
The number of vancomycin-resistant enterococci in Norwegian poultry is too low to be 
included in the statistics described above. However, studies have shown that former use of 
avoparcin, which induces cross-resistance to vancomycin, has selected for a reservoir of 
vancomycin resistant enterococci in Norwegian broiler production (NORM/NORM-VET, 2014). 
Avoparcin was routinely used as a growth promoter in Norwegian broiler and turkey 
production from 1986 until it was banned in 1995. The reservoir has persisted after the ban 
was implemented. An important question is whether the use of narasin has contributed to 
the persistence of this reservoir. 
In the Norwegian surveillance programme NORM-VET, vancomycin resistant E. faecium has 
been identified by selective methods which favor the growth of these bacteria and 
subsequently been tested for resistance to other antibacterials, including narasin. This was 
done in 2009 and 2011 on bacteria isolated from broilers and in 2013 on bacteria isolated 
from turkeys, Table 2.2.1.1-1. The cut-off value for narasin resistance in E. faecium was 
changed in 2013 from 2 mg/L to 4 mg/L as suggested by EUCAST. In this report, an 
epidemiological cut-off of >2 mg/L is chosen for all isolates because >4 mg/L, according to 
the NORM-VET representatives, cuts through MIC distributions for E. faecium from some 
animal categories studied (e.g. broilers) in a manner not in agreement with the concept of 
wild-type distributions. 
When applying a chi square test to the results, the number of narasin resistant E. faecium 
from broilers was significantly higher than expected (p < 0.05). On the other hand, the 
number of narasin resistant isolates from turkey was not higher than expected (p > 0.05). 
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Although these results may indicate a statistical relationship between narasin and 
vancomycin resistance, the number of sample is small. Furthermore, this is in contrast to an 
earlier Norwegian study, where the authors concluded: ”a link between vanA genes and a 
narasin-resistance gene would seem unlikely because the vancomycin sensitive poultry 
enterococci did not express a lower MIC for narasin than the vancomycin-resistant 
enterococci did” (Sorum et al., 2004). Consequently, further studies on Norwegian isolates 
are required before conclusions can be drawn. 
Table 2.2.1.1-1 Observed and expected numbers and percentages of narasin resistant isolates 















Broiler 57 57 100 40 71 <0.0001 
Turkey 16 15 94 12 75 0.08 
* Expected percentage is the percentage of narasin positive isolates among all isolates tested from 
broiler and turkey faeces. 
** p value < 0.05 means that the observed number of narasin resistant isolated differs significantly 
from the expected number. 
In a Swedish laboratory study, 26 vancomycin resistant enterococci isolated from poultry 
were separated into 11 clones. Vancomycin resistance was transferrable from the 
predominant and five minority clones in laboratory experiments. Resistance to narasin was 
co-transferred with vancomycin resistance in four of the six clones, including the 
predominant (Nilsson et al., 2012). Furthermore, according to a personal communication 
from Oskar Nilsson (National Veterinary Institute, Sweden) to one of the authors preparing 
this draft opinion, a putative resistance gene against narasin may have been identified at a 
plasmid also harboring a resistance gene against vancomycin in enterococci from Swedish 
poultry. However, as data is still preliminary, not peer reviewed and not published, further 
studies are needed before any conclusions can be drawn. 
2.2.1.2 Lasalocid 
Only 4 articles fulfilled the criteria to be included in this risk assessment. Only two studies 
were performed in broilers (Appendix I, Table AI-2). 
Resistance to lasalocid: 
C. perfringens and Pediococcus acidilactici and Pervotella (Bacteriodes) isolates were 
susceptible to lasalocid. 
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Cross-resistance between lasalocid and other antibacterial agents:  
Lasalocid-and monensin-resistant adapted cultures of Clostridium aminophilum cultures were 
as susceptible to most antibacterials as non-adapted cultures. However, bacitracin displayed 
a 32-fold greater MIC value in the ionophore-adapted cultures (Houlihan and Russell, 2003). 
2.2.1.3 Monensin 
Thirteen original articles fulfilled the criteria to be included in this risk assessment. The 
published articles report susceptibility testing of monensin towards different bacterial species 
like Enterococcus spp, Pediococcus spp, Clostridium spp, Prevotella spp, Fibrobacter spp, 
Veillonella spp, and anaerobic bacteria isolated from different animal species (Appendix I, 
Table AI-3). The studies were performed in different animal species, but mainly in cattle. 
Only a single study included samples from poultry (Dutta et al., 1983). 
Resistance to monensin: 
No resistance was observed in C. perfringens isolates. Resistance against monensin was 
observed in Clostridium aminophilum, Prevotella, Butyrivibrio, Fibrobacter, Veilonnela, and 
Enterococcus, and in anaerobe bacteria (Appendix I, Table A3). 
Cross-resistance between monensin and other antibacterial agents: 
Full cross-resistance between monensin and salinomycin was found in E. faecium from farm 
animals (Butaye et al., 2001). In a laboratory study using Gram negative rumen bacteria, 
increased resistance to one of these ionophores caused increased resistance to the other. 
Furthermore, cross-resistance to lasalocid and the antibacterial avoparcin was reported 
(Newbold et al., 1993). Enterococcal isolates from cattle fed monensin or monensin-tylosin 
displayed greater levels of resistance towards macrolides (erythromycin and tylosin), but 
there was no effect on the concentrations of the two macrolide resistance genes, ermB or 
tetM, in fecal samples (Jacob et al., 2008). 
Monensin- and lasalocid-resistant adapted cultures ofClostridium aminophilum cultures were 
as susceptible to most antibacterials as non-adapted cultures. However, bacitracin displayed 
a 32-fold greater MIC value in the ionophore-adapted cultures (Houlihan and Russell, 2003).  
In the Norwegian surveillance program NORM-VET, narasin resistant enterococci have been 
isolated from monensin fed turkeys, Table 3.3.2-1, indicating that monensin might induce 
narasin resistance 
 




Twenty-one original articles fulfilled the criteria to be included in this risk assessment. 
Resistance in different bacterial species like S. aureus  and other staphylococcal species, 
Clostridium perferingens, enterococci, Clostridium difficile, Listeria monocytognes, anaerobe 
bacteria from cattle, E. coli, Gram-negative bacteria from pigs, Salmonella were examined. 
The studies were performed in different animal species, human, and foods. 
Resistance to salinomycin: 
E. faecium and E. faecalis are the most commonly reported bacterial species to have 
developed resistance against salinomycin (Butaye et al., 2000; Tremblay et al., 2011; 
Wiggins, 1996; Yoshimura et al., 2000). C. perfringens and S. aureus were susceptible to 
salinomycin in all studies. Anaerobe bacteria from cattle may also develop resistance against 
salinomycin. Enterococcal isolates from poultry in Denmark show high prevalence of 
resistance against salinomycin, which is the most common used coccidiostat in Denmark 
(DANMAP). 
Cross-resistance between salinomycin and other antibacterial agents: 
Full cross-resistance between salinomycin and narasin was evident, whereas no cross-
resistance between these two ionophores, monensin and lasalocid was detected in one of 
the studies (Appendix I, Table AI-4, (Butaye et al., 2000)). 
2.2.1.5 Maduramicin 
Only one study was identified. 
Resistance to Maduramicin 
The study performed by Lanckriet et al. (2010) found that C. perfringens isolates, found in 
poultry were uniformly susceptible to all ionophore agents, including maduramicin (Appendix 
I, Table A5) 
2.2.1.6 Semduramicin 
No study was identified. 
According to FDA: Semduramicin, an ionophorous agent had no remarkable activity against 
Gram-negative microorganisms tested, and activity against selected Gram-positive control 
organisms was minimal 
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2.2.1.7 EFSA´s evaluation 
Several scientific opinions have been prepared by EFSA, regarding use of coccidiostats in 
poultry (EFSA, 2004a; EFSA, 2004b; EFSA, 2004c; EFSA, 2004d; EFSA, 2004e; EFSA, 2004f; 
EFSA, 2007; EFSA, 2010). Terms of reference in all of these opinions were regarding 
development of resistance in bacteria. The EFSA´s opinion from 2004 (EFSA, 2004c) 
concluded the following regarding resistance in bacteria: 
”The MICs of narasin for common intestinal bacterial species such as Enterococcus 
spp. and Clostridium perfringens are basically low but enterococci may develop 
resistance to narasin. There is no cross-resistance to other antimicrobials except to 
salinomycin. Narasin may increase Salmonella-shedding, but there is no reason to 
believe that narasin is different from other polyether ionophores in this respect. There 
are no data on the influence of narasin on the intestinal microflora other than on 
Clostridium perfringens and Salmonella. Narasin, at the levels used for treatment of 
coccidiosis, is also effective in the prevention of necrotic enteritis in chickens.” 
The same information was reflected in the opinion from (EFSA, 2007). EFSA´s opinion from 
2010 (EFSA, 2010) refers to the same literature and databases, which have been reviewed in 
this risk assessment: ”Occurrence of enterococcal resistance to narasin has been observed in 
monitoring programs (NORM-VET, 2006; SVARM 2007, FINRES-vet 2005 - 2006), and 
complete cross-resistance between narasin and salinomycin has also been reported (Butaye 
et al., 2000). The latter opinion concludes that: Resistance development in Enterococci 
against narasin, including cross-resistance to clinical relevant antibacterials, should be 
monitored. 
2.2.1.8 Non-ionophores anticoccidal agents 
Due to lack of antibacterial activity of non-ionophore anticoccidal agents, development of 
resistance against these agents in bacterial species is not expected. 
 Resistance to coccidiostats in coccidia 2.2.2
2.2.2.1 Resistance and cross-resistance 
Sulfonamides were the first modern anticoccidials, and in 1939 Levine (1939) demonstrated 
anticoccidial activity of sulphonamide either used alone or in combination with other non-
ionophore coccidiostats for coccidiosis control. However, a crucial important question related 
to the use of coccidiostats is the development of resistance. The first to suggest that 
resistance might develop to anticoccidial drugs was Horton-Smith in 1952 in abstract 
presented at the 9th World`s Congress, Paris, France, cited in Chapman (1993). However, 
Joyner et al. (1963) stated that resistance do not represent a serious problem in the control 
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of coccidiosis in the field. Nowadays, this is no longer the case, as many drugs have been 
introduced and resistance has arisen to all of them. In their review devoted to anticoccidial 
drug resistance, Abbas et al. (2011) discussed the following topics; what is resistance, type 
of resistance, factors involved in resistance, geographical variations in resistance 
development and resistance management. According to the authors, numerous anticoccidial 
drugs have been used, and resistance to all of them has been reported in different parts of 
the world since the first study was published by Waletzky et al. (1954) (Table 2.2.2.1-1). 
However, it is suggested that ionophores develop resistance at a slower rate than the non-
ionophore non-ionophore coccidiostats. An explanation for this slow acquisition of resistance 
to ionophores may be that they allow for some leakage of sensitive oocysts. This leads to a 
less stringent resistance selection than with non-ionophore non-ionophore coccidiostats. 
http://www.noah.co.uk/issues/briefingdoc/13-anticoccidials.htm Previously it was a general 
opinion that in order to minimize the occurrence of resistance it was of crucial importance to 
shorten the exposure time to anticoccidial drugs as much as possible and to rotate the use of 
various coccidiostats with a different mode of action with successive flocks, combine non-
ionophore coccidiostats and ionophore treatments, or employ shuttle programs during a flock 
grow out (Allen and Fetterer, 2002; Peek, 2010). 
Coccidiostats may be included in different feeds as the sole drug during the life of a flock 
(single-drug program) or in so-called shuttle programs in which several coccidiostats 
(ionophore or synthetic compounds) are used in different feeds in a single flock. Studies 
conducted in which birds were given monensin alone or in shuttle programs with various 
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Table 2.2.2.1-1 Reports of resistance in fowl coccidia against coccidiostats included in this 
assessment. After Chapman (1997) and Abbas et al. (2011) with some additional citation marked with 
* 
Drug Country Resistance described by  Year 
Narasin  USA  Weppelman et al.  1977 
Lasalocid  USA  Weppelman et al.  1977 
 USA Ruff et al.  1985* 
 China Li et al. 2004* 
Monensin USA Jeffers 1974a 
 China Tsang 1980* 
 Gt. Britain Chapman 1982 
 USA Ruff et al.  1985* 
 USA Austine et al. 1986* 
 Germany Stephan et al. 1997 
 China Li et al. 2004* 
Salinomycin  USA Ruff et al.  1985* 
 USA  Jeffers  1989 
 Germany  Stephan et al.  1997 
 India  Yadav and Gupta  2001 
 China Li et al. 2004* 
 Pakistan  Abbas et al.  2008a 
 Iran Arabkhazaeli et al. 2013* 
 USA Chapman and Jeffers 2015* 
Maduramicin  USA  McDougald et al.  1987 
 Germany  Stephan et al.  1997 
 China Li et al. 2004* 
 Pakistan  Abbas et al.  2008a,b 
Semduramicin China Li et al. 2004* 
Robenidine USA Jeffers 1974a 
 USA McLoughlin and Cute 1979* 
 Germany Stephan et al. 1997 
Diclazuril  Czechoslovakia Bedrnik et al. 1991* 
 Brazil  Kawazoe and Fabio  1994 
 Germany  Stephan et al.  1997 
 Pakistan  Abbas et al.  2009* 
 Iran Arabkhazaeli et al. 2013* 
Decoquinata    
Halofuginone France Hamet 1986 
 Germany Stephan et al. 1997 
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Drug Country Resistance described by  Year 
Nicarbazin Britain Hemsley 1964 
 India Gill and Bajwa 1979 
 USA McLoughlin and Cute 1979* 
 Germany Stephan et al. 1997 
 USA Bafundo et al. 2008* 
Readers with further interest on drug resistance in avian are referred to the review papers of 
(Chapman, 1984; Chapman, 1993; Chapman, 1997; Smith et al., 1981), the Ph.D. thesis of 
Peek (2010) and the research paper of Stephan et al. (1997). 
One of the main debates still ongoing amongst coccidiologists is the ability for acquiring 
resistance to one drug by the use of another drug, the so-called cross-resistance (Chapman, 
2007). According to Chapman (1998), “multiple resistance is resistance to more than one 
drug, even though they have different mode of action”. It is therefore of importance to 
evaluate that cross-resistance and multiple resistance are not similar. In an early study, 
Jeffers (1974) displayed that two strains of E. tenella differing in resistance to amprolium 
and decoquinate. Based on their cation selectivity, transport rate capacity and structure, 
three classes of ionophores can be discriminated (Pressman, 1976; Westley, 1982), 
monovalent, monovalent glycoside and divalent ionophores.  Several papers indicate that 
cross resistance is less obvious between products of different classes, for instance between 
maduramicin and monovalent ionophores or between lasalocid and monovalent ionophores  
(Bedrnik et al., 1989; Marien et al., 2007; McDougald et al., 1987). Evidence of incomplete 
cross-resistance within a certain ionophore class is illustrated by the fact that, after years of 
use of the monovalent ionophore monensin, resistance to narasin in United States was 
encountered before the product was commercially launched (Weppelman et al., 1977). 
However, cross-resistance may not always occur between different compounds with similar 
mode of action. (Smith et al., 1981) revealed inconsistent results of cross-resistance in 
Coccidia isolates to lasalocid, monensin, narasin or salinomycin having similar mode of 
action. Weppelman et al. (1977) revealed no differences in efficacy between narasin and 
monensin against E. acervulina, E. tenella and E. maxima. In contrast, lasalocid had an effect 
towards some strains that were not well affected by either narasin or monensin.  Augustine 
et al. (1987) addressed the effect of monensin, salinomycin and lasalocid and revealed that 
all three coccidiostats markedly inhibited invasion of cecal tissues by sporozoites of 
ionophore sensitive (IS) E. tenella. As data suggest difference in ionophore accumulation by 
IS and resistant isolates of E. tenella, the authors suggested that the differences might be 
related to differences in membrane permeability. Bedrnik et al. (1989) investigated the effect 
of monensin, narasin, salinomycin, maduramicin and lasalocid on two field isolates of E. 
tenella obtained from a farm with a long-term occurrence of coccidiosis and revealed that 
monensin, narasin and salinomycin had no effect. In contrast, maduramicin and lasalocid 
controlled them effectively. In an early study, Ryley et al. (1980) evaluated cross resistance 
 
VKM Report 2015: 30  65 
 
 
between monensin and lasalocid and two coccidia strains, one sensitive and one resistant. 
Each treatment starting the day before inoculation and based on observations on mortality, 
fecal score and weight gain it was revealed that optimal control of the sensitive strain was 
revealed at 240 ppm monensin, while 150 ppm lasalocid was efficacious. With the resistant 
strain, results with 240 ppm monensin were less effective, but a bit more effective to those 
achieved with 120 ppm on the sensitive strain. Based on the results, the author suggested 
approximately a 2-fold degree of resistance. With regard to lasalocid, 300 ppm was required 
for the resistant strain to achieve similar degree of control as 150 ppm on the sensitive 
strain, again a 2-fold degree of resistance. The results of Ruff et al. (1985) are of interest, as 
the results revealed that a field strain of E. tenella was markedly less sensitive to narasin, 
lasalocid and monensin than a laboratory isolate that has never been exposed to 
coccidiostats. Abbas et al. (2008) evaluateded multiple resistance in three field isolates of E. 
tenella collected from poultry farms - with a history of prophylactic anticoccidial medication 
failure, and revealed that only one isolate displayed multiple resistance to salinomycin, 
maduramicin and clopidol. 
There may be several reasons for the development of multiple resistance in field isolates; 
altered permeability of the cell membrane so that the drug is no longer taken up or is rapidly 
pumped out of the cell, use of alternative biochemical pathway, modification of the target 
sites in the coccidia (Abbas et al., 2011) as well as genetic recombination (Stephan et al., 
1997). 
2.2.2.2 Resistance to different coccidiostats and combination of drugs 
In an early study, Waletzky and Hughes (1946) revealed that only a few of the 45 
sulfanilamides tested; the halogenated sulfapyrimidines, sulfamethazine and sulfapyrazine, 
which were ten, five and four times as active as sulfaguanidine against E. tenella, 
respectively. Varga and Sréter (1996) investigated the coccidiostat feed supplementation 
efficacy of a combination of monensin (8 p.p.m.) and duokvin (120 p.p.m.) with that of only 
monensin at recommended level of 100 p.p.m. against a field isolate of E. acervulina. The 
authors revealed no significant difference in the chemoprophylactic activity of the 
treatments. In a study with ten Coccidia field isolates from north Germany, Stephan et al. 
(1997) revealed that partial or complete resistance to nicarbazin was noticed in eight 
isolates, maduramicin and halofuginone in seven, to monensin in six, to salinomycin in five, 
to diclazuril in two and to toltrazuril in one field isolate. However, the authors stated that for 
Coccidia strains with low resistance the results can be misinterpreted, as in spite of high 
oocyst index, very good overall results can be obtained due to growth promotion. 
The effect of different coccidiostats supplemented alone or in combination with duokvin (120 
p.p.m.) against Cryptosporidium bailey were investigated by Varga et al. (1996) and revealed 
the following efficacy percentages; lasalocid 45, monensin 37, semduramicin 29, narasin 23 
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and salinomycin 21. However, the efficacy could increase 36-80% by combination with 
duokvin, with the exception of lasalocid. 
When discussing the resistance to coccidiostats, it may also be of importance to notice that   
Kochansky and Pettis (2005) demonstrated that several of the polyether ionophores revealed 
high activity against American foulbrood, caused by Paenibacillus larvae. Narasin was most 
active, followed by lasalocid and salinomycin. 
 Effects of coccidiostats on intestinal microbiota 2.2.3
Antibacterial growth promotion in agricultural animal production has been practiced for 
nearly 70 years in the United States and other countries. Early indications of a beneficial 
effect on production efficiency in poultry was reported by Moore et al. (1946) and numerous 
investigations have reported modulation of the gut microbiota of poultry by antibacterial 
supplements e.g. (Barnes and Goldberg, 1962; Butaye et al., 2003; Ford et al., 1981; George 
et al., 1982). Modulation of the intestinal microbiota towards a “healthy” community by 
feeding probiotics, prebiotics and lactoferrin are investigated e.g. (Alloui et al., 2013; 
Apajalahti et al., 2004; Ducatelle et al., 2015; Geier et al., 2011; Giannenas et al., 2012; 
Oviedo-Rondón et al., 2010; Pourabedin and Zhao, 2015; Saleh et al., 2014; Zhao et al., 
2013) as such supplements improve gastrointestinal health and suppress known intestinal 
and food-borne pathogens. 
Several studies have been performed on the effects of coccidiostats on intestinal microbiota 
in chickens and these studies revealed modulation of the gut microbiota. The effects of 
coccidiostats in focus on in the present assessment on the intestinal microbiota are shown in 
Table 2.2.3-1. To our knowledge, no information is available on the effect of semduramicin, 
robenidine, diclazuril and decoquinate on gut microbiota. One study, (Bailey et al., 1988) 
investigated the effect of nicarbazin in combination with other antimicrobials, but no 
information is available on only nicarbazin administration. 
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Table 2.2.3-1  Effect of coccidiostats on gut microbiota  
Coccidiostats Effect on gut microbiota References 
Narasin Significant reduction of C. perfringens counts (Kaldhusdal et al., 2012) 
Lasalocid Higher total anaerobe counts, Enterobacter spp., 
Enterococcus, ratio of E. coli : Lactobacillus spp. 
No effect on total aerobes, C. perfringens, 
Bifidobacterium spp. 
(Giannenas et al., 2012) 
Monensin No effect on cecal colonization of Salmonella (Manning et al., 1994) 
Crop. No effect on lactobacilli counts. At day one, 
significant reduced numbers of coliforms and 
enterococci. At day five, significant increase in 
number of coliforms, but numbers of enterococci 
were not affected 
Caeca. Lactobacilli counts were significantly 
increased at day one, but no effect was noticed at 
day five. Coliforms were significantly reduced at 
day one, but no effect was revealed at day five. 
Enterococci counts were not significantly affected 
at day one or day five 
(Rada and Marounek, 
1997) 
Significant effect of microbiota. Rich in Clostridia 
(Clostridium irregularis and C. lituseburense) and 
Lactobacillus crispatus, but low in Lactobacillus 
acidophilus 
(Liu and Reynolds, 
1999; Liu et al., 2005) 
Reduced numbers of sequences and numbers of 
operational taxonomic units (OTUs) 
Shannon (diversity) was unaffected 
Depletion of Roseburia, Lactobacillus and 
Enterococcus 
Enrichment of Copracoccus and Anaerofilum 
(Danzeisen et al., 2011) 
Salinomycin No resistance selection in coliforms and 
streptococci. 
(George et al., 1982) 
Significantly reduced the incidence of Salmonella 
shedding at week 6, but no effect on 
Campylobacter shedding 
(Bolder et al., 1999) 
Significantly lower counts of Campylobacter 
perfringens and Lactobacillus salivarius. No effect 
on counts of anaerobic bacteria, C. perfringens, 
coliforms and lactose-negative enterobacteria 
(Engberg et al., 2000) 
Scanning electron microscopy revealed fewer 
bacteria in the ileum 
(Chichlowski et al., 
2007) 
Reduced counts of Lactobacillus-, 
Enterobacteriaceae- and Clostridium-like bacteria 
in the lumen of ileum 
(Olsen et al., 2008) 
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Coccidiostats Effect on gut microbiota References 
 Ileal digesta. Reduced total numbers of bacteria 
and Lactobacillus/Enterococcus caecal digesta. 
Increased total numbers of bacteria, but reduced 
Lactobacillus/ Enterococcus 
(Czerwiński et al., 2012) 
Maduramicin Crop. No effect on lactobacilli counts. At day one, 
significantly reduced numbers of coliforms and 
enterococci. At day five, significant increase in 
number of coliforms, but numbers of enterococci 
were not affected 
Caeca. Lactobacilli counts were significantly 
increased at day one, but no effect was noticed at 
day five. Coliforms were significantly reduced at 
day one, but no effect was revealed at day five. 
Enterococci counts were not significantly affected 
at day one or day five 
(Rada and Marounek, 
1997) 
Halofuginone Chicken fed halofuginone at 3 ppm revealed no 
significant increase in excretion rate of Salmonella 
typhimurium. However, animals fed 6 ppm 
halofuginone showed a significant increase in 
excretion of S. typhimurium 
(Barrow et al., 1988b) 
 Transfer of genes mediating resistance to coccidiostats 2.2.4
2.2.4.1 Bacteria 
The literature searches performed identified only one original scientific paper addressing 
horizontal transfer of resistance against coccidiostats. The paper described transfer of 
horizontal transfer of phenotypic narasin resistance between different clones of E. faecium in 
a laboratory experiment (Nilsson et al., 2012). However, horizontal transfer of a large variety 
of other antibacterial resistance genes is known to occur in bacteria. 
2.2.4.2 Coccidia 
Until recently, the impact of horizontal gene transfer on eukaryotic evolution was thought to 
be limited. However, the rapid increase in publicly available eukaryotic genomic data has 
changed the views on the frequency and subsequent important roles horizontal gene transfer 
may play in eukaryotic evolution (especially unicellular organisms) (Keeling and Palmer, 
2008). Studies on a number of parasitic microbial eukaryotes (including coccidia, but not 
Eimeria) indicate that these have been significantly affected by prokaryote-to-eukaryote 
lateral gene transfers during evolution (Alsmark et al., 2013; Alsmark et al., 2009; Hirt et al., 
2015). A majority of the genes were involved in cell metabolism. A broad range of 
prokaryotic donors has been involved in such transfers, but in particular bacterial groups that 
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share the same habitats as the parasites investigated, including the host microbiota. Possible 
eukaryote-to-prokaryote and eukaryote-to-eukaryote gene transfers have also been 
identified in these parasites. However, the data indicate resistance to coccidiostats being 
horizontally transferred between coccidia strains or between coccidia and bacteria is not 
relevant in a short or medium term perspective, but rather in long term evolution. 
Vertical gene transfer is the transfer of genes from parent to offspring. Studies on E. tenelli 
indicate that strains resistant to different coccidials may produce offspring carrying 
resistance genes from both parent strains due to gene recombination during the sexual 
multiplication stage in the chicken intestine. This means that two parent strains being 
resistant to one coccidiostat each can produce offspring with reduced resistance to both 
coccidiostats (Chapman, 1984).  
2.3 Alternatives to in-feed antimicrobials 
Coccidiostats are approved because they protect the birds against intestinal coccidiosis. The 
most obvious alternative to coccidiostats in the feed is vaccination against coccidia. Coccidia 
are intracellular parasites and are highly immunogenic, which has led to the development of 
vaccines based on live coccidia. Some of these vaccines are based on strains that are still 
pathogenic (‘non-attenuated’ vaccines). Such poultry vaccines are used in the US, but not in 
Europe. Increasing consumer demands for chickens raised without in-feed antimicrobials has 
driven an increasing proportion of the US broiler industry to transition from conventional to 
‘antibacterial-free’ production practices. These practices require no in-feed antibacterial 
growth promoters, no ionophorous coccidiostats and no non-ionophore coccidiostats. Recent 
experience from the USA suggests that presently used non-attenuated vaccines and/or 
administration methods may not yet be fully satisfactory in conventional broiler rearing. A 
significant problem appears to be emergence of necrotic enteritis during the 3rd week of age 
(Schaeffer et al., 2015). 
Research on vaccines based on subunits of coccidial antigens has so far not succeeded in 
producing sufficient protection against coccidiosis. Such killed vaccines would be beneficial 
because of lower production costs and a lower risk of contamination by other pathogens 
(Peek and Landman, 2011). 
Alternatives included in this assessment are vaccines, eradication and feed additives other 
than coccidiostatica. The Panel has not assessed possible effects of other types of 
management changes. 
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 Vaccines used in Europe 2.3.1
The immunogenicity of coccidia can be retained in artificially selected, non-pathogenic 
strains, which has led to the development of live anticoccidial vaccines  that are inherently 
non-pathogenic (Chapman, 2012). Until recently such vaccines have been used mainly in 
chickens reared for egg production, but they are now increasingly used also in the broiler 
industry (Chapman and Jeffers, 2014). This type of anticoccidial vaccine is now used 
increasingly in commercial Norwegian broiler farms, instead of in-feed coccidiostats. So far 
clinical coccidiosis has not been experienced as a significant problem in this transition 
process to broiler rearing without in-feed coccidiostats (A. Løvland, personal 
communication). 
Although there are conflicting experiences with the use of anticoccidial vaccines in broilers, it 
seems clear that such vaccines do induce a protective response against coccidiosis (maybe 
not always early enough?) but do not induce specific immunity against C. perfringens and 
necrotic enteritis. 
As opposed to anticoccidial vaccines, no vaccines against necrotic enteritis caused by C. 
perfringens are yet commercially available. Major challenges in ongoing research on vaccine 
development include selection of the proper combination of antigens as well as the 
identification and implementation of an optimal administration strategy (Mot et al., 2014). 
The lack of commercially available vaccines against necrotic enteritis suggests that the 
abolishment of in-feed ionophorous coccidiostats (with an antibacterial effect against C. 
perfringens causing necrotic enteritis) may be more problematic with regard to necrotic 
enteritis than with regard to coccidiosis. 
 Eradication 2.3.2
An ideal alternative to preventive medication would be eradication from the birds’ 
environment of the causative bacterium C. perfringens and the parasites (Eimeria spp.) 
causing coccidiosis, which is an important predisposing factor for necrotic enteritis. Neither 
of these goals is easy to reach. The coccidia form oocysts, which survive outside the host 
and resist commonly used disinfectants. However, effective products are commercially 
available and their potential may not have been fully utilised up to now. A study based on 
data from 2000 to 2004 produced data suggesting that at least 25 % of Norwegian broiler 
flocks were coccidia negative, but the data also suggested an increasing trend in the 
prevalence of infected flocks (Haug et al., 2008). Eradicating C. perfringens from the broiler 
environment is even more challenging than eradication of coccidia. C. perfringens forms 
spores which can survive even more harsh environmental conditions than the coccidia. 
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 Other feed additives 2.3.3
The EU ban on antibacterial growth promoters prompted increased efforts at developing 
additives which could replace the banned products. Acid-based products, probiotics, 
prebiotics, synbiotics, yeast-based products, plant-derived products, combinations of these, 
and other products have been developed and marketed as feed additives with claimed 
positive effects on the digestive system of broilers and fattening turkeys (Abbas et al., 2012; 
Bozkurt et al., 2013; Dahiya et al., 2006; Dibner and Buttin, 2002; Geier et al., 2010; Stanley 
et al., 2014; Vidanarachchi et al., 2013). These products have been tested for efficacy 
against coccidia with conflicting, non-consistent or non-convincing results (Peek and 
Landman, 2011). Most products developed appear to target the bacterial microbiota rather 
than coccidia. 
2.3.3.1 Acid based products 
The most commonly used organic acids are propionic and formic acids, but at least 12 
different acids have been included in acid-based products 
(http://www.thepoultrysite.com/articles/2372/organic-acidbased-products-market-
evaluation-and-technical-comment ). A majority of products contain more than one acid. 
Organic acids are often combined with salts of organic acids, because such products are 
easier to handle and less corrosive. Organic acids are rapidly metabolised from crop to 
gizzard, which limits their effect on performance and intestinal microbiota, but use of double 
salts (Luckstadt and Mellor, 2011) and/or coating/encapsulation are used to overcome these 
problems. Butyric acid and potassium diformate have been shown to improve broiler 
performance and decrease the incidence of necrotic enteritis caused by C. perfringens  
(Huyghebaert et al., 2011) (Luckstadt and Mellor, 2011). However, organic acids may also 
impair broiler performance, depending on acid type and inclusion levels in the feed (Patten 
and Waldroup, 1988). 
2.3.3.2 Plant products 
Plant products (phytogenic additives) vary widely with respect to botanical origin, processing 
and composition. Many products are based on blends of various active compounds. 
Phytogenic compounds may be classified into herbs (flowering, nonwoody, and nonpersistent 
plants), spices (herbs with an intensive smell or taste commonly added to human food), 
essential oils (volatile lipophilic compounds derived by cold expression, steam or alcohol 
distillation) or oleoresins (extracts derived by non-aqueous solvents) (Windisch et al., 2008).    
The number of in vivo studies on the efficacy of plant products is still quite limited. 
Production efficiency results are contradictory, although a majority of published studies may 
seem to indicate improved performance (Hashemi and Davoodi, 2010; Hippenstiel et al., 
2011).   Blends of thymol and cinnamaldehyde (Bento et al., 2013) and of thymol, carvacol, 
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eugenol, curcumin and piperin (Mitsch et al., 2004) have been demonstrated to reduce 
intestinal counts of Clostridiumperfringens. 
2.3.3.3 Prebiotics, probiotics and synbiotics 
Prebiotics.  Gibson and Roberfroid (1995) defined prebiotics as an "ingredient of the 
nondigestible food ingredients that beneficially affect the host by selectively stimulating the 
growth and / or activity of a limited number of bacterial species already resident in the colon, 
and thus attempt to improve host health”.   Oligosaccharides are commonly used in 
commercial products. Mannan-oligosaccharides have been shown to reduce C. perfringens 
levels in turkeys (Alloui et al., 2013).  
Probiotics are defined by FAO/WHO as ‘live microorganisms which when administered in 
adequate amounts confer a health benefit on the host’ (Kabir, 2009). This definition excludes 
products based on killed bacteria, which is in agreement with the lack of solid documentation 
of the efficacy of non-viable forms of probiotic strains (Aureli et al., 2011; Nurmi and 
Rantala, 1973) detected that gut contents from adult, healthy hens could protect young birds 
against Salmonella infection in the same way as the normal intestinal microbiota of adult 
chickens (Schneitz, 2005). The term ‘competitive exclusion’ was coined to designate this 
phenomenon. Competitive exclusion (CE) products have been associated primarily with 
undefined products, i.e. products based on a high number of partially unknown strains of 
intestinal microbes from healthy individuals. The interest in probiotics as promoters of 
gastrointestinal broiler health is more recent than their use against Salmonella spp. 
Regulatory agencies have been reluctant to approve undefined microbial products due to the 
uncertainty of a consistent composition of the products. This concern has paved the way for 
defined products based on one or a few known strains (Kerr et al., 2013). Defined probiotic 
products marketed for broilers can be categorized as a) Non-spore forming bacteria (usually 
lactobacilli, enterococci, bifidobacteria) and (b) Bacterial spore formers (Bacillus spp.). 
Probiotic bacteria are vulnerable to long-lasting and high temperatures during broiler feed 
processing. A potential advantage of spore formers is their ability to survive feed processing 
and the gastric barrier, although non-spore forming bacteria are usually protected by various 
types of coating intended to ensure delivery to the intestine. The hypothesized mechanism of 
synbiotics is that they increase the levels of beneficial bacteria, compared to the 
administration of probiotics or prebiotics alone (Mookiah et al., 2014; Shimizu et al., 2013) 
and results are sometimes difficult to evaluate due to a poor design (Alloui et al., 2013). 
Partly undefined competitive exclusion products have been demonstrated to reduce levels of 
caecal C. perfringens and improve production results (Schneitz, 2005). A multi-strain 
Lactobacillus spp-based probiotic has been reported to improve average daily weight gain of 
turkeys (Kabir, 2009). Among single strain probiotics, a product based on a Bacillus subtilis 
strain have been shown to reduce intestinal C. perfringens counts and improve feed 
efficiency in a challenge experiment (Jayaraman et al., 2013).  
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2.4 Summary of hazard identification and characterisation 
Resistance to coccidiostats in bacteria 
• All five coccidiostats approved for use in Norway are ionophores that also display an 
antibacterial effect, mainly against Gram-positive bacteria.  Resistance to four of them in 
enterococci and a few other bacteria has been reported. 
• Resistance in C. perfringens, the causative bacterium for the poultry disease necrotic 
enteritis, has not been reported. 
• A limited amount of data may indicate an association between narasin and resistances 
against bacitracin, as well as between narasin and vancomycin. 
• The additional six coccidiostats which are approved in the EU display little or no 
antibacterial effect, and antibacterial resistance is therefore not considered to be a 
relevant subject. 
Resistance to coccidiostats in coccidia 
• Resistance to all the eleven coccidiostats in question has been reported. 
• It has been suggested that ionophores might develop resistance at a slower rate than 
the non-ionophore coccidiostats. 
• Various shuttle and rotation programmes are used to try to avoid or delay development 
of resistance. Information in the scientific literature on the effect of such programmes is 
scarce. 
• Cross-resistance between different ionophores has been reported. 
• Coccidia may develop resistance to more than one coccidiostat that is not due to cross-
resistance, either after exposure to several coccidiostats or by gene recombination during 
the sexual multiplication stage in the chicken intestine. 
• Horizontally transferred resistance against coccidiostats between Coccidia strains or 
between Coccidia and bacteria is not expected to be of importance in a short term 
perspective. 
Alternatives to in-feed antimicrobials 
• Eradication from the birds’ environment of coccidia (Eimeria spp.) causing coccidiosis is 
difficult to achieve because the coccidia form oocysts which survive outside the host and 
resist commonly used disinfectants. 
• Vaccination with non-pathogenic vaccines is now used increasingly in commercial 
Norwegian broiler farms, instead of in-feed coccidiostats. So far (October 2015) 
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coccidiosis has not been reported as a problem in this transition process to broiler rearing 
without in-feed coccidiostats in Norway. 
• Non-antimicrobial feed additives, i.e. acid-based products, probiotics, prebiotics, 
synbiotics, yeast-based products, plant-derived products, combinations of these, and 
other products have been developed and marketed as feed additives. These products 
have been tested for efficacy against coccidia with conflicting, non-consistent or non-
convincing results. The majority of these products appear to target the bacterial 
microbiota rather than coccidia. 
• The Panel has not assessed possible effects of other types of management changes.  
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3 Exposure  
3.1 Literature 
Human exposure to resistant bacteria 
After preliminary searches including multiple combinations of the terms antimicrobial, 
antibacterial, antibacterial, resistance, resistant bacteria, enterococci, humans, farmers, 
workers, infection, transfer, colonization, two review papers from 2006 and 2011 was chosen 
as the main sources of information. 
Human exposure to coccidiostats through handling of feed preparations and feed 
Relevant terms used in database searches using Web of Science, Google Scholar and 
PubMed: TOPIC (Ionophor OR Narasin OR Monensin OR Salinomycin OR Lasolocid OR 
Maduramicin) AND feed AND (occupational exposure OR occupation OR exposure OR 
workers); Timespan: All years 
Human exposure to coccidiostats through handling contaminated manure 
Web of Science: TOPIC: manure AND narasin AND exposure. A similar literature search with 
use of same terms, but replacing narasin with Salinomycin / Monensin / Lasolocid / 
Maudoramicin / Non-ionophore / Diclazuril / Decoquinat / Halofuginon / Nicrabazin was 
included. Also searched for: TOPIC: manure AND antibiotic AND exposure AND human, and 
same terms replacing manure with litter, human with farmer and antibiotic with anticoccidial. 
Human exposure to coccidiostats in poultry products 
Relevant terms used in database searches using Web of Science, Google Scholar and 
PubMed: TOPIC (Ionophore OR Narasin OR Monensin OR Salinomycin OR Lasolocid OR 
Maduramicin) AND (food OR meat OR eggs); Timespan: All years. The Norwegian Food 
Safety Authority’s surveillance reports were also used. 
Environmental exposure to coccidiostats 
A literature search using relevant terms such as; Narasin AND degradation AND soil OR 
manure OR litter, Narasin AND plant uptake, Antibiotic AND plant uptake, Anticoccidial AND 
soil OR manure OR compost using the Advanced Search Builder provided by PubMed or 
same topic word in Web of Science was performed.  A similar literature search with use of 
same terms, but replacing narasin with Salinomycin / Monensin / Lasolocid / Maudoramicin / 
Non-ionophore / Diclazuril / Decoquinat / Halofuginon / Nicrabazin was also performed. 
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Consumption of therapeutic antibacterials 
The following search strings were used to shed light on the risk of increased use of 
therapeutic antimicrobials in poultry production under current production practices if 
anticoccidials with antibacterial effects are replaced by anticoccidials without such effects: 
Web of Science: TOPIC: ((chemical coccidiostat*) OR (chemical anticoccidial)) AND TOPIC: 
(C. perfringens). Timespan: All years. TOPIC: (nicarbazin) AND TOPIC: (C. perfringens). 
Timespan: All years. TOPIC: (from ionophor* to (non-ionophor* OR chemical)) AND TOPIC: 
(broiler OR chick* OR poult*) AND TOPIC: ((therapeutic antibiotic*) OR therap*). Timespan: 
All years. 
PubMed: ((((((ionophore or chemical coccidiostat) OR (ionophore or chemical anticoccidial))) 
AND therap*) AND antibiotic*)) AND (broiler OR chick*). 
Resistance against narasin 
The following search strings were used for literature on resistance in coccidia and C. 
perfringens against narasin: 
Web of Science: TOPIC: (Eimeria) AND TOPIC: (narasin) AND TOPIC: (resistance OR 
tolerance). Timespan: All years. TOPIC: (Eimeria) AND TOPIC: (narasin OR monensin OR 
lasalocid OR salinomycin) AND TOPIC: (resistance OR tolerance) AND TOPIC: (Norwegian 
OR Norway). Timespan: All years. TOPIC: (C. perfringens) AND TOPIC: (narasin) AND 
TOPIC: (resistance OR tolerance). Timespan: All years. 
3.2 Statistics related to in-feed coccidiostats and Norwegian 
poultry production and consumption 
 Use of in-feed coccidiostats in broiler rearing 3.2.1
Conventional broiler rearing has up to 2015 been based on continuous use of in-feed 
coccidiostats from the day of hatch until a few days prior to slaughter. During the last few 
days before slaughter the broilers are offered a feed without coccidiostats. Narasin is the 
only coccidiostat that has been used in Norwegian broiler rearing during the last 15-20 years. 
The in-feed inclusion rate of narasin is 70 mg/kg. The switch to narasin was prompted by 
outbreaks of severe necrotic enteritis in 1995, emerging shortly after the abolishment of in-
feed antibacterial growth promoters. The antibacterial growth promoter that had been use in 
Norway was avoparcin from 1987, and the ionophorous coccidiostat used to most broilers 
from 1988-1995 was monensin. The reason narasin was chosen was probably the fact that 
this ionophore had been used with success and without antibacterial growth promoters in 
Sweden since 1990. 
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Up to 2015 only a small fraction (less than 10 %) of Norwegian broilers has been reared 
without in-feed coccidiostats. In 2014 two major distributors of broiler meat (Nortura and 
Norsk kylling) declared as their intention to abolish all use of in-feed coccidiostats gradually 
during 2015 and 2016. 
 Use of in-feed coccidiostats in turkey rearing 3.2.2
Norwegian slaughter turkeys are offered in-feed coccidiostats from day of hatch until they 
are approximately seven to nine weeks old. Female turkeys are slaughtered at approximately 
11 weeks of age, male turkeys at approximately 17-18 weeks of age. Hence, female and 
male turkeys are raised without coccidiostats approximately 30 and 50 % of their rearing 
period respectively. Because feed consumption is highest during the last part of the rearing 
period, the fractions of feed without coccidiostats are higher than 30 and 50 %. 
 Feed statistics reported by NFSA 3.2.3
In NFSA’s annual report on feed statistics, coccidiostat levels in commercial feeds are 
reported following random samplings conducted during NFSA’s surveillance program each 
year. For 2013, for example, coccidiostat levels were analysed in a total of 81 random 
samples. Among these, 26 samples contained coccidiostat levels in compliance with declared 
amounts by the feed producers and the minimum-maximum concentration ranges specified 
in the Norwegian and Commission regulations (see Tables AIII-1 and AIII-2 in Appendix III). 
Deviations were observed in one sample, in which the level measured was below the 
declared level by the feed producer and the deviation was greater than the method’s level of 
uncertainty (NFSA, 2014). 
Table 3.2.3-1  Use of coccidiostats in poultry feeds from 2009 to 2014 shown as tonn feed 
added coccidiostats and kilogram active substance of the coccidiostats 
Type of 
coccidiostat 





















2009 700 63 11034 885 126781 8621 138516 9569 
2010 0 0 9417 805 133672 9080 143143 9885 
2011 0 0 11325 1060 137320 9394 148645 10454 
2012 0 0 12309 1080 150503 10378 162812 11458 
2013 0 0 13360 1174 178233 12345 191593 13519 
2014 0 0 15824 1313 182790 12409 198614 13722 
 
VKM Report 2015: 30  78 
 
 
 Minimum and maximum content of coccidiostats allowed in complete 3.2.4
diet formulations for poultry 
The minimum and maximum levels of various coccidiostats in complete diet formulations are 
given in Appendix III’s Table AIII-1 for those authorized for use in Norway and the EU and 
Table AIII-2 for those authorized in the EU but not Norway. It is important that the feed 
producers comply with these ranges to aid in avoiding development of antimicrobial 
resistance that may occur when insufficient doses are added and to avoid intoxications that 
may result when excessive doses are added. It is for these reasons the surveillance includes 
monitoring of coccidiostat levels following random sampling of broiler and turkey feeds. As 
indicated in section 3.2.6, in the last five years, non-compliance was observed in one of 26 
samples (3.8%) in 2013 (NFSA, 2014). 
 Animal exposure to coccidiostats 3.2.5
Mean daily feed intake estimate for broilers (5 week production cycle) was calculated to be 
95 g, ranging from 13 to 186 g for day 1 and 35, respectively. Thus, mean daily Narasin 
exposure would be in the range of 5.7-6.7 mg per day, ranging from a minimum of 0.8 to a 
maximum of 13 mg for day 1 and 35, respectively. Estimated cumulative exposures during a 
production cycle as they pertain to current practices in Norway are given in Table 3.2.5-1. 
Mean daily feed intake estimate for turkeys during the first 7-9 week production cycle when 
they receive Monensin-supplemented diets was calculated to be as much as 92 g (range 11-
190 g from week 1 to week 9) for hens and 110 g (range 12-235 g from week 1 to week 9) 
for toms. Thus, mean daily Monensin exposure would be in the range of 6-9 mg (range 0.7-
19 mg) for hens and 7-11 mg for toms (range <1-24 mg). Estimated cumulative exposures 
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Table 3.2.5-1  Estimates of target animal exposure (broilers and turkeys coccidiostat intake) 
















Monensin Broilers 100-125 5 3.3 330-413 
Monensin Turkeys 60-100 9 5.8 for females 348-580 
Monensin Turkeys 60-100 9 6.9 for males 414-690 
Narasin Broilers 60-70 5 3.3 198-231 
* For broilers, in-feed coccidiostat supplementation is practiced during the entire production cycle, 
with the exception of the day(s) just prior to slaughter as prescribed by the applicable withdrawal 
period for each coccidiostat. For turkeys, in-feed coccidiostat supplementation is only practiced during 
the first 7-9 weeks of the total production cycle. 
 Cross-contamination during feed production 3.2.6
During feed production, the coccidiostat-containing premix is added with other feed 
ingredients during feed formulation. Following production of the coccidiostat-containing feed, 
low levels of coccidiostats are retained within the production line, which is a source of cross-
contamination of the next feed produced, in some cases for a non-target species or category 
of animal, e.g. a mammal or layer hens. Especially the initial quantities of feeds that come 
off the production line can contain high levels of coccidiostats and should be discarded. Yet 
some cross-contamination still occurs in feeds for non-target animals, as reflected by 
surveillance data reported by NFSA (see below). 
EFSA has conducted risk assessments of cross-contamination of non-target feedstuffs with 
the registered coccidiostats (EFSA, 2007; EFSA, 2008a; EFSA, 2008b; EFSA, 2008c; EFSA, 
2008d; EFSA, 2008e; EFSA, 2008f; EFSA, 2008g; EFSA, 2008h; EFSA, 2008i; EFSA, 2008j). 
The physicochemical properties of the coccidiostat-containing pre-mixes appear to be of 
relevance for the degree cross-contamination that can occur between batches of feeds made 
in multi-product feed plants, i.e. those that produce feeds for a range of animal 
categories/species. These pre-mix properties will affect the levels of active ingredients that 
are retained within the production line and consequently appear in other feeds. 
In NFSA’s feed surveillance reports (Fôranalyser) over the last five years, all but one feed 
and pre-mix sample for target animals, mainly broilers and turkeys for fattening, tested for 
declared coccidiostat levels have shown compliance (see Table 3.2.6-1). However, numerous 
feed samples for non-target species or categories of animals have contained coccidiostats at 
trace levels, i.e. above or below maximum residue levels (MRLs) as specified by the 
Norwegian “Forskrift om fôrvarer” (Regulation for feedstuffs) of May 2, 2012, indicating low 
levels of cross-contamination. In 70 random samples analysed in 2014, 12 of the samples 
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(17%) contained trace amounts of coccidiostats (NFSA, 2015). In 2013, 17 of 53 (32%; 
NFSA, 2014); in 2012, 12 of 44 samples (27%; NFSA, 2013), in 2011, 15 of 31 samples 
(48%; NFSA, 2012); and in 2010, 1 of 13 samples (8%; NFSA, 2011) contained trace levels 
of coccidiostats. Of the 53 samples analysed in 2013, 11 samples contained traces of 
narasin, three contained traces of narasin and monensin, one contained traces of narasin 
and nicabarcin, and one contained traces of narasin, monensin and salinomycin.  
Table 3.2.6-1  Monitoring coccidiostat content (narasin, monensin, robenidine, salinomycin, 
lasalocid, nicarbazin, diclarzuril and maduramycin) in feedstuffs for target (those meant to receive in-
feed coccidiostats) and non-target (those not meant to receive in-feed coccidiostats) animals under 



















2012 52 8 0 12 (9/3) 
Ruminants1 0 - - - 
Pigs1 18 0 0 0/25 
Poultry1 18 1 0 7/16 
Premixes2 16 7 0 2/0 
Other feeds3 0 - - - 
2013 81 28 1 16 (16/0) 
Ruminants1 11 0 0 0 
Pigs1 19 0 0 5/0 
Poultry1 49 26 1 11/0 
Premixes2 2 2 0 0 
Other feeds3 0 - - - 
2014 70 23 0 13 (11/2) 
Ruminants1 6 0 - 1/0 
Pigs1 20 0 0 5/0 
Poultry1 41 21 0 4/27 
Premixes2 3 2 0 0 
Other feeds3 0 - - - 
1 The feeds for ruminants, pigs and poultry are formulated feeds for the respective animals; 2 Pre-
mixes are generally blended feed ingredients containing single nutrients, such as vitamins and 
minerals, as well as other feed additives; 3 “Other feeds” pertain to formulated feeds for animal 
species other than those specified. 4 Feeds for non-target animals refers to those that are not meant 
to contain coccidiostats; values given in the column are number of analysed samples containing trace 
levels of coccidiostats as a result of cross-contamination that are below MRL/above MRL; MRL = 
maximum residue level; as set by the Norwegian regulations concerning feedstuffs (Forskrift om 
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fôrvarer); 5 Of the 2 pig feeds containing trace levels of coccidiostats above declared values of 0 in 
2012, both contained narasin levels above MRL – 2.3 and 2.4 mg/kg; 6 Of the 8 poultry feeds 
containing trace levels of coccidiostats above declared values of 0 in 2012, one sample contained 
narasin levels above MRL – 0.75 in a feed for other poultry; 7 Of the 6 poultry feeds containing trace 
levels of coccidiostats above declared values of 0 in 2014, 2 contained narasin levels above MRL – 7.3 
mg/kg in a broiler finishing feed and 1.6 mg/kg in a feed for layers. 
 Consumption of poultry products in Norway 3.2.7
The Norwegian production is entirely consumed nationally. In addition to this, there is some 
import of chicken and turkey, but this is at present marginal compared to domestic 
production. The annual production of chicken meat was in 2013: 91 931 000 kg and of 
turkey meat 9 856 000 kg. This corresponds to an annual real consume (eaten) of 
52 353 000 kg poultry meat (http://animalia.no/), approximately 10 kg per person. 
In the Norkost 3 consumption study based on two 24-hour recalls by telephone at least one 
month apart, food amounts were presented in household measures or estimated from 
photographs (Totland et al., 2012). The study was conducted in 2010/2011, and 1787 adults 
(925 women and 862 men) aged 18-70 participated. Mean poultry consumption was 30 
g/day for all participants and 82g/day among those who repoted to eat poultry. 
Table 3.2.7-1 Consumption of poultry in Norkost 3 consumption study (n=1787), gram/day  
Type of product consumed All (n=1787) Women (n=952) Men (n=862) 
 Mean P951 Mean P951 Mean P951 
Broiler meat, g/day 25 131 22 112 28 150 
All broiler products, g/day 27 131 23 113 30 150 
All poultry, g/day 30 136 26 120 34 162 
1 95 percentile 
 
Table 3.2.7-2 Consumption of poultry in Norkost 3 consumption study, gram/day per dose who 
consume poultry (consumers only) 
Type of product consumed All Women Men 
 n mean P951 n mean P951 n mean P951 
Broiler meat, g/day 530 84 188 281 71 150 249 99 258 
All broiler products, g/day 576 83 195 304 71 150 272 96 235 
All poultry, g/day 650 82 199 343 71 162 307 94 232 
1 95 percentile 
Explanation of the tables: The variable named "Broiler meat" is just meat and skins from 
whole broiler, i.e. whole broiler, broiler legs and wings. The variable named "All broiler 
products" is broiler meat plus all products of broiler, e.g. sausages, pies, burgers, snitzel and 
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the like. The last variable is called "Poultry" and here is all consume of broiler, turkey, duck 
and goose merged. 
3.3 Human exposure to resistant bacteria 
 How can humans be exposed to resistant bacteria from animal 3.3.1
production chains? 
Humans may be exposed to coccidiostat resistant bacteria from poultry in a number of ways, 
e.g. by handling live animals, their manure, though slaughtering and processing, and by 
preparation and consumption of meals from poultry products (Figure 3.3.1-1). Routes of 
exposure are by direct contact, ingestion and inhalation. 
A number of studies indicate that animal-human transfer of bacteria resistant to various 
antibacterials has occurred (Reviewed by Marshall and Levy (2011)). The studies focus on 
bacteria in the gastrointestinal tract, and do not include data on bacterial resistance against 
coccidiostats. In general, the studies show that farm and slaughterhouse workers, 
veterinarians, and those in close contact with farm workers are directly at risk of being 
colonized or infected with resistant bacteria through close contact with colonized or infected 
animals, or their manure and litter. Likewise, human consumption of food carrying 
antibacterial-resistant bacteria may result, either directly or indirectly, in acquisition of 
antibacterial-resistant infections. For example in the United States, where gentamicin 
remains the most commonly used antibacterial in broiler production, a revelatory study in 
2007 found that the risk for carrying gentamicin-resistant E. coli was 32 times higher in 
poultry workers than in other members of the community: half of all poultry workers were 
colonized with gentamicin-resistant E. coli, while just 3% of nonpoultry workers were 
colonized (Luangtongkum et al., 2006). In a Dutch study, identical resistance patterns of E. 
coli were found in turkeys, turkey farmers and turkey slaughterers and in broiler, broiler 
farmers and broiler slaughterers, strongly indicating transmission of resistant clones and 
resistance plasmids of E. coli from poultry to humans (Van den Bogaard et al., 2001). In 
Denmark, similar resistance patterns and genes were detected in E. faecalis and E. faecium 
strains from humans, broilers, and swine (Aarestrup et al., 2000).  
Regarding colonization and gene transfer in enterococci, the Panel is not aware of any data 
on coccidiostat resistance genes. However several experiments have been performed with 
bacteria resistant to other antibacterials (reviewed by Angulo et al. (2006)). Only transient 
intestinal carriage was observed in 18 volunteers after ingestion of antibacterial-resistant E. 
faecium from chicken and pork, and all stool samples were negative after 35 days (Sørensen 
et al., 2001). Interestingly, when E. faecium strains of human origin were fed to human 
volunteers, the same duration of colonization was observed (Lauková et al., 2004). This 
suggests that host specificity is not the main issue that determines prolonged enterococcal 
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colonization of the gut. Furthermore, typing of the most common enterococci in the intestine 
of human volunteers showed that the enterococcal flora of the human intestine often 
changed, which may indicate that enterococci in general do not colonize for extended 
periods of time (Gelsomino et al., 2003). However, it has been shown that transfer of 
resistance genes from enterococci of animal origin to enterococci of human origin did occur 
in healthy humans (Lester et al., 2006). Likewise, resistants genes were transferred between 
enterococci of animal and human origin in vivo in the intestinal tracts of mice (Bourgeois‐
Nicolaos et al., 2006; Mater et al., 2005). These studies show that, although enterococci can 
be placed in an environment different from their origin where they may be reluctant to 
colonize, transfer of resistance genes may occur in vivo, in animals as well as in humans. 
The significance of this, however, will depend on the frequency of horizontal transfer and on 
the availability of donor strains. 
 
Figure 3.3.1-1 Theoretical routes for human exposure to coccidiostats and coccidiostat 
resistant bacteria in the poultry production food chain. 
 Coccidiostat resistant bacteria in the Norwegian poultry production 3.3.2
chain 
The Norwegian surveillance programme NORM-VET has been monitoring the prevalence of 
coccidiostat resistant enterococci in the poultry production chain since 2002. However, only 
resistance against narasin has been investigated. Narasin resistant enterococci have been 
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identified in samples from broilers and turkeys, as well as from broiler and turkey meat, as 
summarized in Table 3.3.2-1. In the years not included in the table, narasin resistance was 
not investigated. Each sample taken represents one flock or one piece of meat. Details of the 
sampling procedures are described in Appendix IV. If enterococci were present in a sample, 
one randomly selected strain being either E. faecalis or E. faecium was subjected to 
resistance testing. The cut-off value for narasin resistance in E. faecium was changed in 
2013 from 2 mg/L to 4 mg/L as suggested by EUCAST. In this report, the cut-off of 2 mg/L is 
chosen for all isolates because 4 mg/L, according to the NORM-VET representatives, cuts 
through MIC distributions for E. faecium  from some animal categories studied (e.g. broilers) 
in a manner not in agreement with the concept of wild-type distributions. When using the 
cut-off value of 2 mg/L, percentages are approximate twice as high as those resulting from a 
cut-off of 4 mg/L. 
The data show in general a low percentage of narasin resistant E. faecalis, whereas the 
percentage of resistant E. faecium isolates is high. The total percentage of narasin resistant 
enterococci in the samples is high for both broilers and turkeys. Enterococci (both non-
resistant ant resistant) were isolated from more than 90 % of the faecal samples, and E. 
faecium was the dominant species from both broilers and turkeys. Consequently, the total 
percentage of narasin resistant enterococci was also high in faeces, i.e. 62 % in broilers and 
67 % in turkeys. In the meat samples from broilers, the percentage of enterococci isolated 
was lower (82 %) and only half of these were E. faecium. Therefore the total percentage of 
resistant enterococci was lower than in faeces, i.e. 36 %. The percentage in turkey meat 
was even lower, but this was only tested one of the years, which makes the data less 
reliable. 
Monensin, but not narasin, is used as a coccidiostat in turkeys. The narasin resistance 
observed in enterococci from turkeys is probably due to cross-resistance between monensin 
and narasin. These two coccidiostats belong to the same class of inonophores, and cross-
resistance between the two has been observed in coccidia (Westley, 1982). Very few narasin 
resistant isolates were identified in faeces from layers (1.5 % of all samples), as can be 
expected since coccidiostats are not used in layer feed. 
In addition, E. hirae, which is a pathogen, was isolated from specimens collected in disease 
outbreaks in broiler production in 2010. Resistance to the narasin was detected in 27 of 41 
these isolates (66 %). This disease emerged as a problem in Norwegian broilers around year 
2000, but does not appear to have been of major significance during recent years. 
  
 
VKM Report 2015: 30  85 
 
 
Table 3.3.2-1  Narasin resistant isolates identified in the Norwegian surveillance programme 
Norm-Vet during the years 1999-2014 
Source Year Total no. of 
samples1 
Samples with enterococci Samples with resistant 
enterococci 
   No. % No. % 
Broiler 
faeces 
2002 166 149 90 87 53 
2004 91 84 92 72 79 
2006 219 205 94 165 75 
2011 252 238 94 126 50 
All 
years 
728 676 93 450 62 
Turkey 
faeces 
2007 58 55 95 35 60 
2013 131 128 98 89 68 
All 
years 
189 183 97 124 66 
Broiler 
meat 
2002 212 175 83 43 20 
2004 100 79 79 49 49 
2006 126 103 82 68 54 
All 
years 
438 357 82 160 37 
Turkey 
meat 
2007 107 72 67 24 22 
All 
years 
107 72 67 24 22 
1 Each sample represents one flock or one piece of meat. One enterococcal isolate from each sample 
was tested for resistance. 
 Exposure of workers to coccidiostat resistant bacteria 3.3.3
Broiler: In the NORM-VET surveillance programme enterococci resistant against 
coccidiostats were identified 62 % of the samples (Table 3.3.2-1). Each sample represents 
one flock. The number of flocks per farm per year is usually between six and eight. The 
Panel has no information on whether all sampled flocks are from different farms. However, 
for the purpose of this risk analysis, the Panel assumes that each flock sampled represents 
one farm.  Furthermore, the Panel assumes that if a farm has one flock with resistant 
bacteria, there is a high probability that the other flocks on this farm will harbour such 
bacteria. Consequently, the Panel assumes that the incidence of samples positive for 
resistant enterococci is approximately the same for farms as for flocks. According to the 
NORM-VET reports, sampling is performed one to three weeks before slaughter. As broilers 
are slaughtered at age 28 – 32 days, this implies that they may harbour narasin resistant 
bacteria from quite a young age. 
The bacteria can also survive outside the animal host, e.g. in manure. Furthermore, narasin 
will also be excreted to the manure (see chapter 3.4.3), meaning that in addition to the 
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narasin resistant bacteria from the broilers, other bacteria in the manure may also develop 
narasin resistance. In addition, resistance genes may be transferred between the bacteria in 
the manure by horizontal transfer, thus increasing the number of resistant bacteria. Various 
treatments, e.g. composting, of the manure may reduce the number of enterococci present. 
Assessment of the effects of such methods has not been performed. 
Consequently, when regularly handling manure, as well as equipment, clothing and anything 
else that has been in contact with this including animals, the farmers and other production 
workers will be exposed to resistant bacteria if they are present in the flock. Main route of 
exposure is direct contact. Exposure through inhalation is also possible. Adequate hygienic 
protection procedures will reduce the risk of exposure, e.g. restricted access, protective 
clothing and hygienic barriers, proper procedures for disposal of manure and litter, as well as 
cleaning and disinfection. As far as the panel knows, there is extended use of such 
procedures on Norwegian broiler farms today. The same considerations apply to workers in 
slaughteries and the food processing industry. 
Turkeys: For Norwegian turkeys, the coccidiostat feed additive is not narasin, but 
monensin. It is not known from literature that monensin can induce resistance against 
narasin in enterococci, but indications of cross-resistance between these two coccidiostats 
have been observed in coccidia. There is no information on the prevalence of monensin 
resistant enterococci in the Norwegian turkey production chain. However, 66 % narasin 
resistant enterococcal isolates from Norwegian turkeys is reported. As this is most probably 
due to cross-resistance between narasin and monensin, the cross-resistance may be 
incomplete, indicating that the level of monensin resistance is at least as high as that of 
narasin. Turkeys are slaughtered at ages 11-12 weeks (hens) and 18-20 weeks (roosters) 
and sampled for monitoring of narasin resistant enterococci one to three weeks before. 
Therefore, it is not known how early in life they acquire or develop resistant bacteria. 
However, they are only offered in-feed coccidiostats from day of hatch until they are 
approximately seven to nine weeks old, meaning that resistance development must have 
occurred within this time period. Apart from this, the panel assumes that the same 
considerations apply for turkey as for broiler production. 
 Exposure of consumers to coccidiostat resistant bacteria 3.3.4
Data from the NORM-VET surveillance programme showed that 37 and 22 % of the pieces of 
raw meat from broiler and turkey, respectively, harbored enterococci resistant to narasin. 
Main routes of consumer exposure are direct contact by handling of fresh and frozen raw 
poultry meat and ingestion of non heat treated products. The bacteria will not survive the 
heat treatment of normal cooking of poultry meat and products. The same hygienic 
procedures that are recommended for handling raw meat in general will reduce the risk of 
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exposure, e.g. hygienic barriers between the meat and other food products, proper heat 
treatment, hand wash and general kitchen hygiene. 
3.4 Human exposure to resistance development 
 Development of resistance to coccidiostats in the human microbiota 3.4.1
Bacteria of the human normal microbiota may develop resistance if they are exposed to 
coccidiostats. All human skin and mucosal surfaces are covered by bacteria, i.e. the normal 
microbiota which consists of ten times as many bacterial cells as the human body’s own 
cells. The bacteria of the normal microbiota may be exposed to coccidiostats by direct 
contact, ingestion and inhalation. The Panel is not aware of any information on the level of 
exposure, e.g. the amount of coccidiostats or the time period, necessary for the various 
bacteria to give rise to resistant variants. 
 Human exposure to coccidiostats through handling of pre-mix 3.4.2
preparations and feed 
Instructions for safe handling of veterinary medicinal products and feed additives are 
generally provided with the products, including coccidiostats. Adherence to such instructions 
should minimize the probability of exposure of workers who handle the products during pre-
mix and feed preparation and handling via various routes, including over the skin and 
airways. In the scientific literature, however, occupational exposure of feed mill and farm 
workers has received little attention and certainly as it pertains to the contribution to 
development of antibacterial resistant bacteria in humans. Measures have been implemented 
to reduce human occupational exposure to and absorption of coccidiostats. To reduce 
dusting, and thereby primarily skin and airway exposure but also indirect oral exposure, 
coccidiostat-containing pre-mixes are now in the form of granules rather than powders. Both 
feed mill and farm workers are advised to wear protective equipment, such as masks and 
gloves. However, studies in which occupational exposure to coccidiostats is quantified were 
not found in the peer-reviewed scientific literature and therefore the significance of skin and 
airway exposure to total exposure cannot be quantified accurately. Without the use of 
protective masks and garments it can, however, be assumed that the risk of exposure is 
high, but will be substantially reduced if protective measures are used. In any case, workers, 
including farmers, who prepare and handle coccidiostat-containing pre-mixes and feed 
should be treated as “high consumers” and appropriate measures should be reinforced to 
reduce the risk of development of antibacterial resistant bacteria in these human 
populations. 
The coccidiostats on the market are available in pre-mixes with concentrations in the range 
of 10-200 g/kg for the those registered in Norway (see Table AIII-1 of Appendix III) and 5-
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250 g/kg for those registered in the EU (see Table AIII-2 of Appendix III), depending on the 
active ingredient and producer. Other diluting, inactive ingredients are included in the pre-
mixes at variable levels as technical aids, such as various oils (e.g. soya or mineral oil), 
minerals, starch, sugars, fibre sources (e.g. wheat bran, rice or soybean hulls). The pre-mix 
is incorporated into the formulated feed during the mixing stage. 
The physicochemical properties of the pre-mixes appear to be of relevance for the degree 
and route of exposure of workers. Narasin, for example, can cause irritation to the eyes, has 
been shown to be toxic in dogs when inhaled, and has sensitisation potential with skin 
contact and by inhalation. Due to the sensitising properties of Narasin, EFSA’s FEEDAP Panel 
recommends the use of appropriate personnel protective equipment for the workers (EFSA, 
2004c). In addition, the pre-mixes containing narasin are in the form of granules with a low 
dusting potential. Narasin is not, however, considered as toxic via the oral route and less 
attention has perhaps been directed toward the prevention of oral ingestion. On the other 
hand, when protecting against inhalation, masks protecting both the nose and mouth are 
generally used.  
For some of the registered coccidiostats, safety provisions are provided in the Norwegian and 
Commission Regulations governing their use (Table 3.4.2-1). 
Table 3.4.2-1  Summarizes of the safety precaution specified for each registered coccidiostat 
according to the Norwegian and Commission Regulations governing their use 






Narasin X X X 
Monensin-Na   (X) X X 
Lasalocid-Na    
Salinomycin-Na    
Maduramicin ammonium 
alfa 
X X X 
Nicarbazin    
Narasin+Nicarbazin X   
Robenidine HCl    
Decoquinate    
Semduramicin    
Diclazuril X X X 
Halofuginone    
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 Human exposure to coccidiostats through handling contaminated 3.4.3
manure 
Workers can be exposed to manure (manure is here used as term for excreta and litter, be 
aware of different use of terminology in the literature) at different stages; i) during 
slaughter, ii) transporting manure out of poultry house – normally with use of tractor-, iii) 
cleaning the poultry house (after slaughtering and starting up with new stock) where 
residues of manure will be removed manually, iv) during handling stored manure or during 
composting, v) spreading manure at agricultural fields, and vi) handling of manure for 
production of commercial poultry fertilizer products. The extent of exposure depends on 
which stage workers are in contact with manure, which measures are taken during the work, 
and the coccidiostat residue levels in manure. In an EFSA report regarding environmental 
risk assessment of additives, products and substances used in animal feed (EFSA, 2007), 
estimation of residue levels in manure was based on the assumption 100% excretion of 
unchanged parent coccidiostats. This approach is an overestimation and in order to obtain a 
more realistic exposure concentration in excreta or manure, pharmacokinetics data for the 
given coccidiostat in addition to their reduction rate during storage/treatment of manure is 
needed. 
3.4.3.1 Excretion of coccidiostats and residue levels in excreta and manure 
Excretion studies with use of 14C-labelded coccidiostats have been performed.  As shown in 
section 3.4.4, narasin excretion more than 85 % of 14C-labelled narasin within 48 h (FAO, 
2009b) and 81.9 % within 3 days (Catherman et al., 1991) have been measured. Another 
study reported by EFSA (1991) where nicarbazin and narasin were given in combination, 
showed that 80 % and 99% of recommended dosage was excreted, respectively, whereas 
30 % of excreted narasin was parent narasin and 20 % as hydroxylated metabolites. Six 
major metabolites which incorporated the dihydroxy and trihydroxynarasin structure were 
identified and they accounted for 20 % of the parent antibacterial activity and for a very 
weak ionophoric activity. The fate of the remaining 50 % is not known, but the antimicrobial 
activity of the excreted product is low. The data reported by FAO (2009b) showed that 
narasin was extensively metabolized by chicken liver and that oxidation was the primary 
metabolism pathway. Fifteen metabolites and the parent narasin were found in the excreta 
and that both distribution and relative magnitude of radioactivity from liver and excreta were 
similar. 
A comprehensive experimental study investigating chicken excretion kinetics of six 
coccidiostats (non-labeled substances), their reduction during storing and composting and 
plant uptake, has been performed by Gent University – Laboratory of Food Analysis and 
Institute for Agricultural and Fisheries research (Ghent, 2012). Of the five coccidiostats 
approved in Norway, only maduramicin was not included in this study. The selection of 
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substances was based on chemical structure, lipid solubility, working mechanisms and their 
application in Europe. For instance, for the coccidiostats approved in Norway the octanol-
water coefficient (log Kow) ranged from 2.4 for salinomycin (EFSA, 2004d) to 6.74 for 
lasalocid (Swan, 2012). These two substances reflect more than twenty thousand times 
difference in hydrophobicity which again reflects the difference in bioavailability and water 
solubility. 
In this study (Ghent, 2012), manure was defined as wet excreta only and litter defined as 
excreta, bedding material, feathers, wasted feed and wasted water. In order to avoid 
confusion, the term manure will be used for excreta in bedding material in the present risk 
assessment. The excreta without bedding, collected from broilers kept in digestibility cages, 
represented the worst-case scenario residue concentration of the coccidiostats. In this study 
a wood shaving thickness of approximately 10 cm was used (and more added when manure 
became too wet). A summary of the coccidiostats concentration measured in feed, excreta 
and manure is shown in Table 3.4.3.1-1. Narasin concentration in manure in the same range 
as found in the Ghent study have been observed in commercial poultry farms (average 12.7 
mg/kg dm)(Furtula et al. 2010) and in an experimental study (13 mg/kg dm) (Eggen et al., 
2011; Østensvik, 2008). 
The residue concentration of coccidiostats in fresh manure will in addition to excretion 
kinetics be influenced by the production practice such as room- and floor temperature and 
the depth of bedding layer. In Norwegian poultry production it is recommended to use 
approximately 1 and 2-3 cm layer of bedding material for broiler and turkey, respectively 
Bagley (2002). Thus, it might be expected a lower dilution effect which again might result in 
higher residue level of coccidiostats in manure with the Norwegian practice than the 10 cm 
bedding layer used in the study at Ghent University.  
It was recently observed that many pharmaceuticals which are excreted by humans as 
conjugates are reconjugated back to active parent compounds in wastewater treatment 
plants (Verlicchi et al. 2012). The extent of conjugation of coccidiostats in poultry is not 
known, neither the possibility for reconjugation during e.g. storage or composting. 
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Tab 3.4.3.1-1  Coccidiostat concentration in feed, excreta and manure (Ghent, 2012). 
Measured concentrations in excreta and manure are given in fresh weight (fw) and dry matter (dm) 
Substance Dosage in feed 
(mg/kg) 
Reported mean residue levels in excreta and manure before 
storage/composting (mg/kg) 
 Expected Measured Excreta (fw) Excreta (dm) Manure (fw) Manure (dm) 
Narasin1 50 46 ± 10 6.2 ± 2.0 21.8 7.0 ± 2.0 14.3 
Monensin1 120 137 ± 30 23.6 ± 5.7 78.9 12.0 ± 0.6 24.2 
Salinomycin1 70 80 ± 6 3.6 ± 0.3 10.4 3.8 ± 0.9 7.3 
Lasalocid1 100 109 ± 28 20.9 ± 2.7 102.7 15.9 ± 6.2 36.8 
Nicarbazin2 50 43 ± 5 18.8 ± 1.5 66.5 26.3 ± 2.6 53.4 
Diclazuril2 1 1.160 ± 0.003 0.28 ± 0.02 0.9 0.29 ± 0.01 0.6 
1regulated in Norway; 2regulated in Europe and not in Norway 
3.4.3.2 Disappearance of coccidiostats during storage and composting  
The term ‘disappearance fate’ includes several removal processes. In addition to abiotic and 
biotic degradation, physical trapping in nanopores in soil particles, immobilization due to 
covalent binding to organic matter (also called unextractable residue) (Kästner et al., 2014), 
and evaporation of volatile substances are part of this term. The disappearance fate of 
substances will depend on their physicochemical properties and the present biotic and abiotic 
environment; such as the microbial community and activity, temperature, redox conditions 
and water content to mention some factors. There are some studies on disappearance of 
coccidiostats in manure during storage and composting (e.g. (Ghent, 2012; Sun et al., 2014; 
Žižek et al., 2014), but high variation in disappearance fates are observed.  
In the study by Ghent University, manure was first stored in bins for two months without any 
composting was initiated (< 40°C). Then the compost process was speeded up and 
performed in small scale vessels for 1.5 month (41-62°C). The average reduction during the 
storage period (< 40°C) was 22% for diclazuril and for the other coccidiostats in the range 
of 68-96% (Table 3.4.3.2-1). During the composting process (> 40°C) the reduction 
efficiency of diclazuril increased to 79%, which was a 57% additional reduction. A storage 
study of fresh excreta at room temperature during one month was also performed. The 
average reduction was 4% for diclazuril, 33-39% for lasalocid and nicarbazin, and 78% and 
83% for salinomycin and narasin, respectively. The coefficient of variation for the manure 
data was high. For narasin it was 88%, and the measured concentration of monensin was 
higher after storage than before. This demonstrates the challenge of representative sampling 
due to the inhomogeneity of manure which forms clumps and which also might lead to 
different environmental conditions, e.g. redox-conditions, within a sample. The coefficients 
of variation in fresh manures were much lower and ranged from 8.1 to 24.3%.  
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In addition to the inhomogeneity of manure, the abiotic and biotic factors mentioned above 
determine the rates of the different disappearance processes and are also part of the 
explanation of the observed high difference in reduction rates.  
Sun et al. (2014) performed a degradation study in broiler manure (excreta and bedding 
material) which demonstrated high influence of water content and temperature; reduction of 
salinomycin and narasin in manure was stimulated with enhanced water content, and at 
optimal water content, reduction occurred both at 35 and 45 °C but was inhibited at 60 °C. 
Independent of water content and temperature, no monensin reduction in manure occurred.  
However, abiotic reduction of monensin in soil microcosms was observed in the same study.  
Composting has been demonstrated to enhance the reduction rates; e.g. for salinomycin 
half-life a few days (Hansen et al., 2012; Ramaswamy et al., 2010), for monensine half-lives 
from 22 day in manure and 11 day during composing (Dolliver et al., 2008) and for lasalocid 
during aging manure and composting half-lives 62 day and 18 days, respectively, (Žižek et 
al., 2014). There exist a numbers of papers regarding composting of therapeutic veterinary 
and human antibacterials but since reduction fate is so dependent on substances’, properties 
of these data are not useful for this risk assessment. 
To summarize, it is reasonable to assume that workers in contact with well composted 
manure will be exposed to lower coccidiostat levels than workers in contact with stored 
manure. Workers in contact with fresh excreta or manure have highest probability for 
exposure of highest residue levels of coccidiostats. There are few studies of coccidiostats 
excretion in chicken, both concerning reliable residue levels of parent compounds in excreta, 
and which metabolites are excreted. Furthermore, the ability of such metabolites to induce 
resistance in microorganisms is not known. Due to lack of knowledge, it is difficult to perform 
a realistic exposure evaluation for workers handling poultry manure.  
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Table 3.4.3.2-1 Reported residue concentrations of coccidiostats, given in µg/kg fresh weight (fw) and dry matter (dm), in excreta and manure before 
and after storage or composting at different temperatures (Ghent University, 2012) 
Substance Residue concentration ± standard deviation (SD) in 
manure and litter before storage or composting (µg/kg) 
Reported mean residue levels in manure and litter after storage/composting (µg/kg) 
Manure Litter Manure after 1 month 
storage (room temp) 
Litter after 2 months 
composting (<40°C) 
Litter after 2 months 
composting (>40°C) 
fw dm fw dm fw dm % 
red. 
fw dm % 
red. 
fw dm % red. 
Narasin1 6155 ± 956 21749 7019 ± 1975 14252 1370 ± 
1206 
3795 83 335±332 1614 89 155±78 467 97 
Monensine1 23615 ± 5741 78848 11982 ± 569 24231 43015 ± 
9502 
110436 0 1256±755 5255 78 438±211 1375 94 
Salinomycin1 3586 ± 327 10364 3827 ± 906 7303 1144 ± 585 2304 78 73±10 320 96 43±6 160 98 
Lasalocid1 20891 ± 2741 102658 15921 ± 6212 36812 22964 ± 
10834 
68652 33 1055±223 5718 84 328±116 1262 97 
Nicarbazin2 18823 ± 1517 66512 26291 ± 2590 53383 14548 ± 
6069 
40299 39 3533±1134 17027 68 2081±983 6268 88 
Diclazuril2 278 ± 24 890 294 ± 11 602 325 ± 42 856 4 91±8 467 22 38±3 129 79 
1 approved for use in Norway; 2 approved for use in Europe and not in Norway 
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 Human exposure to coccidiostats in poultry products 3.4.4
One question that arises is whether humans are exposed to coccidiostats when consuming 
chicken flesh or other products. Traditionally, all veterinary medicinal products administered 
to food-producing farm animals must be discontinued for a set period of time to avoid 
human exposure to the drugs when they consume the animal products. This time period is 
called the withdrawal period. Continuous surveillance measures of animal products are an 
important task of national regulatory agencies to control compliance of farmers and 
veterinarians to these withdrawal periods. The length of the withdrawal period is dependent 
on the length of time drug residues remain in the animal body, which may differ considerably 
depending on the animal tissue and drug in question. Thus so called pharmacokinetic 
investigations of drugs are important to map the bioavailability, absorption, metabolism and 
elimination of drug residues, which include both the parent drug and any bioactive 
metabolites, in various animal products meant for human consumption, and thus determine 
withdrawal periods for specific drugs. Maximum residue limits (MRLs) in animal tissues are 
set for each drug for various practical and scientific reasons. One important reason is that 
the sensitivity of detection for a given drug may vary, depending on the method employed. 
This sets constraints on the ability of regulating bodies to set a zero tolerance for any drug 
residues in any animal product. 
Because coccidiostats 1) are regulated as feed additives rather than as medicinal products, 
and 2) the principal effect of coccidiostats is on the coccidia and microbiota within the lumen 
of the intestinal tract, relatively few exhaustive reports from conventional pharmacokinetic 
studies reporting concentrations of coccidiostats in animal tissues exist in the peer-reviewed 
scientific literature. However, the metabolism and elimination of most ionophore 
coccidiostats have been reported to be rapid from breast and leg/thigh muscle tissue from 
broilers fed rations containing coccidiostats (Catherman et al., 1991; FAO, 2009a; FAO, 
2009b; Henri et al., 2012; Olejnik et al., 2014; Peippo et al., 2005), as reflected by the short 
withdrawal times (0-5 days) registered for each coccidiostat (see Table AIII-1 and AIII-2 in 
Appendix III). MRLs in animal tissues following the withdrawal times are at the µg/kg wet 
weight level, also indicating generally rapid metabolism and elimination from tissues. Most 
coccidiostats, however, are lipophilic, which means that residues accumulate at higher levels 
in tissues with higher fat content, such as the fat, skin, and liver. This is taken into 
consideration, however, with these tissues generally used as marker tissues when setting 
MRLs, as well as for testing during surveillance. 
One major challenge, which has received more recent attention by the scientific community, 
is the accumulation of coccidiostats and other drug residues in eggs (see review by Goetting 
et al. (2011)). Human exposure to ionophore coccidiostats due to the consumption of eggs 
was generally considered nearly non-existent as mature, egg-laying hens are not fed 
coccidiostat-containing rations. However, the accidental exposure of laying hens to 
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coccidiostats due to cross-contamination that can occur at feed mills (see section 3.2.6) 
cannot be completely ruled out, which also makes it nearly impossible for farmers and 
veterinarians to comply with withdrawal periods accordingly. As exemplified in a recent study 
by Olejnik et al. (2014), low level exposure of laying hens to rations supplemented with 0.27 
mg/kg semduramicin, which normally has a 5 day withdrawal time, led to detection of 
semduramicin levels well above MRL (set at 2 µg/kg) in three of six liver samples (mean for 
the 6 samples 2.57; SD 2.47 µg/kg) and all ovarian yolk samples (mean for the 5 samples 
19.5; SD 8.9 µg/kg). Undetectable levels (<0.1 µg/kg) or values under the MRL were 
observed in spleen, heart, breast muscle, thigh muscle, gizzard and ovarian tissue. A recent 
review (Goetting et al., 2011) mapped the coccidiostat residues found in eggs from hens 
exposed to both therapeutic and below therapeutic levels, such as levels that may occur as a 
result of cross-contamination, in rations. The number of days from last treatment until 
residues was no longer detected were reported, as far as the exhaustive review of the 
literature would allow. With the exception of monensin, all other coccidiostats required 
substantially longer periods of time (>3 [for salinomycin] to >60 [for nicarbazin] days) than 
the set withdrawal periods for residues of each coccidiostat to clear whole eggs and/or egg 
yolks. 
Thus human exposure to coccidiostats with the consumption of eggs due to cross-
contamination of feeds for laying hens may be higher than with consumption of muscle 
tissue from broilers and other poultry fed rations containing coccidiostats. This becomes 
particularly apparent from data reported in the Norwegian Residue Monitoring Programme, 
summarised in Table 3.4.4-1. Coccidiostats have not been detected in poultry meat in the 
last five years of surveillance. In the same period, however, numerous eggs (of the 133-150 
sampled per year) have been found to contain trace levels of coccidiostats and 1-3 eggs 
have contained levels above MRLs nearly every year.  In 2014, Norwegians were reported to 
consume on average 12.5 kg eggs per year. In 2012, 61 758 metric tonnes of eggs were 
produced in Norway, increasing steadily from a level of 47 400 metric tonnes in 2002. 
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Table 3.4.4-1  Summary of coccidiostat residues reported in foods of animal origin from the 
‘Residue monitoring programme’ in the last five years. The number of non-compliant poultry samples 
in which levels were above the maximum residue levels (MRLs) are reported, as well as the number of 
egg samples in which anti-coccidials were detected at trace levels (above or below MRL). Total 
number of samples analysed are given in parentheses 
Year Food item1 
 Poultry2 Eggs Other3 
2014 0 (67) 1 above MRL (N) (150) 0 
2013 0 (63) 0 above MRL; 8 under MRL (N) (140) 0 
2012 0 (47) 3 above MRL (2N, 1M); 11 under MRL (N) (133) 0 
2011 0 (51) 1 above MRL (N); 12 under MRL (N) (140) 0 
2010 0 (59) 2 above MRL (N) (133) 0 
1 MRLs for narasin (N) and monensin (M) is 2 µg/kg; and for lasalocid (L) 150 µg/kg; 
2 “Poultry” is muscle tissue from broilers, turkeys and layers (hens); 
3 “Other” indicates anti-coccidials analysed in meat from other terrestrial animals, including imports 
A toxicological risk assessment of human exposure to coccidiostats via the food chain has 
also recently been conducted (Dorne et al., 2013) and a risk characterization of coccidiostats 
for human health after intake of animal products from non-target species fed cross-
contaminated diets at 2%, 5% and 10% of the maximum levels authorized in target species, 
and related to acceptable daily intakes (ADIs) from a toxicological perspective. This data can 
also give information regarding human exposure as it relates to the development of 
antibacterial-resistant bacteria in humans. However, a full risk characterization from this data 
is not possible at this time. 
  
 
VKM Report 2015: 30   97 
 
 
Table 3.4.4-2  Risk characterization of coccidiostats for human health from a toxicological 
perspective after intake of animal products from non-target species fed cross-contaminated diets at 
2%, 5% and 10% of the maximum levels authorized in target species, and related to acceptable daily 
intakes (ADIs). Adopted from Dorne et al. (2013) 
Coccidiostat ADI (µg/kg 
BW per 
day) 
Animal products % ADI after cross-
contamination 
2% 5% 10% 
Ionophoric 
coccidiostats 
     
Lasalocid 5 Eggs/liver/skin 3 13 27 
Maduramicin 1 Liver/skin/fat and muscle 0.7 1.9 3.7 
Monensin 3 Liver and eggs 0.1 0.3 0.6 
Narasin 5 Liver and eggs 0.07 0.35 0.17 
Salinomycin 5 Liver and eggs 0.2 0.4 0.8 
Semduramicin 1.25 Muscle/liver 2 5 10 
Non-ionophoric 
coccidiostats 
     
Decoquinate 75 Eggs/liver/kidney/muscle/skin/fat 0.14 0.38 0.75 
Diclazuril 29 Eggs/liver/kidney/muscle/skin/fat 0.016 0.04 0.08 
Halofuginone na Eggs/liver/kidney/muscle/skin/fat na na na 
Nicarbazin 770 Eggs/liver/muscle 0.04 0.09 0.18 
Robenidine 37.5 Eggs/liver/kidney/muscle/skin/fat 0.9 2.2 4.3 
The question arises whether coccidiostats will be sufficiently denatured during heat 
treatment of poultry meat and eggs consumed by humans to eliminate the danger of 
development of antibacterial-resistant bacteria. The effect of processing on numerous 
veterinary residues in foods was reviewed by Moats (1999). The conclusions drawn were 
that 1) normal cooking procedures for meat, even to “well-done”, may not be sufficient to 
inactivate even the more heat sensitive compounds, and 2) the relevance to human 
exposure is uncertain since the activities of the various degradation products are largely 
unknown. See also section 3.3 for effects of heat treatment on coccidiostat denaturation. 
Pharmacokinetic data 
Narasin 
Peippo et al. (2005) fed 30 male and 30 female broiler chickens (Ross 508-hybrid) 
unmedicated starter rations from 1-14 days of age before feeding grower ration 
supplemented with 0, 3.5 or 70 mg narasin per kg feed until slaughter. Tissues were 
sampled from three birds fed the 70 mg/kg narasin ration following withdrawal times of 0, 3 
or 5 days, while four birds fed 0 and 3.5 mg/kg narasin rations tissues were sampled without 
any withdrawal time. Birds were fed unmedicated rations during the withdrawal time. Birds 
had free access to feed and water during the entire feeding trial. The tissues sampled were 
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plasma, leg muscle and breast muscle. Narasin was determined by time-resolved 
fluoroimmunoassay and results shown in Table 3.4.4-3. 
Table 3.4.4-3  Concentration of narasin in plasma and muscle tissues of broilers fed rations 
containing 0, 3.5 or 70 mg nrasin/kg feed (from Peippo et al. (2005))  
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ND: not detected; limit of detection (LOD): 0.6 µg/kg; limit of quantification (LOQ): 1.8 µg/kg 
As indicated by the data when narasin was present in the diet (i.e. no withdrawal time) it 
was efficiently absorbed from the intestinal lumen and entered the blood stream of chickens, 
with concentrations closely reflecting the ration levels. In the muscle, however, narasin 
concentrations were considerably reduced compared to plasma levels and the muscle levels 
did not follow ration levels as closely. Following 3 and 5 day withdrawal periods, no narasin 
was detected in any tissues, indicating that it is rapidly metabolized. 
The above conclusions were generally confirmed by other, HPLC-based data reported by  
FAO (2009b). This method was reportedly somewhat less sensitive with an LOD and LOQ of 
10 and 25 µg/kg, respectively. Narasin residues were not detected in muscle at any time 
following ration withdrawal (0, 6, 12 and 24 h), while kidney samples contained <25 µg/kg 
(the LOQ) at 0 h and not detectable levels thereafter. Liver and skin/fat samples contained 
46.2 and 67.1 µg/kg, respectively, at 0 h. Six hours following withdrawal no narasin was 
detected in liver, while 39.1 µg/kg was detected in skin/fat, which was reduced to <25 µg/kg 
and none detected at withdrawal times of 12 and 24 h, respectively. 
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The fate of narasin following exposure to higher ration levels than the 80 mg/kg used in the 
two above-mentioned broiler studies have also been reported FAO (2009b). This has 
practical importance, e.g. following possible over-dosing that may occur unintentionally at 
feed mills. Broilers exposed to 80 or 160 mg/kg narasin in rations fed from day 0 to day 42 
(approximately one production cycle). Narasin residues were analysed in tissues at 2, 24, 72, 
120 and 168 h following withdrawal of narasin-containing feed using bio-autography using 
Bacillus stearothermophilus  var. calidolactis C-953 as the indicator organism (LOQ 25 
µg/kg). For both the 80 and 160 mg/kg rations, narasin was detected 2 h following 
withdrawal in skin and fat and in one skin sample at 24 h following withdrawal in the 160 
mg/kg group. No narasin was detected in any muscle, liver or kidney samples at any time 
following withdrawal or in skin and fat samples following the 24 h withdrawal period. 
In a study reported with rats, radioactivity following a single oral dose of 2.3 mg (0.596 
µCi/mg) 14C-labelled narasin was followed to more closely evaluate the absorption and 
elimination of narasin (FAO, 2009b). Using rats in metabolism cages, elimination via urine 
versus faeces could be observed, which is generally difficult to accomplish with broilers. An 
average of 75% of the radioactive dose was eliminated 52 h post-dosing, in which only 1.1% 
of the excreted radioactivity was found in the urine and the remainder (98.9%) in the 
faeces. Rats equipped with a catheter in the bile duct provided data indicating that 15% of 
the dose was absorbed and eliminated through the heaptic system. Narasin was also 
reported to be rapidly eliminated from tissues of broilers (FAO, 2009b). Four 8-week old 
broiler chickens fed a ration containing 80 mg narasin/kg feed were given a single, oral 
(encapsulated) dose of 14C-labelled narasin. Excreta were collected from the chickens daily 
and analysed for radioactivity. More than 85% of the radioactive dose was excreted within 
48 hours. 
Similar results were obtained in a third narasin study with broilers and quail (Catherman et 
al., 1991), however in that study 14C-labelled narasin was injected by cardiac puncture and 
therefore not considered as applicable to farming conditions and human dietary exposure. In 
this latter study, it took 3 days for an average of 81.9% of the radioactive dose to be 
excreted in broilers, while 75% was excreted in quail. Some tissue differences in elimination 
were also reported, with 80% and 92% of the dose clearing the plasma of broilers and quail, 
respectively, whereas in both broilers and quail, the liver, heart, fat, skin and ovarian tissue 
contained traces of radioactivity 1 d post-injection, while muscle and kidney contained no 
traces of radioactivity 1 d post-injection. Radioactivity was detected in excreta up to day 12 
post-injection, but at narasin-equivalent levels well below the MRL of 50 µg/kg set for broiler 
tissues (see Appendix III, Table AIII-1). 
Narasin metabolites have been reported in both liver and in excreta, with at least some 
similar metabolites observed in both (FAO, 2009b). Unchanged narasin represents ca. 5% of 
total narasin residues in hepatic tissue. Narasin metabolites have at least twenty times less 
antimicrobial activity (tested with Bacillus subtilis) than the narasin A. 
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The data summarized above confirms that a withdrawal period of 1 day is sufficient to 
reduce narasin levels to below MRLs, but possibly not completely eliminate trace levels of 
narasin and/or its metabolites, from poultry tissues consumed by humans. 
Monensin 
In turkeys and chickens fed rations containing 100 mg/kg monensin, Henri et al. (2012) 
reported 30% bioavailability in chickens and 1% in turkeys. Residues were rapidly eliminated 
from plasma, liver and muscle tissue, and following 8 h of withdrawal, monensin was not 
detected in liver, breast or thigh muscle. Fatty tissue retained monensin longer, but was near 
or below MRL at 24 h and below detection levels 72 h following withdrawal. Data supporting 
this has been reported by FAO (2009a).The data summarized above confirms that a 
withdrawal period of 1 day is sufficient to reduce monensin levels to below MRLs, but 
possibly not completely eliminate trace levels of monensin and/or its metabolites, from 
poultry tissues consumed by humans. 
Salinomycin 
In chickens fed rations containing 70 mg/kg salinomycin, Henri et al. (2012) reported 15% 
bioavailability. Residues were rapidly eliminated from plasma and muscle tissue, and 
following 8 h of withdrawal, salinomycin was not detected in plasma or breast muscle. Fatty 
tissue retained salinomycin longer, but was not detected in any tissues 24 h following 
withdrawal. 
The data summarized above confirms that a withdrawal period of 1 day is sufficient to 
reduce salinomycin levels to below MRLs, but possibly not completely eliminate trace levels 
of salinomycin and/or its metabolites, from poultry tissues consumed by humans. 
 Environmental exposure to coccidiostats  3.4.5
Poultry manure is a valuable fertilizer and poultry manure-based compost or poultry manure 
is either applied directly to agricultural fields by farmers, stored for later land application or 
transported for further treatment (composting, heating etc.) and preparation for commercial 
fertilizers. Poultry manure-based fertilizers are used in agriculture as well as gardens and 
kitchen gardens.  
As discussed under section 3.4.3, the coccidiostats concentrations in manure when applied 
as fertilizer will vary and depend on the excretion kinetics, their chemical physicochemical 
properties, and the manure history (fresh, stored, treated). In soil the coccidiostats might 
undergo different processes; abiotic and biotic degradation, trapping in nanpores, 
immobilization to non-extractable residues, leachates and runoff from soil to nearby water 
recipients or taken up by plants and soil-living organisms. These disappearance processes 
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depend on the environmental condition and factors such as temperature, redox, light 
exposure, as well as microbial activity. 
Even there are several papers related to environmental fate of pharmaceuticals, also 
veterinary medicine from manure (Boxall et al., 2003; Du and Liu, 2012; Hailling-Sørensen et 
al., 1998; Sarmah et al., 2006), the coccidiostats have been scarcely included. It is only 
during the last decade research related to environmental occurrence and fate of the 
ionophore coccidiostats has been performed. These substances’ physiochemical properties 
and interaction with other elements and the influence of pH related to their pKa values is 
complicated, and there is no consensus on their environmental behavior as discussed by   
Hansen et al. (2012). However, there are some environmental measurements of ionophores 
in different matrixes, including agriculture runoff water, sediments in recipients and 
agriculture soil (e.g. (Bak et al., 2013; Hansen et al., 2012; Sun et al., 2013a).  
Monensin, salinomycin and narasin have been measured in runoff from manure-fertilized 
lands in a US study (water samples n=17) in maximum concentrations 2389, 9022 and 348 
ng/L, respectively (Sun et al., 2013b). In top soil from the same field (soil samples n=10), 
only monensin was detected over analytical detection limit and in the range of 5-183 μg/kg 
(average 101 μg/kg). The median and maximal concentration of these coccidiostats in 
poultry manure from farms in the area were 291, 4607, and 237 μg/kg  and 4057, 21878 
and 3310 μg/kg,respectively (Sun et al., 2013b). In real samples from Denmark performed 
related to establishing an analytical methodology and not an environmental survey, 
monensin was detected in soil and manure in ng/kg-level, salinomycin only in the sediment 
sample, while narasin was detected in soil and sediment sample (Bak et al., 2013). Lasalocid 
was not detected above limit of detection level.   
It is well known that plants take up pharmaceuticals, possible also as active uptake for 
certain structures (Eggen and Lillo, 2012), that uptake and further translocation within plants 
is related to the physicochemical properties, and there are significant differences between 
plant species (e.g. (Eggen and Lillo, 2012; Sallach et al., 2015)). There are several studies 
related to plant uptake of therapeutic pharmaceuticals (Boonsaner and Hawker, 2015; Boxall 
et al., 2006; Wu et al., 2014), including antibacterials, but few with coccidiostats (Broekaert 
et al., 2012; Eggen et al., 2011; Ghent, 2012). In the Ghent University study, two different 
coccidiostats application approaches were used for studying uptake of coccidiostats in carrot, 
potato, lettuce, zucchini and tomato; one was addition of manure (see Table 3.4.3.1-1 for 
coccidiostat concentrations) reflecting a field dose of 10 tons/ha and the other using excreta 
spiked with premix coccidiostats to mimic a worst-case scenario.  
In the manure-added soil, only nicarbazin and monensin were detected in carrot and lettuce, 
respectively. Nicarbazin residue in unpeeled carrot was in range of 8.7-10.7 μg/kg dw (1.1-
1.4 μg/kg fw) and the monensin in lettuce in range of 9.6-49.3 μg/kg dw (0.4-2.0 μg/kg fw). 
In the worst-case scenario, exctreata spiked with pre-mix, nicarbazin was found in unpeeled 
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potato and courgette, lasalocid in unpeeled potato and carrot, and monensin in lettuce and 
unpeeled potato (used only ¼ doses due to phytotoxic effects on potato growth). Due to 
phytotoxic properties, possible uptake of monensin and nicarbazin in carrot were not 
available. No uptake was measured in tomatoes. 
Humans might be exposed to coccidiostats via plants grown in manure-based compost or 
manure-amended soil; but only relevant for crops with significant uptake of coccidiostats via 
roots (e.g. root vegetables) or leave-vegetables with manure transferred to leaves via rain 
splash (e.g. lettuce). The measured monensin in lettuce grown in manure amendment soil 
but no uptake in root vegetables found in the same study indicates that transfer via leave is 
a transfer pathway to consider. Based on uptake data from the comprehensive study by Gent 
University, and related to food consumption data and acceptable daily intake, it was claimed 
unlikely to pose a direct threat to public health (Broekaert et al., 2012).  
Environmental risk or exposure of non-target organisms is not part of this risk assessment 
and not discussed. Runoff of none-ionophore veterinary antibacterials and uptake from 
aquatic plants should not be ignored when determining human exposure to antibacterials 
(Boonsaner and Hawker, 2015). 
Risk due to spreading ionophores in the environment has last years received more scientific 
attention. How to optimize treatment of manure before land application and sustainable 
manure storage are now also put on the agenda. Measures to reduce transfer of 
coccidiostats to the environment through controlled and optimized storage of manure 
stimulating degradation of coccidiostats is possible and should be considered.  
Research related to antibacterial resistance genes from application of manure has recently 
been published (Furtula et al., 2010; Joy et al., 2013; Zhang et al., 2014; Zhu et al., 2013) 
but there are no knowledge available for evaluation such risk today. 
3.5 Use of therapeutic antibacterials 
 Use of therapeutic antibacterial agents for poultry in Norway 3.5.1
In Norway, veterinary medicinal products (VMPs) are prescription only and have to be 
dispensed to veterinarians and animal owners through pharmacies.  An exemption from this 
is medicated feed – i.e. feed containing premixes of antimicrobial agents that are dispensed 
through authorised feed mills; presently this applies only for antimicrobials used in fish 
farming. Both pharmacies and feed mills have to purchase VMPs through licenced 
wholesalers. The wholesalers are mandated to report their sales to the Norwegian Institute 
of Public Health (NIPH). 
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The Norwegian Veterinary Institute gather detailed data on sales of antibacterial veterinary 
medicinal products (VMPs) from NIPH for the NORM-VET report. The data are collected at 
package level and include among others information on the dosage form for each 
antibacterial VMP. 
Commercial poultry is treated against bacterial infections by adding the antibacterial VMP 
through drinking water. Currently three VMPs applicable for treatment through drinking 
water are sold in Norway (NORM-VET, unpublished data). 
Until recently the major sales in Norway of dosage form applicable for treatment through 
drinking water represented an amoxicillin VMP approved for poultry only (Figure 3.5.1-1).  As 
from 2012, phenoxymethylpenicillin (authorised for poultry only) is used increasingly. 
Statistics for 2014 and 2015 have not been available, but it is likely that 
phenoxymetylpenicillin is the predominant compound presently used to treat bacterial 
disease in commercial Norwegian poultry. The reason for this change is an increased 
awareness of the presence of extended spectrum betalactamase (ESBL)-producing Gram-
negative bacteria in poultry. Minor amounts of an enrofloxacine VMP (authorised at EU level 
for use in the target species chickens, turkeys and rabbits) are also sold (presumed mainly to 
non-commercial poultry and pet birds). 
Although these products might be used in other animal species as well, the data presented in 
Figure 3.5.1-1 is thought to give a valid estimate on therapeutic use of antibacterial VMPs in 
poultry in Norway. 
  
 




Figure 3.5.1-1 Sales, in kg active substance, in Norway of antibacterial veterinary medicinal 
products applicable for treatment of poultry during the years 2004-2013 (NORM-VET, unpublished 
data).  In addition 0.1 to 0.7 kg enrofloxacine is sold annually during this period 
 Use of therapeutic antibacterials in broilers 3.5.2
Therapeutic antibacterials are rarely used in Norwegian broilers. Data from Animalia 
(Norwegian Meat and Poultry Research Center, Thorbjørn Refsum, personal communication 
2015) indicate that only one single conventional (i.e. using in-feed coccidiostats) broiler flock 
was treated during the time span from January 2013 until October 2014. Because 8000 
flocks were slaughtered during this time period, this figure corresponds to a treatment 
frequency of 0.01 %. During the same time span a total of 800 organic (no in-feed 
coccidiostats) broiler flocks were slaughtered, and 1.5 % of these flocks (corresponding to 
12 flocks) were treated.  This difference between conventional and organic flocks is 
statistically significant, suggesting an increased probability of using therapeutic antibacterials 
in flocks reared without in-feed coccidiostats. 
A Norwegian study collecting data from a total of 120 conventional broiler flocks reared 
during 2003-2006 indicated use of therapeutic antibacterials in 2.0 % (1/49) of flocks offered 
feed with coccidiostats and in 5.6 % (4/71) of the flocks offered feed without coccidiostats 
(Kaldhusdal, 2006). Although these figures suggest a difference between flocks with and 
without coccidiostats, the low numbers of flocks in this study preclude any firm conclusions 
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 Use of therapeutic antibacterials in turkeys 3.5.3
Data from Animalia (Norwegian Meat and Poultry Research Center, Thorbjørn Refsum, 
personal communication 2015) indicate that 22 of 159 turkey flocks (13.8 %) were treated 
with therapeutic antibacterials during 2014. Most of these cases were associated with clinical 
necrotic enteritis. The occurrence varies substantially with time and will probably be lower in 
2015. Such cases are usually treated with phenoxymetylpenicillin, a compound with an 
optimal combination of efficacy and narrow spectrum of activity. The majority of cases of 
treatment with therapeutic antibacterials take place in flocks that are offered feed 
supplemented with coccidiostats. Turkey feeds cannot be supplemented with narasin and 
salinomycin. In particular narasin has been assumed to be more efficient than other 
ionophores in preventing necrotic enteritis, an assumption which is supported by MIC data 
on C. perfringens strains from broilers (Martel et al., 2004).Probability of increased use of 
therapeutic antibacterials for poultry associated with changed usage of in-feed coccidiostats. 
 Probability of increased use of therapeutic antibacterials associated 3.5.4
with changed usage of in-feed coccidiostats 
The coccidiostat presently used in Norwegian broiler rearing (narasin) is a polyether 
antibacterial (also called an ionophore) which has an effect against the bacterium causing 
necrotic enteritis (C. perfringens) as well as against coccidiosis, which is a predisposing 
factor for necrotic enteritis. If this coccidiostat is replaced with an coccidiostat without the 
antibacterial effect e.g. nicarbazin or diclazuril, see (Lanckriet et al., 2010; Lensing et al., 
2010) and no other factors are changed, the specifically growth-suppressing activity against 
C. perfringens is removed, which will enable this bacterium to proliferate more easily in the 
broiler intestine. If we assume that the new coccidiostat are equally efficient against relevant 
coccidia as narasin, the risk of necrotic enteritis, and therefore also the risk of use of 
therapeutic antibacterials, is likely to increase. If the new coccidiostat is more effective 
against relevant coccidia, the risk of necrotic enteritis is more dependent upon other 
predisposing factors than coccidiosis and can therefore vary with the presence or absence of 
such factors. 
The net outcome depends on the efficacy of narasin and the new coccidiostat against 
relevant strains of coccidia present in Norwegian broiler farms. No data on resistance to 
ionophores in coccidial strains from Norwegian poultry farms have been found. The 
evaluation therefore must be based on general knowledge.  Development of resistance in 
coccidia against ionophores (Augustine et al., 1987; Chapman, 1993; Peek and Landman, 
2003) and reduced activity against coccidia shown by ionophores as compared with non-
ionophore coccidiostats (Peeters et al., 1994) has been documented from other countries . 
However, development of resistance in coccidia has been demonstrated for all 11 EU-
authorized coccidiostats, including the non-ionophore coccidiostats. Because ionophores 
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(narasin from 1996, other ionophores from 1988) have been used almost continuously in 
Norwegian farms since 1988, it is possible that the anticoccidial efficacy of the ionophores 
may have been reduced.  However, no reports of increasing problems with clinical or 
subclinical coccidiosis in Norwegian poultry has been found, which suggests that resistance 
to ionophores in coccidia has been of minor importance up to now. 
Coccidiosis is not the only predisposing factor for necrotic enteritis, and other factors (e.g. 
feed factors) will change under commercial conditions. If these changes favour C. 
perfringens proliferation and toxin production, the lack of a specific antibacterial effect of a 
non-ionophorous coccidiostat will involve an increased risk. The same will apply if coccidia 
strains develop tolerance or resistance to the new coccidiostat. 
No data indicating a development of resistance in C. perfringens against narasin has been 
documented (Johansson et al., 2004; Lanckriet et al., 2010; Martel et al., 2004; Silva et al., 
2009a; Watkins et al., 1997), in spite of widespread use of this ionophore in many countries 
for several decades. 
Provided these considerations are valid, a replacement of narasin (without any other 
changes) over time is likely to lead to intermittently or continuously higher levels of use of 
therapeutic antibacterials. This is particularly likely to be the case in broilers, which up to 
now have been offered feeds supplemented with narasin. The situation is slightly different in 
turkeys, which are offered feeds supplemented with ionophores that are not considered as 
efficient against necrotic enteritis as narasin, although data on lasalocid are contradictory 
(Lanckriet et al., 2010; Martel et al., 2004). 
 Probability of increased use of therapeutic antibacterials for poultry 3.5.5
if in-feed coccidiostats are replaced by anticoccidial vaccines 
The literature on the effects of replacing in-feed coccidiostats with anticoccidial vaccines is so 
far scarce. Preliminary reports from the US suggest that this strategy may be associated with 
outbreaks in commercial farms of necrotic enteritis at 2-3 weeks of age. These outbreaks 
appeared to be associated with suboptimal vaccine delivery preventing sufficiently early 
development of immunity to coccidia, thus allowing pathogenic coccidia strains 
(environmental and possibly also the non-attenuated vaccine strains that are used in the US 
but not in Europe) to act as a predisposing factor for necrotic enteritis (Mozisek et al., 2015; 
Schaeffer et al., 2015). An experimental study conducted in an initially coccidia-free 
environment indicated that intestinal C. perfringens counts were considerably higher in 
vaccinated birds than in unvaccinated birds given narasin (Waldenstedt et al., 1998), which 
is not surprising given the fact that narasin (but not anticoccidial vaccines) exerts a directly 
suppressing effect on C. perfringens. 
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Up to now conventional broiler rearing has been based on the use of in-feed coccidiostats. 
Production of broiler meat without such additives has constituted a small fraction of the total 
production volume, and has been based on a less intensive production system (less 
concentrated feeds, slower growth rate, lower stocking density and so forth) associated with 
higher production costs. 
This situation is now changing. Two major Norwegian broiler meat distributors have declared 
their intention to abolish the use of in-feed coccidiostats before 2017, and an increasing 
number of broiler flocks have been raised without coccidiostats in 2015. These flocks have 
been treated at day-old with a live attenuated anticoccidial vaccine, and such vaccination is 
likely to become an integrated part of a combination of alternative measures replacing in-
feed coccidiostats. In addition to these industry efforts, a research project (2015-2018) 
initiated by the industry and lead by the Norwegian Veterinary Institute will provide new data 
on the preventive effect of non-antibacterial in-feed additives on gastrointestinal health in 
broilers. These projects will provide a lot of data and knowledge about the consequences of 
abolished use of in-feed coccidiostats in conventional broiler rearing, but so far we do not 
have enough data to fully evaluate the impact on usage of therapeutic antibacterials. 
Initial experience with conventional commercial flocks (treated with an anticoccidial vaccine 
and offered feeds without narasin) reared without any other specific management changes 
suggests that clinical necrotic enteritis may occur sporadically. However, outbreaks of 
necrotic enteritis will not necessarily be treated with therapeutic antibacterials. The 
possibility of using in-feed narasin as a measure to control clinical cases of necrotic enteritis 
is now being explored by the industry (personal communication, Atle Løvland). If this 
treatment strategy is successful, an increase in the use of therapeutic antibacterials may turn 
out to be unnecessary. 
Anticoccidial vaccines can potentially prevent coccidiosis and thereby remove an important 
predisposing factor for necrotic enteritis. However, such vaccines do not induce specific 
immunity against necrotic enteritis, which is caused by the bacterium C. perfringens and may 
appear even in the absence of coccidiosis. It is therefore likely that if in-feed coccidiostats 
are replaced with anticoccidial vaccines and no other changes are done, the likelihood of 
necrotic enteritis will increase. On this background it is important to identify other changes in 
management, including non-antibacterial feed additives that can contribute to 
gastrointestinal health in broilers reared without in-feed coccidiostats. 
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3.6 Summary of exposure  
Human exposure to narasin resistant bacteria in Norway 
• In the Norwegian surveillance programme NORM-VET 2002 - 2013, the percentage of 
flocks tested with narasin resistant enterococci in faecal samples was 62 % for broilers 
and 67 % for turkeys. 
• The percentage of meat samples contaminated with narasin resistant enterococci was 36 
% for broiler meat and 22 % for turkey meat. 
• Farmers and other production workers that without proper protective measures 
regularly handle animals and manure from flocks with resistant bacteria are likely to be 
exposed to narasin resistant bacteria. 
• Consumers that without proper kitchen hygiene measures handle contaminated fresh or 
frozen raw poultry meat may be exposed to narasin resistant bacteria. 
• Consumers are not likely to be exposed to narasin resistant bacteria by eating properly 
heat treated poultry meat and poultry products. 
Human exposure to coccidiostats in Norway 
• Workers that without protective measures prepare coccidiostat premixes, and prepare 
or handle coccidiostat containing feeds, are likely to be exposed to coccidiostats. 
• Workers that without protective measure handle manure from coccidiostat fed poultry, 
either directly or after storage, or prepare commercial fertilizer products based on such 
poultry manure, are likely to be exposed to residue levels of coccidiostats. 
• Consumers of poultry meat and meat products from coccidiostat fed poultry are not 
likely to be exposed to narasin. 
• Manure from coccidiostat fed poultry might be a source of transfer of coccidiostats to the 
environment, both during improper storage/composting and run-off of coccidiostats to 
nearby recipients, and after manure is applied as fertilizer to soil. 
Use of therapeutic antibacterials 
• If the ionophore coccidiostats used in Norway is replaced by one or more coccidiostats 
with no antibacterial effect and no other changes are done, this is over time likely to lead 
to intermittently or continuously higher levels of use of therapeutic antibacterials due to 
increased incidence of nectrotic enteritis. 
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• If coccidiostats are replaced with anticoccidial vaccines and no other changes are done, 
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4 Risk characterisation 
4.1 Risk characterisation 
The probabilities and risks are characterized as: 
• Negligible (extremely low) 
• Low (possible, but not likely) 
• Medium (likely) 
• High (almost certain) 
• Not assessable  
 Resistance to coccidiostats in bacteria 4.1.1
Available data show that the enterococci isolated from poultry given feed with the 
coccidiostat ionophores narasin, monensin and salinomycin may become resistant to these 
agents. In particular, the prevalence of resistant E. faecium has been found to be high. Data 
regarding enterococcal resistance against the ionophores lasalocid and maduramicin are 
lacking. However, lasalocid was reported to induce resistance to Clostridium aminophilum in 
a laboratory experiment. On the other hand, resistance in the poultry pathogen C. 
perfringens has not been reported against any of the ionophores. Data regarding resistance 
in other Gram-positive bacterial species of the normal microbiota of animals and humans is 
scarce. It is probable that resistance can be transferred between bacteria of the same 
species, and possibly also between bacteria of different species. 
Present information indicates that the non-ionophore coccidiostats do not induce resistance 
in bacteria. 
Furthermore, the Panel has no information on possible differences between the ionophores 
regarding their probability to induce resistance, and is not aware of any such data from 
clinical trials or practical use of rotation or shuttle programmes. However, due to similarity in 
the chemical structure and mode of action of ionophore agents, it can be suggested that 
rotation between ionophores may not have any impact to minimize the development of 
resistance in bacteria. This is supported by the fact that cross-resistance between ionophores 
has been shown. Data regarding rotation between ionophore and non-ionophore agents is 
also lacking. Therefore, the Panel has no evidence to claim that such programmes may 
contribute to reduce antibacterial resistance. 
A few studies may indicate a possible association between resistance against narasin and 
resistance against other antibacterials like vancomycin and bacitracin in enterococci. 
However, there is at present no conclusive evidence that the ionophore coccidiostats induce 
resistance against other antibacterial agents, but this should be further studied. 
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 Resistance to coccidiostats in coccidia 4.1.2
All the coccidiostats have been shown to induce resistance in coccidia. Resistance testing of 
coccidia is less standardized and more complicated than for bacteria, thus explaining the 
general lack of surveillance data. It is suggested that ionophores induce resistance 
development at a slower rate than non-ionophore coccidiostats. An explanation for this slow 
acquisition of resistance to ionophores may be that they allow for some leakage of sensitive 
oocysts which leads to a less stringent resistance selection than with non-ionophore 
coccidiostats. After introduction of monensin, the first ionophore on the market in the 1970’s, 
these drugs are still predominant in the prevention of coccidiosis, supporting the hypothesis 
of slow resistance development. 
Cross-resistance is observed, e.g. between narasin, monensin and salinomycin. Even though 
numerous papers have reported coccidiostat resistance and cross-resistance, these topics 
merit further investigations especially related to those having different mode of action. 
Furthermore, there is little information available on the effect of exchange of coccidiostats on 
coccidiostat resistance development. 
 The effect of coccidiostats on intestinal microbiota 4.1.3
Compared to the numerous papers published on intestinal microbiota, the topic effect of 
coccidiostats on composition and development of the normal intestinal microbiota has 
received less attention. Consequently, the Panel is not aware of any information on whether 
coccidiostats may exert changes in the composition of the intestinal microbiota and thereby 
indirectly affect the prevalence of bacteria resistant to other antimicrobials. 
 Human exposure to antimicrobial/coccidiostat resistant bacteria 4.1.4
Surveillance data may indicate that as many as 2/3 of the broiler and turkey farms at given 
may harbor narasin resistant bacteria. Without risk-reducing measures, farm workers who 
are frequently in direct or indirect contact with manure are therefore considered to have a 
high probability of exposure to narasin resistant bacteria. This is also in agreement with data 
from the literature. Various treatments, e.g. composting, of the manure may reduce the 
number of resistant bacteria present. Assessment of the effects of such methods has not 
been performed. Production workers that through transport, slaughter and processing are in 
contact with manure from a large number of flocks without risk-reducing measures may also 
have a high probability of exposure to narasin resistant bacteria. However, the data indicate 
that the probability associated with handling of carcasses and meat is medium, as narasin 
resistant enterococci were found in only 1/3 of the meat samples. The main route of 
exposure for farm and production workers is direct contact, but inhalation of contaminated 
aerosols or dust particles is also possible. Various risk-reducing measures are normally 
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applied in all parts of production, meaning that the probabilities in real life are lower than the 
presented theoretical ones. 
The main routes of exposure for consumers are direct contact by handling raw fresh or 
frozen meat and ingestion of food that is not heat-treated. Heat-treated poultry products 
constitute a negligible probability of exposure to narasin resistant bacteria, both by handling 
and by ingestion.  Without risk-reducing measures the consumer probability of exposure to 
resistant bacteria when handling raw meat is considered to be low to medium. The 
probability will be lower if risk-reducing measures are applied. However, the Panel does not 
know to which extent such measures are applied in the private households. 
Although intestinal colonization of humans with various antimicrobial resistant bacteria has 
been reported in literature, there is no such available information regarding narasin resistant 
enterococci. Nor is there any information on the probability of transfer of narasin resistance 
genes from poultry enterococci to bacteria in the normal microbiota of humans or to human 
pathogens. One important reason for the lack of such studies is that a gene or genes coding 
for narasin resistance have not yet been identified. 
Consequently, it is not known to what extent exposure to narasin resistant enterococci from 
poultry will lead to colonization in humans, and if so, under what conditions and for how 
long. Furthermore, the consequences of such colonization are unknown, as ionophore 
coccidiostats are not used to treat infectious diseases in humans, and cross- or co-resistance 
with resistance to antibacterials considered important in human medicine has so far not been 
confirmed. 
 Human exposure to coccidiostats  4.1.5
Bacteria of human normal microbiota may theoretically develop resistance if they are 
exposed to coccidiostats. All human skin and mucosal surfaces are covered by bacteria, i.e. 
the normal microbiota that consists of ten times as many bacterial cells as the human body’s 
own cells. The bacteria of the normal microbiota may be exposed to coccidiostats by direct 
contact, ingestion and inhalation. Little relevant information has been found regarding the 
amount and/or time period of exposure of bacteria to ionophores that is needed for them to 
develop coccidiostat resistance. For example, no information exists regarding the practical 
implications of human or non-target animals’ intermittent exposure to low (at or just above 
MRLs) or trace (below MRLs) levels of coccidiostat residues for antimicrobial resistance 
development among their endogenous microbiota. 
4.1.5.1 Human exposure to coccidiostats in feed 
Without risk reducing measures, the probability of coccidiostat exposure is high for workers 
preparing pre-mixes, feeds at feed mills as well as farmers handling feeds at poultry farms. 
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Use of protective clothing including masks and gloves, as well as normal hygienic precautions 
such as washing hands and equipment following pre-mix/feed handling should minimize the 
probability of exposure to low. 
Based on current knowledge it is not possible to estimate the probability of real life 
occupational exposure of feed handlers to coccidiostats. These groups may, however, be 
considered “high consumers” and monitoring them for coccidiostat exposure and subsequent 
antimicrobial resistance development among their endogenous bacterial populations may be 
indicative of the upper risk situation that the current use of coccidiostats in poultry feeds 
may have for the human population. 
4.1.5.2 Human exposure to coccidiostats in manure 
Without risk reducing measures, the probability for exposure of coccidiostats is high for 
workers handling manure; during slaughter, transport of manure out of the poultry house 
and during cleaning the poultry house (poultry production), during the spread of manure on 
agricultural fields. For workers in contact with manure after long-term storage, composting 
or other treatment, lower probability of exposure to coccidiostats is expected. The probability 
for exposure for workers producing commercial poultry manure-based fertilizers is unknown. 
The probability of exposure will depend on the measures taken. With good guidelines for use 
of protection equipment the probability for human exposure should be very low.  
Based on today’s knowledge, it is not possible to evaluate probability for transfer of 
coccidiostats to edible crops. A worst case scenario could be applying fresh manure (using 
appr.1 cm bedding) or short term stored manure to agricultural fields. From the study by 
Ghent University, uptake of nicarbazin, monensin and lasalocid in the root vegetables and 
lettuce were observed, but the risk evaluation from Ghent University based on their own 
results was that it is unlikely to pose a direct threat to public health (Broekaert et al., 2012). 
4.1.5.3 Human exposure to coccidiostats in poultry carcasses and products 
Adherence to withdrawal periods before slaughter apparently minimizes the probability of 
exposure from consumption of poultry meat to negligible, as indicated by surveillance data 
(see section 3.4.4). 
Cross-contamination of feeds meant for laying hens with coccidiostats in feed mills may 
occur, and surveys have shown coccidiostat levels above MRLs in 0.7-2.3% of eggs on the 
Norwegian market. Since narasin appears to be relatively heat tolerant up to 70°C, which is 
a temperature that may be expected for eggs following commonly used/practiced heat 
treatment, it is likely that high consumers of eggs may be intermittently exposed to 
coccidiostats at levels at or above MRLs. 
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Based on current knowledge it is not possible to perform a risk evaluation for consumer 
exposure to low levels (at or somewhat above MRLs) of coccidiostats in eggs. High 
consumers of eggs may experience intermittent exposure to low levels of coccidiostats, but it 
is currently not known whether such exposure will contribute to antimicrobial resistance 
development among the consumers’ endogenous bacterial populations. 
 Probability of increased use of therapeutic antibacterials for poultry 4.1.6
when using alternative measures of coccidiosis control 
Probability of increased use of therapeutic antibacterials for poultry if 
coccidiostats with antibacterial effects are replaced by coccidiostats without such 
effects: Ionophorous coccidiostats suppress the growth of C. perfringens, the cause of 
necrotic enteritis. If the ionophores are replaced by coccidiostats without antibacterial effect 
and nothing else is changed, the probability of increased use of therapeutic antibacterials to 
treat necrotic enteritis is high (i.e. almost certain). The magnitude of the increase is difficult 
to predict. 
Probability of increased use of therapeutic antibacterials for poultry if in-feed 
coccidiostats are replaced by anticoccidial vaccines: Anticoccidial vaccines do not 
induce specific immunity against necrotic enteritis, which is caused by the bacterium C. 
perfringens. The probability of increased use of therapeutic antibacterials to treat necrotic 
enteritis is therefore high (i.e. almost certain) if in-feed coccidiostats are replaced with 
anticoccidial vaccines and no other changes are made. The magnitude of the increase is 
difficult to predict. 
It is, however, likely that other changes will be made following a replacement of ionophorous 
coccidiostats with anticoccidial vaccines or non-ionophore coccidiostats, in particular if the 
increase in use of therapeutic antibacterials is substantial. The Norwegian industry is already 
exploring the possibility of using in-feed narasin to treat cases of clinical necrotic enteritis. If 
this treatment strategy succeeds, an increased use of therapeutic antibacterials may not 
become necessary even if the number of clinical cases increases. Further, numerous 
alternative non-antibacterial products for feed supplementation have been developed and 
marketed. Some of these products have been demonstrated to reduce intestinal counts of C. 
perfringens and may therefore be able to reduce the number of cases requiring treatment. 
None of these individual products appear to be as efficient as narasin, and more work is 
needed to compare the effect of combinations of alternative products with the effect of 
narasin. Other types of management changes are also likely to be encouraged if the use of 
narasin and other ionophores is abolished.  
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4.2 Summary of risk characterisation  
Resistance in bacteria and coccidia 
• All coccidiostats approved in Norway are ionophores which may induce resistance in both 
bacteria and coccidia. 
• The probability of bacteria developing resistance varies between the bacterial species, 
whereas the probability of coccidia developing such resistance is unknown. 
• Cross-resistance between ionophores is observed in both bacteria and coccidia. 
• In bacteria, a possible association between resistance to ionophores and resistance to 
other antibacterials is indicated, but further studies are required to validate these 
findings. 
• The Panel is not aware of any information on whether coccidiostats may indirectly affect 
the prevalence of bacteria resistant to other antibacterials by exerting changes in the 
composition of the intestinal microbiota. 
• The additional six coccidiostats approved in the EU may induce resistance in coccidia, but 
have no effect on bacteria. 
Human exposure to coccidiostat resistant bacteria or coccidiostats in Norway 
A risk assessment cannot be performed as the consequences of human exposure to 
coccidiostats or to narasin resistant enterococci from poultry are unknown. Consequently, 
only the probability of exposure has been assessed. 
The probabilities are characterized as: 
Negligible (exstremely low), Low (possible, but not likely), Medium (likely), High (almost 
certain) or Not assessable 
All probabilities are assessed under the assumption that risk-reducing measures are not 
applied. Risk-reducing measures will lower the probabilities 
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Table 4.2-1 Probability of human exposure to narasin or narasin resistant bacteria in Norway if 











Handling coccidiostat premix H 
Not applicable 






Handling feed with coccidiostats H Not applicable 
Handling fresh manure from poultry given feed 
with coccidiostats 
H H 
Handling live animals and equipment  
contaminated with manure from poultry given 
feed with coccidiostats 
N to L H 
Handling composted manure from poultry 
given feed with coccidiostats 
M Not assessed 
Handling commercial poultry manure-based 
fertilizers 
Not assessed Not assessed 
Handling carcasses and meat  N M 
Consumers Handling raw meat N L to M 
Ingestion of sufficiently heat-treated meat N N 
1 Probability levels: N = Negligible (exstemely low), L = Low (possible, but not likely), M = Medium 
(likely), H = High (almost certain) 
Probability of increased use of therapeutic antibacterials for poultry when using 
alternative measures of coccidiosis control 
Ionophorous coccidiostats suppress the growth of C. perfringens, the cause of necrotic 
enteritis. If the ionophores are replaced by coccidiostats without antibacterial effect or 
anticoccidial vaccines and nothing else is changed, increased use of therapeutic 
antibacterials to treat necrotic enteritis is likely. The magnitude of the increase is difficult to 
predict. 
It is, however, likely that other changes will be made following a replacement of in-feed 
coccidiostats with anticoccidial vaccines, in particular if the increase in use of therapeutic 
antibacterials is substantial. The Norwegian industry is already exploring the possibility of 
using in-feed narasin to treat cases of clinical necrotic enteritis. If this treatment strategy 
succeeds, an increased use of therapeutic antibacterials may not become necessary even if 
the number of clinical cases increases. Further, numerous alternative non-antibacterial 
products for feed supplementation have been developed and marketed although none of 
these individual products appear to be as efficient as narasin. Other types of management 
changes are also likely to be encouraged if the use of narasin and other ionophores is 
abolished.  
 




Development and transfer of resistance to coccidiostats in bacteria 
The number of scientific publications on the effect of ionophores on the development of 
antimicrobial resistance is small for lasalocid and maduramicin, and lacking for 
semduramicin. More data is available for narasin, monensin and salinomycin. Since narasin 
and monensin are used in Norwegian poultry farming the panel considers the scientific basis 
strong enough to conclude that anti-microbial resistance is induced by ionophores in 
conditions found in Norway. 
The panel has chosen to consider it likely that horizontal transfer of resistance against 
coccidiostats may occur since transfer of a large variety of other antibacterial resistance 
genes is known to occur in bacteria. However, only one scientific study describes such 
transfer, reporting horizontal transfer of resistance against narasin in vitro. Furthermore, as 
none of the a coccidiostat resistance genes have been described in scientific literature, it is 
not known to which degree these genes are located on tansferrable gene 
elements.Consequently the frequency of such gene transfer is not known. 
Cross- or co-resistance between coccidiostats and other antimicrobials in bacteria 
A statistical association was found between resistance against narasin and bacitracin, and 
between narasin and vancomycin. In addition, two publications report laboratory studies that 
may support these data; one studying narasin resistance and vancomycin resistance and 
enterococci, and one studying lasalocid resistance and bacitracin resistance in Clostridium 
aminophilum. However, the amount of data is very limited, and the level of uncertainty is 
high. More studies are needed before any firm conclusions can be drawn, and especially the 
characterization of resistance gene(s) against narasin would elucidate a possible link 
between resistance against narasin and resistance against bacitracin or vancomycin in 
enterococci. 
Probability of increased use of therapeutic antibacterials in poultry production 
under current production practices if coccidiostats with antibacterial effects are 
replaced by coccidiostats without such effects, or replaced by anticoccidial 
vaccines  
The conclusion that this probability is high is based on the assumption that other 
predisposing factors for necrotic enteritis than coccidiosis are important and prevalent in the 
broiler environment. Our knowledge about the relative importance of coccidia and other 
predisposing factors for necrotic enteritis is limited. Although this risk is high, the degree of 
increase in use of therapeutic antibacterials is uncertain as data on this is limited. Also, if the 
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use of therapeutic antibacterials increases significantly, other management changes are likely 
to be implemented in the field in order to counteract such a development.  
Human exposure to coccidiostat resistant bacteria 
Estimation of probability levels of exposure to resistant bacteria are based on data from the 
Norwegian surveillance program NORM-VET. Concerning data from faeces of live animals, 
the sampling unit of concern is flock. The Panel has assumed that the prevalence of positive 
farms equels that of positive flocks. In addition, there may have been relatively large 
differences between the age of the chicken flocks at the time of sampling, and sampling 
procedures have been changed over the years; all adding to the uncertainty of the estimated 
prevalences. 
Furthermore, the estimated prevalences of resistant bacteria, both in faeces and on raw 
meat, are based on investigations on two species of bacteria only, i.e. E. faecium and E 
faecalis. There are no surveillance data on prevalences in other bacterial species of the 
normal microbiota of poultry. Thus, the prevalences of may be underestimated. 
Probability of human exposure and resistance development among endogenous 
microbiota of workers and consumers exposed to coccidiostats  
Real life exposure probabilities in humans handling coccidiostats (feed mill workers, farmers 
etc.) has not been quantified because such exposure will to a large extent depend on the 
use of protective measures. The Panel does not have information on the actual use of 
protective measures. Therefore the probabilities are given according to a worst case 
scenario. In real life where people are likely to use some kind of protective measures the 
probabilities will be lower. Without such measures, absorption across the skin and mucous 
membranes of the respiratory tract may occur, but the subsequent risk to development of 
antibacterial resistant strains of bacteria among endogenous bacterial populations is not 
known. 
Nor have the consequences of intermittent, low level exposure of coccidiostats by consumers 
at or somewhat above MRLs in poultry products for development of antibacterial resistant 
strains of bacteria among endogenous populations been investigated. The temperature 
stability of various coccidiostats merit documentation as well, as does the ability of 
denaturation products following heat treatment to induce the development of antibacterial 
resistant strains of bacteria in consumers. 
These uncertainties do not allow the Panel to conclude more specifically regarding the 
probabilities and risks of human coccidiostat exposure among workers or consumers with 
subsequent resistance development among their respective endogenous microbiota. 
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Probability of exposure of coccidiostats for workers handling poultry manure 
Several studies confirm residual coccidiostats in poultry exctreta and manure. The 
concentration levels depend on numbers of factors; e.g. the age and treatment of the 
manure, the properties of the substances and the environmental conditions. The risk for 
exposure of workers handling manure is higher in contact with fresh or short-time stored 
manure than composted manure. A study performed by Ghent University on request by EFSA 
gives a reliable indication of the residue levels which is expected to find in excreta and 
manure during storage, composting and transfer to certain crops of the studied coccidiostats. 
However, due to differences in practical apects and the high variation in disappearence fate, 
the concentration levels the workers might be exposed for can be either lower or higher than 
observed in this study. The challenge of sampling of non-homogenous matrix, such as 
manure, might influence the results, and should be considered during interpretation of data.  
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6 Answers to the terms of reference 
The probabilities and risks are characterized as: 
• Negligible 
• Low (Unlikely, but possible) 
• Medium (Likely) 
• High (Almost Certain) 
• Not assessable 
6.1 To what extent can the 11 EU-authorised coccidiostats 
induce resistance and/or cross-resistance in bacteria? 
Among these 11 coccidiostats six are ionophores and five are non-ionophore coccidiostats. 
Five of the ionophores are reported to display antibacterial effects. Four of these, i.e. 
Narasin, Lasalocid, Monensin and Salinomycin, have been reported to induce resistance in 
various bacteria. However, there are large variations between bacterial species tested 
regarding the prevalence of resistance, e.g. resistance is often identified in the enterococci of 
the normal microbiota, but not in the pathogen C. perfringens. Whether these variations are 
due to differences between the bacteria, the coccidiostats and/or the magnitude of the 
coccidiostat exposure is not known. 
The ionophore Maduramicin also exhibits antibacterial activity. Only one study addresses the 
development of resistance to this coccidiostat in bacteria. This was in C. perfringens, where 
resistance development was not observed. However, based on its antibacterial effect it is 
reasonable to believe that bacteria also may develop resistance against this agent. 
The ionophore Semduramicin sodium is reported to have limited effect on bacteria, and data 
on its ability to induce resistance in bacteria has not been found. 
The five non-inophore coccidiostats, i.e. Robenidine, Diclazuril, Decoquinate, Halofuginon 
and Nicarbazin, do not display antibacterial effect, and are therefore not expected to induce 
resistance in bacteria. 
Cross-resistance between ionophores has been reported, e.g. between narasin and 
salinomycin, and between salinomycin and monensin. 
There is at present no confirmed cross- or co-resistance in bacteria between coccidiostats 
and other antibacterial agents. However, an association is suggested between ionophore 
resistance and resistance against the antibacterials vancomycin and bacitracin, and the 
possibility that such an association will be confirmed by future research cannot be excluded. 
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In conclusion, resistance to and cross-resistance between ionophore coccidiostats has 
been reported in a few bacterial species, mainly enterococci. Studies of resistance 
development in C. perfringens have not shown such development. Resistance against other 
antibacterials induced by ionophores has been suggested but not confirmed. 
6.2 To what extent can the 11 EU-authorised coccidiostats 
induce resistance in coccidia? 
All the coccidiostats have been shown to induce resistance in coccidia. Resistance testing of 
coccidia is less standardized and more complicated than for bacteria, thus explaining the 
general lack of surveillance data. 
It has been suggested that ionophores induce resistance development at a slower rate than 
non-ionophore coccidiostats, possible due to ionophores allowing for some leakage of 
sensitive oocysts that leads to a less stringent resistance selection than with non-ionophore 
coccidiostats. After the introduction of monensin, the first ionophore on the market in the 
1970’s, these drugs are still predominant in the prevention of coccidiosis, supporting the 
hypothesis of slow resistance development. 
Most of the initially marketed non-ionophore coccidiostats have disappeared from the market 
due to their rapid induction of resistance development. However, the ones in use today may 
appear to induce resistance less rapidly. 
Cross-resistance is observed between ionophores, e.g. between narasin, monensin and 
salinomycin. 
In conclusion, all the coccidiostats have been shown to induce resistance in coccidia, but 
cross-resistance has only been demonstrated between ionophores. 
6.3 Are there advantages or disadvantages associated with the 
development of resistance in bacteria under the current 
practice in Norway with only five coccidiostats available 
compared to the 11 EU authorised coccidiostats? 
All five coccidiostats approved in Norway are ionophores that display antibacterial effect. 
Bacterial resistance against four of them, i.e. Narasin, Lasalocid, Monensin and Salinomycin, 
has been reported. Data is lacking for the fifth ionophore, i.e. Maduramicin, but based on its 
antibacterial effect it is reasonable to believe that bacteria also may develop resistance 
against this agent. The Panel has no information on possible differences between these five 
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coccidiostats regarding probability to induce resistance, cross-resistance or co-resistance in 
different bacteria. 
One of the six coccidiostats, which is only authorized in the EU, i.e. Semduramicin, is also an 
ionophore. However this ionophore is reported to have a limited effect on bacteria, and data 
regarding its potential ability to induce resistance in bacteria has not been found. The rest of 
the coccidiostats, i.e. Robenidine, Diclazuril, Decoquinate, Halofuginon and Nicarbazin, are 
non-ionophore coccidiostats which do not display antibacterial effect and are therefore not 
believed to induce resistance in bacteria. Consequently, these coccidiostats offer coccidiosis 
prevention without the risk of inducing resistance in bacteria. 
Although it is generally accepted that antibacterial rotation or cycling may reduce the risk of 
resistance development in bacteria, this may not apply to ionophores. Due to similarity in the 
chemical structure and mode of action of ionophores, rotation between them will most likely 
not contribute to minimizing the development of resistance in bacteria. This is supported by 
data showing cross-resistance between the ionophores narasin and salinomycin, as well as 
between salinomycin and monensin. The Panel is not aware of any data from clinical trials or 
practical use of rotation of different coccidiostats aiming to minimize development of 
resistance in bacteria, either with rotation between different ionophores, or between 
ionophores and non-ionophore coccidiostats. Consequently, the effect of rotation of 
coccidiostats on resistance development in bacteria is not known. 
It must be noted that when responding to this term, the Panel has not considered any other 
properties of the coccidiostats than the ability to induce resistance in bacteria. 
In conclusion, if all eleven coccidiostats were approved in Norway, coccidiostats without 
antibacterial effect would be available, thus offering coccidiosis prevention with a negligible 
risk of inducing resistance in bacteria. 
6.4 Are there advantages or disadvantages associated with the 
development of resistance in coccidia under the current 
practice in Norway with only five coccidiostats available 
compared to the 11 EU authorised coccidiostats? 
All five coccidiostats approved in Norway are ionophores with similar mechanisms of action.  
When resistance against one of them is developed, the probability of cross-resistance against 
several of others is high. Five of the remaining six coccidiostats that are only authorized in 
EU are non-ionophore coccidiostats with different modes of action, and cross-resistance 
between these and ionophores are not expected. 
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To reduce development of resistance, different shuttle and rotation programmes are used. In 
shuttle programmes, two or more coccidiostats are used during the grow-out of a flock, e.g. 
one for starter and others for grower and finisher. In rotation progammes, the coccidiostats 
used are changed at regular intervals, e.g. between flocks. In both programmes, the 
alternation is usually between non-ionophore coccidiostats and ionophores. Furthermore, 
coccidiocidal non-ionophore coccidiostats are reported to be used to reduce the infection 
pressure of coccidiosis, in a so-called clean-up program. There is little information in the 
scientific literature on the effectiveness of such programmes. None of these programmes can 
be used in Norway as non-ionophore coccidiostats are not available. 
It should be noted that when responding to this term, the Panel has not considered any 
other properties of the coccidiostats than the ability to induce resistance in coccidia. 
In conclusion, if all eleven coccidiostats were approved in Norway, coccidiostats without 
cross-resistance to ionophores would be available, thus offering the possibility to use shuttle 
and rotation programmes to reduce development of resistance in coccidia. 
6.5 What are the risks of antibacterial resistance being 
developed in and/or transferred to people (workers) 
handling coccidiostat preparations, feed, poultry, poultry 
meat or manure from poultry production using coccidiostat 
feed additives? If so, what risk-reducing measures are 
available? 
A risk assessment cannot be performed as the consequences of development of resistance or 
colonization of resistant bacteria in the human normal microbiota are unknown. Ionophore 
coccidiostats are not used to treat infectious diseases in humans, and no cross- or co-
resistance with antibacterials considered important in human medicine have been confirmed. 
Consequently, only the probability of exposure has been assessed. The probabilities are 
characterized as: Negligible (extremely low), Low (possible, but not likely), Medium (likely), 
High (almost certain) or Not assessable. 
Transfer of coccidiostat resistant bacteria to people. If risk-reducing measures are not 
applied, the probability of exposure to coccidiostat resistant bacteria is considered to be high 
for handling of manure, as well as equipment, clothing and anything else that has been in 
contact with this, including live animals. Various treatments, e.g. composting, of the manure 
may reduce the number of resistant bacteria present. Assessment of the effects of such 
methods has not been performed.The probability is considered to be medium for handling 
poultry carcasses and raw meat, as well as equipment, clothing and anything else that has 
been in contact with this. Direct contact and inhalation are the most probable routes for 
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exposure of workers to coccidiostat resistant bacteria.  Risk-reducing measures are e.g. 
restricted access, protective clothing, hygienic barriers between “contaminated” and “clean” 
zones and equipment, proper procedures for handling of manure, regular and thorough 
cleaning and disinfection, and regular monitoring of bacterial contamination of the 
production premises. 
The Panel has no information on whether transferred bacteria will colonize the human body, 
either transiently or permanently. Furthermore, there is no information on the probability of 
exchange of resistance genes from transferred bacteria to bacteria of the human natural 
microbiota or to pathogens. 
Development of coccidiostat resistant bacteria in people. Bacteria of the human 
normal microbiota might develop resistance if they are exposed to coccidiostats. Little 
relevant information has been found regarding the level of exposure, e.g. the amount of 
coccidiostats, or the time period necessary for the various bacteria to give rise to resistant 
variants. 
If risk-reducing measures are not applied, the probability of exposure to coccidiostats is 
considered high for workers handling of pre-mix feed preparations and feed. The probability 
is medium to high for workers handling manure. The probability is negligible for handling 
carcasses and raw meat. Most probable routes of exposure for workers are direct contact 
and inhalation. Personal risk-reducing measures are protective clothing including masks 
covering nose and mouth. Automation, restricted access, regular cleaning, ventilation and 
waste control will also contribute to risk reduction. 
6.6 What are the risks of antibacterial resistance being 
developed in and/or transferred to people (consumers) 
handling and eating meat from poultry production using 
coccidiostat feed additives? 
A risk assessment cannot be performed as the consequences of any development of 
resistance or colonization of resistant bacteria in the human normal microbiota are unknown. 
Ionophore coccidiostats are not used to treat infectious diseases in humans, and no cross- or 
co-resistance with antibacterials considered important in human medicine have been 
confirmed. Consequently, only the probability of exposure has been assessed. The 
probabilities are characterized as: Negligible, Low (possible, but not likely), Medium (likely), 
High (almost certain) or Not assessable 
Transfer of coccidiostat resistant bacteria to people. The probability of exposure to 
coccidiostat resistant bacteria is negligible for ingestion of heat treated meat and meat 
products, and low to medium for handling of fresh or frozen raw meat. The routes of 
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exposure to coccidiostat resistant bacteria are direct contact and ingestion. Risk-reducing 
measures are the same as recommended for handling raw meat in general, e.g. hygienic 
barriers between the meat and other food products, proper heat treatment, hand wash and 
general kitchen hygiene. 
The Panel has no information on whether transferred bacteria will colonize the human body, 
either transiently or permanently. Furthermore, there is no information on the probability of 
exchange of resistance genes from transferred bacteria to bacteria of the human natural 
microbiota or to pathogens. 
Development of coccidiostat resistant bacteria in people. Bacteria of the human 
normal microbiota may develop resistance if they are exposed to coccidiostats. Little relevant 
information has been found regarding the level of exposure, e.g. the amount of 
coccidiostats, or the time period necessary for the various bacteria to give rise to resistant 
variants. The probability of exposure to coccidiostats through handling or ingestion of poultry 
meat and meat products is negligible. 
6.7 What are the risks of an increase in the therapeutic use of 
antibacterials in poultry production under current 
production practices if coccidiostats with antibacterial 
effects are replaced by coccidiostats without such effects? 
The presently used coccidiostats are ionophores that suppress the growth of C. perfringens, 
the cause of necrotic enteritis. C. perfringens also plays a role in the severity of the Gizzard 
Erosion and Ulceration syndrome (GEU) in chicken. The majority of cases are subclinical with 
impaired production performance as the main consequence. Necrotic enteritis is very well 
controlled in broilers when the in-feed coccidiostat narasin is used. C. perfringens appears to 
be slightly less sensitive to the in-feed coccidiostat monensin which is used for turkeys, and 
this may explain the more frequent use of therapeutic antibacterials in this production. 
If the ionophores are replaced by non-ionophore coccidiostats without antibacterial effect 
and no other management changes are implemented, there is a high probability of an 
increased frequency of outbreaks of these diseases and hence an increase in number of 
flocks that need treatment with antibacterials. The magnitude of the increase is difficult to 
predict. Coccidiosis is one of the predisposing factors of necrotic enteritis. If the new 
coccidiostats  are more efficient against coccidia than  the ionophores presently used, this 
may reduce the risk of necrotic enteritis, but probably not to the same level as with 
ionophores, as other risk factors may still be present. The Norwegian industry is currently 
exploring the possibility of treating outbreaks with antibacterials that are not used as 
therapeutic antimicrobials in human medicine. If this approach succeeds, the probability of 
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increased use of conventional therapeutic antibacterials with relevance to human medicine 
will be low. 
In conclusion, increased use of therapeutic antibacterials is likely if currently used 
ionophores are replaced by non-ionophore coccidiostats or anticoccidial vaccines, but the 
magnitude of this increase cannot be predicted. Further, if disease in broiler chickens can be 
treated with antibacterials not considered important to human medicine, the impact of such 
an increase will be low. 
6.8 Do alternative measures exist that can be employed to 
reduce the risk of coccidiosis in broiler chickens as 
effectively as coccidiostats? 
Eradication of coccidia from the birds’ environment is difficult to achieve because the coccidia 
form oocysts that survive outside the host and resist commonly used disinfectants. However, 
effective disinfectants are commercially available and their potential may not have been fully 
utilised up to now. 
Vaccination is another option. Coccidia are intracellular parasites that are highly 
immunogenic, which has allowed the development of vaccines based on live coccidia. Some 
of these vaccines are based on strains that are still pathogenic (‘non-attenuated’ vaccines), 
others are based on non-pathogenic (‘attenuated’) strains. Both types of vaccines are able to 
induce protective immunity. Only non-pathogenic vaccines are used in Europe. This type of 
anticoccidial vaccine is now used increasingly in commercial Norwegian broiler farms, instead 
of in-feed coccidiostats. So far coccidiosis has not been reported as a problem in this 
transition process to broiler rearing without in-feed coccidiostats in Norway. 
A third type of alternative measures is non-antibacterial feed additives. Acid-based products, 
probiotics, prebiotics, synbiotics, yeast-based products, plant-derived products, combinations 
of these, and other products have been developed and marketed as feed additives with 
claimed positive effects on the digestive system of broilers and fattening turkeys. These 
products have been tested for efficacy against coccidia with conflicting, non-consistent or 
non-convincing results. The majority of these products appear to target the bacterial 
microbiota rather than coccidia. 
The Panel has not assessed possible effects of other types of management changes. 
In conclusion, assessed alternative measures are, eradication of the coccidian, vaccination 
and non-antibacterial feed additives. Based on current knowledge, the panel finds 
vaccination to probably be the best alternative.  
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7 Data gaps 
Consequences of human exposure to coccidiostats or coccidiostat resistant 
bacteria 
The use of coccidiostats with an antibacterial effect in poultry feed can create a reservoir of 
resistant bacteria that may theoretically spread to humans both by direct contact with 
animals and manure, as well as through the food supply. Furthermore, bacteria of the 
human normal microbiota may theoretically develop resistance if they are exposed to 
coccidiostats, and farmers and other workers in the poultry production chain may be 
exposed to in-feed coccidiostats when handling feed and manure. 
However, the risk of human exposure to coccidiostat resistant bacteria, as well as to 
coccidiostats, is not assessable as there is little information on the consequences of such 
exposure. Few relevant data have been found in scientific literature on the potential 
establishment of coccidiostat resistant bacteria form poultry in the human microbiota, either 
transitionally or permanently. Furthermore, there is no information on the probability of 
exchange of coccidiostat resistance genes from bacteria of poultry orrigin to bacteria of the 
human natural microbiota or to pathogens. 
Likewise, information on the level of exposure, e.g. the amount of coccidiostats or the time 
period necessary for the various bacteria in the human normal microbiota to give rise to 
resistant variants is lacking. For example, the presumed regular and potentially high levels of 
occupational exposure among feed mill and farm workers to coccidiostats and the risk of 
development of antibacterial resistant bacteria among their endogenous bacteria populations 
is currently unknown but may be a source of valuable information to map such risk among 
“high consumers”. Furthermore, the ability of intermittent exposure of consumers to low 
levels, particularly MRLs, of coccidiostat residues in poultry products to induce development 
of antibacterial resistant bacteria is unknown, but would be of practical importance to guage 
the need for any change in regulations regarding these feed additives. Likewise, concrete 
information on the heat sensitivity of various coccidiostats and the ability of denaturation 
products to induce antibacterial resistant bacteria is of practical importance for consumers of 
poultry products that are generally heat-treated before consumption. 
In order to risk assess workers’ possibility for developing antibacterial resistance due to 
residual levels of coccidiostats in manure, more knowledge regarding the excretion kinetic of 
parent compounds and metabolites, their antibacterial resistance activity and their 
degradation and removal fate during storage and different treatment processes of manure is 
required. 
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The effect of narasin in poultry feed on development and prevalence of resistance 
to other antimicrobials 
The coccidiostat narasin is used as additives in poultry feed to prevent coccidiosis caused by 
coccidian parasites. Narasin also inhibits or kills various bacterial species, and it is shown that 
bacteria in the normal microbiota of poultry, i.e. enterococci, develop resistance to narasin.  
Although narasin is not used to treat infectious diseases in humans, data may indicate an 
association with resistance to antibacterials considered important in human medicine. 
However, data addressing this question is scarce. Furthermore, the fact that genes 
conferring resistance to narasin have not been described in scientific literature makes 
confirmation of such information in practice impossible. 
Narasin and other ionophore coccidiostats may theoretically also indirectly influence 
development of resistance to other antimicrobials by altering the composition of the normal 
intestinal microbiota of chicken. It is not unlikely that ionophores can favour Gram negative 
bacteria in general, because most of these compounds suppress the growth of Gram positive 
bacteria. However, it is not known whether the ionophores in this way can specifically favour 
any subgroup of resistant Gram negative bacteria. 
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Scientific literature on ionophore coccidiostatic agents, 
approved and with marketing authorization in Norway as feed-
additive to poultry (narasin, salinomycin, monensin, lasolocid, 
and maduramicin) 
 
Table AI-1 Bacterial resistance against narasin 





















the vanA gene in 
some clones. 
Fard et al., 
2010 














et al., 2010 
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and a combination of 
narasin and nicarbazin 
maduramicin, and 
salinomycin. 
Nicrabazin did not 
inhibit C. 
perferingens 
isolates even at a 
concentration of 
128 microg/ml. 






















































from poultry. -  
Johansson 























agents were also 
low, except for 
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All strains were 
uniformly sensitive 













was detected in 
66% of the strains 
investigated. Sixty-
three percent of 
the strains showed 
low-level resistance 
to lincomycin.  
Butaye et 
al., 2002 
























seen.  Tetracycline 
and tylosin was a 
frequent 
occurrence of 
resistance in all 
three enterococcal 
species tested. For 
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solely for growth 
promotion was 
more prevalent in 
E. faecium strains 





was found only in 




















VKM Report 2015: 30   160 
 
 


















figh among strains 
from poultry meat. 
Butaye et 
al., 2000 












whereas in pig 
strains, resistance 
was less common. 








evident. There was 
no cross resistance 
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was seen for both 
bacterial species. 




















Narasin and 18 different 
antimicrobial agents, 
which are used 
therapeutically and as 
growth promoters in 
animals in USA. 
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Table AI-2 Bacterial resistance against lasalocid 










Cobos et al., 
2011 
Mexico Lambs Pediococcus 
acidilactici 
(the number 




































Nicrabazin did not 
inhibit C. 
perferingens 
isolates even at a 
concentration of 
128 μg/ml. 



















All strains were 
uniformly 











were active at 
very low 
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detected in 66% 
of the strains 
investigated. 
Sixty-three 








USA Cattle Clostridium 
aminophilum 



















C. aminophilum F 




cultures. The only 
antibiotic that 
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Jacob et al., 
2014 






















Enterococcus isolates from 
cattle fed monensin or 
monensin and tylosin had 





additives did not appear to 
increase the presence or 
concentration of either 
ermB or tetM resistance 
elements in cattle 














All islates were 




















All islates were 
susceptible to narasin 
and monensin. 
Cobos et al., 
2011 
Mexico Lambs Pediococcus 
acidilactici 
(the nmber 




P. acidilacti  was 
susceptible to both 
monensin and lasolocid 











All strains were uniformly 
sensitive to the ionophore 
antibiotics monensin, 
lasalocid, salinomycin, 
maduramicin and narasin. 
 

























active at very low 
concentrations, but low-
level acquired resistance 
was detected in 66% of 
the strains investigated. 
Sixty-three percent of the 
strains showed low-level 




USA Cattle Clostridium 
aminophilum 















polymyxin B and 
bacitracin 
Monensin- and lasalocid-
resistant C. aminophilum F 
cultures were as 
susceptible to most 
antibiotics as non-adapted 
cultures. The only 
antibiotic that seemed to 
have a common 
mechanism of resistance 
was bacitracin, and the 
ionophore-adapted 




Belgium Farm and 
pet animals 
E. faecium 










antibiotics, like narasin, 
used solely for growth 
promotion was more 
prevalent in E. faecium 
strains than in E. faecalis 
strains. 
Narasin resistance, fully 
cross-resistant with 
salinomycin was found 
only in E. faecium from 
farm animals, mainly 
broilers. 
Resistance against growth 
promoter agents monensin 
 



















and flavomycin was not 
detected. 
Todd et al., 
2001 
USA Cattle Prevotella 
spp. (15) 
Monensin Strains that were 
repeatedly transferred 
with sublethal doses 
tolerated (resistant) more 





USA Cattle Prevotella 
byrantii 
Monensin Prevotella bryantii cultures 
treated with monensin 
grew more slowly than 
untreated cultures, but 
only if the monensin 
concentration was greater 
than 1 microM. Cultures 
that were repeatedly 
transferred (eight 
transfers or 25 doublings) 
with monensin always 
grew rapidly, even at a 10 
microM concentration. 
Todd et al., 
1999 









HD4, and M. 
elsdenii B159 
Monensin Gram-positive ruminal 
bacterial species are 
generally susceptible to 
monensin, but some 
bacteria can adapt and 
increase their resistance. 
This resistance could be 
explained by the ability of 
these low G + C Gram-










In vitro study: 
All three species became 
 






















more resistant to the 
ionophore with which they 
were grown. Increased 
resistance to one 
ionophore caused 
increased resistance to the 
other, and cross-















Monensin Prevotella (Bacteroides) 
ruminicola subsp. 
ruminicola 23 and P. 
ruminicola subsp. brevis 
GA33 by stepwise 
exposure to increasing 
concentrations of 
monensin. The resulting 
resistant strains (23MR2 
and GA33MR) could 
initiate growth in 
concentrations of 
monensin which were 4 to 
40 times greater than 
those which inhibited the 
parental strains. Resistant 
strains also showed 
enhanced resistance to 
nigericin and combinations 
of monensin and nigericin 
but retained sensitivity to 
lasalocid. 
Dutta et al., 
1983 














All strains were classified 
as susceptible to 
avoparcin, carbadox, 
furazolidone, monensin, 
nitrovin and ronidazole. 
 

















USA Heifers Anaerobic 
bacteria 
Monensin Monensin-resistant 
bacteria may be present in 
greater numbers in the 
rumens of animals fed 
monensin-supplemented 
diets. However, greater 
proportions of monensin-
resistant organisms were 
not necessarily associated 
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E. faelacis (7%) and E. 
faecium (12.8%) of the 





























Denmark Human with 
diarrhoea 





and salinomycin had 
MIC-values comparable 
or slightly lower than 




et al., 2010 






The C. perferingens 
isolates examined were 



























did not inhibit C. 
perferingens isolates 
even at a concentration 
of 128 μg/ml. 
Fluckey et 
al., 2009 













While all isolates were 
resistant to 
chloramphenicol, only 
0.4% was resistant 
against salinomycin.  
Diarra et 
al., 2007 










The proportions of 
isolates positive for sulI, 
aadA, and integron class 
1 were significantly 
higher in salinomycin-
treated chickens than in 
the control or other 
treatment groups. 
Mcgowan 














Only 2 isolates (1.1%) of 
the isolates were 
salinomycin-resistant. 
Resistant against 
linomycn and bacitracin 










The susceptibility to 
salinomycin and 
doxycycline was high but 
the MICs for aivlosin 
varied 
 






















lly infected)  


























Supplementation of the 
diet with an coccidiostat 
drug does not appear to 
affect antimicrobial 
resistance or the level of 























































All strains were uniformly 








active at very low 
concentrations, but low-
level acquired resistance 
was detected in 66% of 
the strains investigated. 
Sixty-three percent of 
the strains showed low-
level resistance to 
lincomycin.  
Yoshimura 
et al., 2000 

















detected in all 
enterococcal species, 
ranging from 12.4% of 
E. faecium isolates to 
50% of E. hirae isolates. 
Aarestrup 








Only a limited number of 
the isolates, all from 
Danish broilers were 
categorized as resistant 
against monensin or 
salinomycin. 
 


























salinomycin and narasin 
in enterococci was 
frequent among poultry 
strains, whereas in pig 
strains, resistance was 
less common. No 
resistance was found 
against monensin and 
lasalocid. Full cross 
resistance between 
salinomycin and narasin 
was evident. There was 
no cross resistance 
between these two 
ionophores and 







bacteria (E. coli, 







and 3) animal 
























Acquired resistance to all 
currently used growth 
promoting antimicrobials 
was found. A frequent 
occurrence of resistance 
was observed to 
avilamycin, avoparcin, 
bacitracin, flavomycin, 
spiramycin, tylosin and 
virginiamycin, whereas 
resistance to carbadox, 
monensin, olaquindox 















salinomycin was high in 
enterococci of various 
sources, however no 
 

















(1435) Streptomycin resistance were observed 















against bacitracin was 
detected in some isolates 
from poultry and bovines 
and resistance to tylosin 
and virginiamycin in 
some strains from all 
species investigated. 
Overall, the prevalence 
of resistance was 
comparable to the low 
levels recorded in 1979 
in Cl. perfringens isolates 
























et al., 1986 
Kansas, 
USA 
Cattles Anaerobic bacteria Salinomycin 
(cattle fed diets 
with and without 
salinomycin. 
Salinomycin-resistant 
bacteria increased from 
7.6 to 15.6% in 
salinomycin-fed steers 
but remained unchanged 
in control steers. 
Salinomycin had no 
effect on cellulolytic and 
lactate-utilizing bacteria, 
but the proportion of 
 













amylolytic bacteria was 
higher in salinomycin-fed 














polyethers of monensin, 
salinomycin and lasalocid 
were generally adequate 
in low concentrations 
while there was a high 
level of resistance to 
three tetracyclines in 90 
per cent of the strains 
and all isolates were 
insusceptible to 
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Nicrabazin did not 
inhibit C. 
perferingens 









Investigations on possible associations between narasin 
resistance and resistance to other antimicrobial agents in E. 
faecium – as provided by the Norwegian Veterinary Institute 
 
 









Minimum and maximum content of coccidiostats allowed in complete diet formulations for poultry 
Table AIII-1 Overview of coccidiostats registered in Norway 
Generic name; 
Trade name(s), 













Other provisions, incl. withdrawal times, MRL-
values in animal products 
Regulation 
mg/kg complete feed with 
moisture content 12% 
Lasalocid A natrium  
Avatec 150 G;  15 g/100 









































No withdrawal time specified 
Shall not be mixed with other coccidiostats 
Dangerous for equines 
MRL (for chickens): 
Liver and kidney: 50 µg/kg wet wt 
Milk: 1 µg/kg wet wt 
Other: 5 µg/kg wet wt 
MRL (for turkeys, pheasants, etc.): 




Cygro 10 g; 10 g/kg 



















Use prohibited at least 3 days before slaughter 
Shall not be mixed with other coccidiostats 
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Dangerous for equines 
MRL 
Liver and skin/fat: 150 µg/kg wet wt 
Kidney: 100 µg/kg wet wt 
Muscle: 30 µg/kg wet wt 
Monensin-natrium 
Elancoban G100; 10 
g/100g 
Elancogran 100; 10 
g/100 g 
Elancoban G200; 20 
g/100 g 
(Eli Lilly & Co Ltd) 
----------------------------- 




























































Use prohibited at least 1 day before slaughter  
Shall not be mixed with other coccidiostats 
MRL: 
Skin and fat: 2 µg/kg wet wt 




Use prohibited at least 1 day before slaughter Shall 
not be mixed with other coccidiostats 
Dangerous for equines 
MRL: 
Skin and fat: 25 µg/kg wet wt 
Liver, kidney and muscle: 8 µg/kg wet wt 





Monteban G100; 100 














Use prohibited at least 1 day before slaughter  
MRL: 
Egg: 2 µg/kg wet wt 
Milk: 1 µg/kg wet wt 
Liver: 50 µg/kg wet wt 
Other animal products: 5 µg/kg wet wt 
 
Salinomycin natrium 










Use prohibited at least 1 day before slaughter 
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microGranulat; ; 120 





Kokcican 120 G (KRKA 




























































Dangerous for equines and turkeys 
MRLs: 
Egg: 3 µg/kg wet wt 
Liver: 5 µg/kg wet wt 
Other animal products: 3 µg/kg wet wt 
----------------------------------------------------------- 
Use prohibited at least 1 day before slaughter 
Dangerous for equines and turkeys 
MRL: 
Egg: 3 µg/kg wet wt 
Liver: 5 µg/kg wet wt 
Other animal products: 3 µg/kg wet wt 
-------------------------------------------------------------- 
Use prohibited at least 3 days before slaughter 
Dangerous for equines and turkeys 
MRL: 
All animal products: 5 µg/kg wet wt 
Source: Annex 1 and 2 of «Forskrift om tilsetningsstoffer til bruk i fôrvarer» 
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Table AIII-2 Overview of coccidiostats registered in the EU (Ref:. EU (2014) EU Register of Feed Additives pursuant to Regulation (EC) No 1831/2003; 

















Other provisions, incl. withdrawal period, 
MRL-values in foodstuffs of animal origin 
mg/kg complete feed with 
moisture content 12% 
Decoquinate 
















No withdrawal time specified 
MRL 
Liver and skin/fat: 1000 µg/kg wet wt 
Kidney: 800 µg/kg wet wt 
Muscle: 500 µg/kg wet weight 
Diclazuril 
Clinacox 0.5 %; 
0.50 g/100 g (Eli 
Lilly and Co. 
Ltd/Janssen 
Pharmaceutica NV) 


















No withdrawal time specified 
MRL 
Liver: 1500 µg/kg wet wt 
Kidney: 1000 µg/kg wet wt 
Muscle and skin/fat: 500 µg/kg wet wt 
Halofuginone 
hydrobromide 
Stenorol; 6 g/kg 
(Huvepharma NV) 
C16H17BrClN3O






































Use prohibited at least 5 days before slaughter 
Dangerous for equines 
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EU regulation no 37/2010 
Maduramicin 
ammonium alpha 






















Use prohibited at least 3 days before slaughter 
Shall not be mixed with other coccidiostats 
Dangerous for equines 
MRL 
Liver and skin/fat: 150 µg/kg wet wt 
Kidney: 100 µg/kg wet wt 
Muscle: 30 µg/kg wet wt 
Monensin-natrium 






















































Use prohibited at least 1 day before slaughter 
Shall not be mixed with other coccidiostats 
Dangerous for equines 
MRL: 
Skin and fat: 25 µg/kg wet wt 
Liver, kidney and muscle: 8 µg/kg wet wt 
 
Use prohibited at least 3 days before slaughter 

















No withdrawal period 
Dangerous for equine species, turkeys and rabbits 
MRL: 
50 µg/kg wet wt for all tissues from broilers 
 





Maxiban G160; 1:1 
ratio, 80 g/kg for 

























Use prohibited at least 1 day before slaughter 
Shall not be mixed with other coccidiostats 
Dangerous for equines, rabbits and turkeys 
MRL 
Narasin: 
Liver, muscle, kidney, skin/fat: 50 µg/kg wet wt 
Dinitrocarbanilide (DNC): 
Liver: 15000 µg/kg wet wt 
Kidney: 6000 µg/kg wet wt 


















Use prohibited at least 1 day before slaughter 
MRL 
Liver: 15000 µg/kg wet weight 
Kidney: 6000 µg/kg wet weight 
Muscle and skin/fat: 4000 µg/kg wet weight 
Robenidine HCl 































































Use prohibited at least 5 days before slaughter 
MRL (chickens) 
Liver: 800 µg/kg wet wt 
Kidney: 350 µg/kg wet wt 
Muscle: 200 µg/kg wet wt 
Skin/fat: 1300 µg/kg wet wt 
 
Use prohibited at least 5 days before slaughter 
MRL (turkeys) 
Liver and skin/fat: 400 µg/kg wet wt 
Muscle and kidney: 200 µg/kg wet wt 
 
 






Use prohibited at least 5 days before slaughter 




120 g/kg (KRKA, 

































Use prohibited at least 3 days before slaughter 
Dangerous for equines and turkeys 
MRL: 
5 µg/kg wet wt for all animal products 
Semduramicin 
Aviax 5 %; 51.3 















Use prohibited at least 5 days before slaughter 
MRL 
? 
Source: Council Directive (EC) 70/524/EEC … Amendments to Regulations (EC) Nos. 2430/1999 and/or 1831/2003 
 
 




Sampling of poultry faecal material and poultry meat in NORM-
VET – as provided by the Norwegian Veterinary Institute 
 
 





VKM Report 2015: 30   189 
 
